eyes20180630

0001437749-18-014778.txt : 20180807 0001437749-18-014778.hdr.sgml : 20180807 20180807173006 ACCESSION NUMBER: 0001437749-18-014778 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180807 DATE AS OF CHANGE: 20180807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SECOND SIGHT MEDICAL PRODUCTS INC CENTRAL INDEX KEY: 0001266806 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 000000000 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36747 FILM NUMBER: 18999218 BUSINESS ADDRESS: STREET 1: 12744 SAN FERNANDO ROAD, BLDG. 3 CITY: SYLMAR STATE: CA ZIP: 91342 BUSINESS PHONE: 818-833-5000 MAIL ADDRESS: STREET 1: 12744 SAN FERNANDO ROAD, BLDG. 3 CITY: SYLMAR STATE: CA ZIP: 91342 10-Q 1 eyes20180630_10q.htm FORM 10-Q eyes20180630_10q.htm

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended June 30, 2018

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from ________ to ________

Commission File Number 333-198073

Second Sight Medical Products, Inc.

(Exact name of Registrant as specified in its charter)

California

02-0692322

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer Identification No.)

12744 San Fernando Road, Suite 400, Sylmar, CA 91342

(Address of principal executive offices, including zip code)

(818) 833-5000

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐ (Do not check if a smaller reporting company)	Smaller reporting company ☒

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 3, 2018, the issuer had 67,074,542 shares of common stock issued and outstanding.

Table of Contents

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

FORM 10-Q

TABLE OF CONTENTS

PART I	FINANCIAL INFORMATION

Item 1.	Financial Statements

	Condensed Consolidated Balance Sheets as of June 30, 2018 (unaudited) and December 31, 2017	3
	Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2018 and 2017 (unaudited)	4
	Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2018 and 2017 (unaudited)	5
	Condensed Consolidated Statements of Stockholders’ Equity for the six months ended June 30, 2018 and 2017 (unaudited)	6
	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2018 and 2017 (unaudited)	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24

Item 4.	Controls and Procedures	24

PART II	OTHER INFORMATION

Item 1.	Legal Proceedings	25

Item 1A.	Risk Factors	25

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	27

Item 3.	Defaults Upon Senior Securities	27

Item 4.	Mine Safety Disclosures	27

Item 5.	Other Information	27

Item 6.	Exhibits	28

SIGNATURES		28

Table of Contents

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Condensed Consolidated Balance Sheets

(in thousands)

	June 30,			December 31,
	2018			2017
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	7,476		$	7,839
Accounts receivable, net		718			1,831
Inventories, net		3,567			2,700
Prepaid expenses and other current assets		599			795

Total current assets		12,360			13,165

Property and equipment, net		1,191			1,299
Deposits and other assets		66			33

Total assets	$	13,617		$	14,497

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,220		$	752
Accrued expenses		2,071			2,425
Accrued compensation expense		2,448			2,611
Accrued clinical trial expenses		1,074			779
Contract liabilities		260			48

Total current liabilities		7,073			6,615

Commitments and contingencies

Stockholders’ equity:
Preferred stock, no par value, 10,000 shares authorized; none outstanding		—			—
Common stock, no par value; 200,000 shares authorized; shares issued and outstanding: 67,075 and 57,630 as of June 30, 2018 and December 31, 2017, respectively		216,805			202,156
Common stock issuable		—			153
Additional paid-in capital		42,434			40,522
Accumulated other comprehensive loss		(604	)		(572	)
Accumulated deficit		(252,091	)		(234,377	)

Total stockholders’ equity		6,544			7,882

Total liabilities and stockholders’ equity	$	13,617		$	14,497

See accompanying notes.

Table of Contents

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017

Net sales	$	1,907		$	2,236		$	2,883		$	3,245
Cost of sales		836			1,127			1,504			2,254
Gross profit		1,071			1,109			1,379			991

Operating expenses:
Research and development, net of grants		2,422			1,949			4,895			3,796
Clinical and regulatory		1,126			684			2,475			1,298
Selling and marketing		2,879			2,447			5,891			4,682
General and administrative		2,632			2,901			5,875			5,642
Total operating expenses		9,059			7,981			19,136			15,418

Loss from operations		(7,988	)		(6,872	)		(17,757	)		(14,427	)
Interest income		27			29			43			36

Net loss	$	(7,961	)	$	(6,843	)	$	(17,714	)	$	(14,391	)

Net loss per common share – basic and diluted	$	(0.12	)	$	(0.12	)	$	(0.29	)	$	(0.28	)

Weighted average common shares outstanding – basic and diluted		64,418			56,513			61,750			51,380

See accompanying notes.

Table of Contents

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Condensed Consolidated Statements of Comprehensive Loss

(in thousands)

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017

Net loss	$	(7,961	)	$	(6,843	)	$	(17,714	)	$	(14,391	)

Other comprehensive income (loss):
Foreign currency translation adjustments		(77	)		92			(32	)		122
Comprehensive loss	$	(8,038	)	$	(6,751	)	$	(17,746	)	$	(14,269	)

See accompanying notes.

Table of Contents

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

(in thousands)

	Common Stock				Common Stock Issuable						Additional Paid-in		Notes Receivable for Stock Option			Accumulated Other Comprehensive			Accumulated			Total Stockholders’ Equity
	Shares		Amount		Shares			Amount			Capital		Exercises			Loss			Deficit
Balance, December 31, 2016		42,701	$	186,769		77		$	153		$	30,697	$	(2	)	$	(608	)	$	(205,861	)	$	11,148
Issuance of shares of common stock and warrants, net of issuance costs		13,653		13,647		—			—			6,021		—			—			—			19,668
Issuance of shares of common stock in connection with employee stock purchase plan		193		189		—			—			—		—			—			—			189
Fair value of stock options issued for services		—		—		—			—			20		—			—			—			20
Common stock issuance for services		223		262		(59	)		(132	)		—		—			—			—			130
Release of restricted stock units		24		—		—			—			—		—			—			—			—
Stock-based compensation expense		—		—		—			—			1,916		—			—			—			1,916
Repayment of notes receivable for stock option exercises		—		—		—			—			—		1			—			—			1

Net loss		—		—		—			—			—		—			—			(14,391	)		(14,391	)
Foreign currency translation adjustment		—		—		—			—			—		—			122			—			122

Balance, June 30, 2017		56,794	$	200,867		18		$	21		$	38,654	$	(1	)	$	(486	)	$	(220,252	)	$	18,803

	Common Stock				Common Stock Issuable						Additional Paid-in		Accumulated Other Comprehensive			Accumulated			Total Stockholders’ Equity
	Shares		Amount		Shares			Amount			Capital		Loss			Deficit
Balance, December 31, 2017		57,630	$	202,156		82		$	153		$	40,522	$	(572	)	$	(234,377	)	$	7,882
Issuance of shares of common stock, net of issuance costs		8,981		13,970		—			—			—		—			—			13,970
Issuance of common stock in connection with employee stock purchase plan		226		261		—			—			—		—			—			261
Common stock issued or issuable for services		133		262		(82	)		(153	)		—		—			—			109
Release of restricted stock units		24		—		—			—			—		—			—			—
Stock-based compensation expense		—		—		—			—			1,912		—			—			1,912
Exercise of common stock warrants		5		7		—			—			—		—			—			7
Exercise of common stock options		76		149		—			—			—		—			—			149

Net loss		—		—		—			—			—		—			(17,714	)		(17,714	)
Foreign currency translation adjustment		—		—		—			—			—		(32	)		—			(32	)
Balance, June 30, 2018		67,075	$	216,805		—		$	—		$	42,434	$	(604	)	$	(252,091	)	$	6,544

See accompanying notes.

Table of Contents

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Condensed Consolidated Statements of Cash Flows

(in thousands)

	Six Months Ended June 30,
	2018			2017
	(unaudited)
Cash flows from operating activities:
Net loss	$	(17,714	)	$	(14,391	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		222			229
Stock-based compensation		1,912			1,916
Bad debt recovery		—			(36	)
Inventory reserve		61			(1,456	)
Common stock issuance for services		109			130
Changes in operating assets and liabilities:
Accounts receivable		1,100			(704	)
Inventories		(947	)		1,887
Prepaid expenses and other assets		161			13
Accounts payable		471			(528	)
Accrued expenses		(344	)		206
Accrued compensation expenses		(162	)		224
Accrued clinical trial expenses		294			3
Contract liabilities		213			56
Deferred grant revenue		—			(104	)
Net cash used in operating activities		(14,624	)		(12,555	)

Cash flows from investing activities:
Purchases of property and equipment		(116	)		(151	)
Net cash used in investing activities		(116	)		(151	)

Cash flows from financing activities:
Net proceeds from rights offering		—			19,688
Net proceeds from sale of common stock		13,970			—
Proceeds from repayment of note receivable		—			1
Proceeds from exercise of options, warrants and employee stock purchase plan		417			189
Net cash provided by financing activities		14,387			19,878

Effect of exchange rate changes on cash and cash equivalents		(10	)		82
Cash and cash equivalents:
Net increase (decrease)		(363	)		7,254
Balance at beginning of period		7,839			10,875
Balance at end of period	$	7,476		$	18,129

Supplemental cash flow information:
Non-cash financing and investing activities:
Fair value of stock options issued for services	$	—		$	20

See accompanying notes.

Table of Contents

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Notes to Condensed Consolidated Financial Statements

(unaudited)

1. Organization and Business Operations

Second Sight Medical Products, Inc. (“Second Sight,” “we,” “us,” or “the Company”) was incorporated in the State of California in 2003. Second Sight develops, manufactures and markets implantable visual prosthetics to enable blind individuals to achieve greater independence.

In 2007, Second Sight formed Second Sight Medical Products (Switzerland) Sàrl, initially to manage clinical trials for its products in Europe, and later to manage sales and marketing in Europe and the Middle East. As the laws of Switzerland require at least two corporate stockholders, Second Sight Medical Products (Switzerland) Sàrl is 99.5% owned directly by us and 0.5% owned by an executive of Second Sight as of June 30, 2018. Accordingly, Second Sight Medical Products (Switzerland) Sàrl is considered 100% owned for financial statement purposes and is consolidated with Second Sight for all periods presented.

Our current product, the Argus II retinal prosthesis system (“Argus II”), entered clinical trials in 2006, received CE Mark approval for marketing and sales in the European Union (“EU”) in 2011, and approval by the United States Food and Drug Administration (“FDA”) for marketing and sales in the United States in 2013. We began selling the Argus II in Europe at the end of 2011, Saudi Arabia in 2012, the United States and Canada in 2014, Turkey in 2015, Iran, Taiwan, South Korea and Russia in 2017, and Singapore in 2018.

Going Concern

From inception, our operations have been funded primarily through the sales of our common stock and warrants, as well as from the issuance of convertible debt, research and clinical grants, and limited product revenue generated from the sale of our Argus II product. During 2016 and 2017 and the six months ended June 30, 2018, we funded our business primarily through:

	●	Issuance of common stock in our rights offering in June 2016, which provided net cash proceeds of $19.5 million.
	●	Issuance of common stock and warrants in our rights offering in March 2017, which provided net cash proceeds of $19.7 million.
	●	Issuance of common stock through our At Market Issuance Sales Agreement during the fourth quarter of 2017 and first quarter of 2018, which provided $5.1 million of net cash proceeds.

●

Issuance of common stock in a stock purchase agreement in May 2018, which provided net cash proceeds of $10.0 million.

●

Revenue of $2.9 million in the first six months of 2018, and $8.0 million and $4.0 million, for the year ended December 31, 2017 and 2016, respectively, generated by sales of our Argus II product.

We entered into a stock purchase agreement on May 3, 2018 with entities beneficially owned by Gregg Williams for the purchase of 6,756,757 shares of common stock priced at $1.48 per share, the last reported sale price of the common stock on that date. Gregg Williams is Chairman of the Board of Directors of Second Sight. This placement of common stock provided net proceeds of $10 million. No warrants or discounts were provided and no placement agent or investment banking fees were incurred in connection with this transaction. The shares issuable to the purchasers under the Securities Purchase Agreement were issued pursuant to an exemption from registration under Rule 506 of Regulation D, which is promulgated under the Securities Act of 1933. We relied on this exemption from registration based in part on representations made by the purchasers.

In November 2017, we entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley FBR Inc. and H.C. Wainwright & Co., LLC, as agents (“Agents”) pursuant to which we may offer and sell, from time to time through either of the Agents, shares of our common stock having an aggregate offering price as set forth in the Sales Agreement and a related prospectus supplement filed with the SEC. We agreed to pay the Agents a cash commission of 3.0% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. During January and February 2018, we sold 2.2 million shares of common stock which provided net proceeds of $4.0 million under the Sales Agreement. No shares have been sold since February 2018 under the Sales Agreement.

Our financial statements have been presented on the basis that our business is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We are subject to the risks and uncertainties associated with a business with one product line and limited commercial product revenues, including limitations on our operating capital resources and uncertain demand for our products. We have incurred recurring operating losses and negative operating cash flows since inception, and we expect to continue to incur operating losses and negative operating cash flows for the foreseeable future. Management has concluded that there is substantial doubt about our ability to continue as a going concern, and our independent registered public accounting firm, in its report on our 2017 consolidated financial statements, has raised substantial doubt about our ability to continue as a going concern.

We do not have sufficient funds to support our operations for the next 12 months from the date of issuance of these financial statements. We anticipate that we will seek to fund our operations through public or private equity or debt financings, grants, collaborations, strategic partnerships or other sources. However, we may be unable to raise additional capital or enter into such other arrangements when needed on favorable terms or at all. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidates, or we may be unable to expand our operations, maintain our current organization and employee base or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations.

Table of Contents

2. Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements

Basis of Presentation

These unaudited interim financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and following the requirements of the United States Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In our opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our financial position and our results of operations and cash flows for periods presented. Certain prior year amounts have been reclassified to conform to the current year presentation. These statements do not include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended December 31, 2017, contained in our Annual Report on Form 10-K filed with the SEC on March 20, 2018. The results of the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.

Significant Accounting Policies

Our significant accounting policies are set forth in Note 2 of the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2017.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. We adopted this ASU on January 1, 2018 retrospectively, the cumulative effect of the initial application on our accumulated deficit on that date was immaterial.

We generate our revenue from the sale of our Argus II retinal prosthesis systems, which include the implant and external components. Our product sales generally consist of the implant and related surgical supplies and may include a performance obligation related to post-surgical support.

We sell our products through two main sales channels: 1) directly to customers who use our products (the “Direct Channel”) and 2) to distribution partners who resell our products (the “Indirect Channel”).

Under the Direct Channel, we sell our systems to customers who use our products and we receive payment directly from customers who use our products. Under our Indirect Channel, we have entered into distribution agreements that allow the distributors to sell our systems and fulfill performance obligations for surgical support and post-surgical support.

We determine revenue recognition through the following steps:

•

Identification of the contract, or contracts, with a customer

•

Identification of the performance obligations in the contract

•

Determination of the transaction price

•

Allocation of the transaction price to the performance obligations in the contract

•

Recognition of revenue when, or as, we satisfy a performance obligation

Revenue is generally recognized upon surgical implant, unless we have a significant post-surgical support performance obligation. We recognize revenue when a material reversal is no longer probable. Conditions that preclude us from recognizing revenue generally involve new customers with no reimbursement or reimbursement history, and depends on third-party behavior beyond our control, uncertain payment cycles over an extended period of time, and our limited historical experience with these arrangements.

Management does not believe that any other recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

3. Concentration of Risk

Credit Risk

Financial instruments that subject us to concentrations of credit risk consist primarily of cash, money market funds, and trade accounts receivable. We maintain cash and money market funds with financial institutions that management deems reputable. We extend differing levels of credit to our customers, and typically do not require collateral.

Customer Concentration

The following tables provide information about disaggregated revenue by service type, customer and geographical market.

The following table shows our revenues by customer type during the three and six months ended June 30, 2018 and 2017:

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017

Direct customers	$	1,798	$	1,695	$	2,456	$	2,704

Distributors		109		541		427		541

Total	$	1,907	$	2,236	$	2,883	$	3,245

Table of Contents

During the three and six months ended June 30, 2018 and 2017, the following customers each comprises greater than 10% of our total revenues:

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017

Customer 1		15	%		11	%		15	%		11	%
Customer 2		12	%		—	%		8	%		—	%
Customer 3		7	%		—	%		10	%		—	%
Customer 4		6	%		10	%		8	%		7	%
Customer 5		—	%		14	%		3	%		9	%
Customer 6		—	%		13	%		2	%		9	%
Customer 7		—	%		12	%		7	%		12	%

As of June 30, 2018 and December 31, 2017, the following customers each comprises greater than 10% of our total accounts receivable:

	June 30, 2018			December 31, 2017
	(unaudited)
Customer 1		20	%		17	%
Customer 2		20	%		8	%
Customer 3		19	%		—	%
Customer 4		16	%		—	%
Customer 5		12	%		—	%
Customer 6		12	%		—	%
Customer 7		—	%		16	%
Customer 8		—	%		11	%

Geographic Concentration

During the three and six months ended June 30, 2018 and 2017, regional revenue based on customer locations which each comprises greater than 10% of our total revenues, consist of the following:

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017

United States		56	%		50	%		55	%		52	%
France		19	%		11	%		13	%		10	%
Italy		15	%		11	%		15	%		11	%
Korea		6	%		10	%		8	%		7	%
Taiwan		—	%		14	%		3	%		9	%

Foreign Operations

The accompanying condensed consolidated financial statements as of June 30, 2018 and December 31, 2017 include assets amounting to $2.2 million and $2.7 million, respectively, relating to operations of our subsidiary based in Switzerland. It is possible that unanticipated events in foreign countries could disrupt our operations.

Table of Contents

4. Fair Value Measurements

The authoritative guidance with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.

Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.

Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.

Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.

Cash equivalents which includes money market funds are the only financial instrument measured and recorded at fair value on our consolidated balance sheet, and they are valued using Level 1 inputs.

Assets measured at fair value on a recurring basis are as follows (in thousands):

	Total		Level 1		Level 2		Level 3

June 30, 2018 (unaudited):
Money market funds	$	7,379	$	7,379	$	—	$	—

December 31, 2017:
Money market funds	$	7,235	$	7,235	$	—	$	—

5. Selected Balance Sheet Detail

Inventories, net

Inventories consist of the following (in thousands):

	June 30,			December 31,
	2018			2017
	(unaudited)
Raw materials	$	643		$	485
Work in process		2,137			2,620
Finished goods		2,913			1,660

		5,693			4,765

Allowance for excess and obsolete inventory		(2,126	)		(2,065	)
Inventories, net	$	3,567		$	2,700

Table of Contents

Property and equipment

Property and equipment consist of the following (in thousands):

	June 30,			December 31,
	2018			2017
	(unaudited)
Laboratory equipment	$	2,468		$	2,450
Computer hardware and software		1,423			1,329
Leasehold improvements		298			298
Furniture, fixtures and equipment		46			46

		4,235			4,123

Accumulated depreciation and amortization		(3,044	)		(2,824	)

Property and equipment, net	$	1,191		$	1,299

Contract Liabilities

Contract liabilities consist of the following (in thousands):

Beginning balance, December 31, 2017	$	48
Consideration received in advance of revenue recognition		233
Revenue recognized		(21	)
Ending Balance, June 30, 2018	$	260

6. Equity Securities

Common Stock Issuable

Non-employee members of our Board of Directors have been paid for their services in common stock on June 1 of each year based on the average closing prices for the immediately preceding twenty trading days. During the six months ended June 30, 2018, we issued a total of 132,996 shares of common stock for annual service through May 31, 2018 to the board members. Our Director Compensation Policy was amended in December 2017 and board members may elect to receive compensation in cash or stock options, effective with the annual period commencing June 1, 2018.

Potentially Dilutive Common Stock Equivalents

As of June 30, 2018 and 2017, we excluded the potentially dilutive securities summarized below, which entitle the holders thereof to potentially acquire shares of common stock, from our calculations of net loss per share and weighted average common shares outstanding, as their effect would have been anti-dilutive (in thousands).

	June 30,
	2018		2017

Common stock warrants issued to underwriter of initial public offering		802		802
Common stock warrants issued in connection with convertible debt		—		1,038
Common stock warrants issued in connection with March 2017 rights offering		13,647		13,652
Common stock options		7,072		5,536
Common stock issuable		—		18
Restricted stock units		59		107
Employee stock purchase plan		234		222

Total		21,814		21,375

Table of Contents

7. Warrants

A summary of warrants activity for the six months ended June 30, 2018 is presented below (in thousands, except per share and contractual life data).

						Weighted Average
				Weighted		Remaining
	Number of			Average		Contractual
	Shares			Exercise Price		Life (in Years)
Warrants outstanding as of December 31, 2017		15,130		$	2.15		3.90
Issued		—
Exercised		(5	)		1.47
Forfeited or expired		(676	)		5.00

Warrants outstanding as of June 30, 2018		14,449		$	2.01		3.60

Warrants exercisable as of June 30, 2018		14,449		$	2.01		3.60

The intrinsic value of warrants outstanding as of June 30, 2018 was $2.6 million.

8. Stock-Based Compensation

A summary of stock option activity under our 2011 Equity Incentive Plan (“2011 Plan”) for the six months ended June 30, 2018 is presented below (in thousands, except per share and contractual life data).

						Weighted Average
				Weighted		Remaining
	Number of			Average		Contractual
	Shares			Exercise Price		Life (in Years)
Options outstanding as of December 31, 2017		5,675		$	4.87		7.40
Granted		2,465		$	2.00
Exercised		(76	)	$	1.95
Forfeited or expired		(992	)	$	3.98

Options outstanding as of June 30, 2018		7,072		$	4.03		6.97

Options exercisable as of June 30, 2018		2,766		$	6.17		4.40

The estimated aggregate intrinsic value of stock options exercisable as of June 30, 2018 was $8,000. As of June 30, 2018, there was $5.0 million of total unrecognized compensation cost related to outstanding stock options that will be recognized over a weighted average period of 2.9 years.

During the six months ended June, 2018, we granted stock options to purchase 2,464,872 shares of common stock to certain employees and a contractor. The options are exercisable for a period of ten years from the date of grant at prices ranging from $1.80 to $2.07 per share, which was the fair value of our common stock on the respective grant dates. The options generally vest over a period of four years. The fair value of these options, calculated using the Black-Scholes option-pricing model, was determined to be $3.1 million ($1.09 to $1.30 per share) using the following assumptions: expected term of 5.50 to 6.11 years, volatility of 67.0%, risk-free interest rate of 2.32% to 3.00%, and expected dividend rate of 0%.

During the six months ended June 30, 2018, we recorded $0.4 million of stock-based compensation expense related to stock option modifications for executive transitions.

Table of Contents

The following table summarizes restricted stock unit (“RSU”) activity for the six months ended June 30, 2018 (in thousands, except per share data):

	Number of Shares			Weighted Average Grant Date Fair Value Per Share

Outstanding as of December 31, 2017		83		$	12.43
Awarded		—			—
Vested		(24	)		—
Forfeited/canceled		—			—
Outstanding as of June 30, 2018		59		$	12.43

As of June 30, 2018, there was $0.7 million of total unrecognized compensation cost related to the outstanding RSUs that will be recognized over a weighted average period of 1.1 years.

We adopted an employee stock purchase plan in June, 2015 for all eligible employees. At June 30, 2018 the maximum number of shares that may be issued under the plan is 1,550,000. During the six months ended June 30, 2018, 225,887 shares were issued under the stock purchase plan.

Stock-based compensation expense recognized for stock-based awards in the condensed consolidated statements of operations for the three and six months ended June 30, 2018 and 2017 is as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017

Cost of sales	$	63	$	67	$	127	$	148
Research and development		107		75		211		132
Clinical and regulatory		11		44		103		93
Selling and marketing		92		112		215		206
General and administrative		354		637		1,256		1,337
Total	$	627	$	935	$	1,912	$	1,916

9. Litigation, Claims and Assessments

Twenty-two oppositions have been filed by third-parties in the European Patent Office each challenging the validity of a European patent owned or exclusively licensed by us. The outcome of the challenges is not certain. However, if successful, they may affect our ability to block competitors from utilizing some of our patented technology in Europe. We do not believe a successful challenge will have a material effect on our ability to manufacture and sell our products, or otherwise have a material effect on our operations.

We are party to litigation arising in the ordinary course of business. It is our opinion that the outcome of such matters will not have a material effect on our results of operations.

Table of Contents

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q as well as our audited 2017 financial statements and related notes included in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission (“SEC”) on March 20, 2018. In addition to historical information, the discussion and analysis here and throughout this Form 10-Q contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited, to those set forth under “Risk Factors” in Part II, Item 1A of this report.

Second Sight was founded in 1998 with a mission to develop, manufacture, and market prosthetic devices that are intended to create an artificial form of useful vision for blind individuals. Our principal offices are located in Los Angeles, California. We also have an office in Lausanne, Switzerland that manages our commercial operations and supports clinical activities in Europe, the Middle East, and Asia-Pacific.

Our current product, the Argus ^®II system (“Argus II”), treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. RP is a hereditary disease, affecting an estimated 1.5 million people worldwide including about 100,000 people in the United States, that causes a progressive degeneration of the light-sensitive cells of the retina, leading to significant visual impairment and ultimately blindness. The Argus II is the only retinal prosthesis approved in the United States by the Food and Drug Administration (“FDA”), and was the first approved retinal prosthesis in the world. By creating an artificial form of useful vision in patients who otherwise have total sight loss, the Argus II can provide benefits that include:

●

restoring independence through a renewed ability to navigate independently in unfamiliar environments;

●

improving patients’ orientation and mobility, such as locating doors and windows, avoiding obstacles, and following the lines of a crosswalk;

●

allowing patients to feel more connected with people in their surroundings, such as seeing when someone is approaching or moving away;

●

providing patients with enjoyment from being “visual” again, such as locating the moon, tracking groups of players as they move around a field, and watching the moving streams of lights from fireworks;

●

enabling some patients to re-enter the workforce through multiple vocations that become possible because of Argus II; and

●

improving patients’ well-being and ability to perform activities of daily living.

The Argus II system provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and there is no clear evidence that it can slow or reverse the progression of the disease. The majority of patients receive a significant benefit from the Argus II, however results can vary and some patients report receiving little or no benefit.

Our major corporate, clinical and regulatory milestones include:

●

In 1998, Second Sight was founded.

●

In 2002, we commenced clinical trials in the U.S. for our prototype product, the Argus I retinal prosthesis.

●

In 2007, we commenced clinical trials in the U.S. for the Argus II, which later became our first commercial product.

●

In 2011, we received marketing approval in Europe (CE Mark) for the Argus II.

●

In 2013, we received marketing approval from the FDA in the U.S. for the Argus II.

●

In 2014, we launched the Argus II in the U.S., completed our initial public offering (“IPO”), and began trading on NASDAQ under the symbol “EYES.”

●

In January 2016, we successfully implanted and activated a wireless cortical visual prosthesis in a human.

●

In November 2017, the FDA granted Expedited Access Pathway Designation for the Orion.

●

In the first quarter of 2018, first-in-human Orion was successfully implanted, activated and tested at the Ronald Reagan UCLA Medical Center (“UCLA”).

Currently, we have approximately 130 employees involved in the development (research, engineering and clinical), manufacture, and commercialization of the Argus II system and future products.

Table of Contents

Going Concern

From inception, our operations have been funded primarily through the sales of our common stock and warrants, as well as from the issuance of convertible debt, research and clinical grants, and limited product revenue generated by the sale of our Argus II System. During 2016 and 2017 and the six months ended June 30, 2018, we funded our business primarily through:

	●	Issuance of common stock in our rights offering in June 2016, which provided net cash proceeds of $19.5 million.
	●	Issuance of common stock and warrants in our rights offering in March 2017, which provided net cash proceeds of $19.7 million.

	●	Issuance of common stock through our At Market Issuance Sales Agreement during the fourth quarter of 2017 and first quarter of 2018, which has provided $5.1 million of net cash proceeds.
	●	Issuance of common stock in a stock purchase agreement in May 2018, which provided net proceeds of $10.0 million.

●

Revenue of $2.9 million in the first six months of 2018, and $8.0 million and $4.0 million, for the year ended December 31, 2017 and 2016, respectively, generated by sales of our Argus II product.

In November 2017, we entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley FBR Inc. and H.C. Wainwright & Co., LLC, as agents (“Agents”) pursuant to which we may offer and sell, from time to time through either of the Agents, shares of our common stock having an aggregate offering price as set forth in the Sales Agreement and a related prospectus supplement filed with the SEC. We agreed to pay the Agents a cash commission of 3.0% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. During January and February 2018, we sold 2.2 million shares of common stock for additional net proceeds of $4.0 million under the Sales Agreement. No shares have been sold since February 2018 under the Sales Agreement. We are utilizing these proceeds to further develop and enhance our products, support operations and for general corporate purposes.

Table of Contents

Insurance Reimbursement

Obtaining reimbursement from governmental and private insurance companies is critical to our commercial success. Due to the price of the Argus II system, our sales would be limited without the availability of third party reimbursement. In the U.S., coding, coverage, and payment are necessary for the surgical procedure and Argus II system to be reimbursed by payers. Coding has been established for the device and the surgical procedure. Coverage and payment vary by payer. The majority of Argus II patients are eligible for Medicare, and coverage is primarily provided through traditional Medicare, sometimes referred to as Medicare Fee-for-Service (“FFS”) or Medicare Advantage. A small percentage of patients are covered by commercial insurers.

●

Medicare FFS patients – Coverage is determined by Medicare Administrative Contractors (“MACs”) that administer various geographic regions of the U.S. The Argus II is authorized for coverage, when medically necessary in eight of 12 MAC jurisdictions (comprising 31 states). Effective January 1, 2018, the Centers for Medicare and Medicaid Services (“CMS”) established a 2018 national average payment rate of $122,500 for both the procedure and the Argus II retinal prosthesis system when furnished in a hospital outpatient department. On July 25, 2018 the Centers for Medicare and Medicaid Services (CMS) posted the proposed rule and related proposed rates for the calendar year (CY) 2019. Medicare Hospital Outpatient Prospective Payment Systems (OPPS) and the CY 2019 Ambulatory Surgical Center (ASC) payment system. In these postings, CMS proposes a national average Medicare hospital outpatient rate for CY 2019 of $137,501 for Argus II and the associated surgical implantation procedure, and a proposed national average ASC rate of approximately $134,225 for the Argus II and related implantation procedure. The CY 2019 final rule and CY 2019 final rates are expected to be released in November 2018.

●

Medicare Advantage patients – Medicare Advantage plans are required to cover the same benefits as those covered by the MAC in that jurisdiction. For example, if a MAC in a jurisdiction has favorable coverage for the Argus II, then all Medicare Advantage plans in that MAC jurisdiction are required to offer the same coverage for the Argus II. Individual hospitals and ASCs may negotiate contracts specific to that individual facility, which may include additional separate payment for the Argus II implant system. In addition, procedural payment is variable and can be based on a percentage of billed charges, payment groupings or other individually negotiated payment methodologies. Medicare Advantage plans may allow providers to confirm coverage and payment for the Argus II procedure in advance of implantation. Since 2015 a large majority of all Medicare Advantage pre-authorization requests for Argus II procedures were granted.

●

Commercial insurer patients – Commercial insurance plans make coverage and payment rate decisions independent of Medicare, and contracts are individually negotiated with facility and physician providers.

We retain employees and utilize consultants with insurance reimbursement expertise dedicated to expand and enhance coverage decisions. Currently, eight of 12 Medicare jurisdictions authorize coverage of the Argus II in 31 states, two territories and the District of Columbia when medically necessary, including:

● CGS (J15 -- Ohio and Kentucky),

● Palmetto GBA (JM -- Virginia, (excluding Part B for Arlington and Fairfax counties), West Virginia, North Carolina and South Carolina),

● Palmetto GBA (JJ – Alabama, Georgia and Tennessee),

● NGS (J6 -- Minnesota, Illinois and Wisconsin),

● NGS (JK -- Connecticut, New York, Maine, Massachusetts, New Hampshire, Rhode Island and Vermont),

● FCSO (JN -- Florida, Puerto Rico and the U.S. Virgin Islands),

● Novitas (JH-- Arkansas, Colorado, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas) and

● Novitas (JL -- Delaware, District of Columbia, Maryland, New Jersey and Pennsylvania)

We are actively engaged with the remaining MACs and are committed to supporting their requests for additional information and clinical evidence. We expect that additional positive coverage decisions will be issued over time but cannot predict timing or ultimate success with each MAC.

Within Europe, we have obtained reimbursement approval or funding in Germany, France, one region of Italy, and a Commissioning through Evaluation (CtE) program in England.

We are seeking additional reimbursement approvals in other countries in Europe and international markets.

Table of Contents

In France, we were selected to receive the first “Forfait Innovation” (Innovation Bundle) from the Ministry of Health, which is a special funding program for breakthrough procedures to be introduced into clinical practice. As part of this program, we are conducting a post-market study in France which has enrolled a total of 18 subjects who are being followed for two years. The French program also funds implantation of up to 18 additional patients that are not part of the post-market study. After review of the study’s results, we expect Argus II therapy to be covered and funded through the standard payment system in France. However, we can provide no assurance that the French government will continue to fund the Argus II after the first 36 implants.

In December 2016, NHS England announced it would cover 10 Argus implantations as part of a CtE program. The CtE program is especially designed for treatments that show significant promise for the future, while new clinical and patient experience data are collected within a formal evaluation program. This program is similar to the Forfait Innovation program in France. NHS England is known to be under significant financial pressure and also highly selective in adopting innovative technologies – which must demonstrate sufficient value for the cost expended. This program is progressing slower than expected and we now believe implants under this program will not begin until late 2018 or early 2019.

To date, our marketing activities have focused on raising awareness of the Argus II with potential patients, implanting physicians, and referring physicians. Our marketing activities include exhibiting, sponsoring symposia, and securing podium presence at professional and trade shows, securing journalist coverage in popular and trade media, attending patient meetings focused on educating patients about existing and future treatments, and sponsoring information sessions for the Argus II. In the United States, our efforts will focus on media advertisements dedicated to RP patients and their families. These advertisements will be placed in geographic areas where we have Centers of Excellence committed to Argus II.

Product and Clinical Development Plans

The Argus II is currently approved for RP patients with bare or no light perception in the US, and in Europe for severe to profound vision loss due to outer retinal degeneration, such as from RP, choroideremia, and other similar conditions. The number of people who are legally blind due to RP is estimated to be about 25,000 in the US, 42,000 in Europe, and about 375,000 total worldwide. A subset of these patients would be eligible for the Argus II since the approved baseline vision for the Argus II is worse than legally blind (20/200). We commissioned 3^rd party market research for the size of the RP market that resulted in an estimate of approximately 1,500 patients in the U.S. with advanced RP that could be treated with the Argus II given the eligibility criteria of our label.

We believe an opportunity exists to expand the use of our Argus II technology to better sighted individuals with RP who are currently not being treated. To achieve this market expansion, we have taken steps to request US label expansion with FDA and endeavor to improve the technology’s performance, including:

●

Clinical trials with better-vision individuals;

●

Development of advanced retina stimulation techniques that we believe can improve the quality or usefulness of the vision provided by Argus II;

●

Redesigns of the externals (glasses, camera, and video processing unit) that will provide a next-generation platform capable of supporting the commercial implementation of improved image processing capabilities and advanced retina stimulation techniques in late 2018 or 2019.

We believe that we can further expand our market to include nearly all profoundly blind individuals, other than those who are blind due to preventable diseases or due to brain damage, by developing a visual cortical prosthesis. We refer to this product as the Orion visual prosthesis system. We estimate that there are approximately 5.8 million people worldwide who are legally blind due to causes other than preventable conditions, RP or AMD. We commissioned 3^rd party market research for the potential market for Orion that resulted in initial estimates of over 500,000 individuals in the U.S. who are legally blind due to Glaucoma, Diabetic Retinopathy, Optic Nerve Disease and Eye Trauma and a potential U.S. addressable market of more than 70,000 individuals from this population with vision defined as bare light or no light perception. If approved for marketing, the FDA and other regulatory agencies will determine the subset of these patients who are eligible for the Orion.

Our objective in designing and developing the Orion visual prosthesis system is to bypass the optic nerve and directly stimulate the part of the brain responsible for vision. We submitted an IDE application to the FDA in 2017 to begin a human feasibility study of the Orion^TM visual prosthesis system. Enrollment began for this study in January 2018 and, to date, the five planned subjects have been implanted and had their devices activated; four at UCLA and one at the Baylor College of Medicine (“Baylor”). In addition, during the second quarter of 2018, we submitted and received approval from the FDA to enroll a sixth subject. We are screening for the sixth subject at Baylor. This study will confirm initial findings in our human pilot study we announced in the fourth quarter of 2016 and provide the first human data of a fully functional wireless visual cortical stimulator system including the external video camera system. This initial study in a small number of subjects, if successful, should also form the basis for an expansion to our next clinical trial in 2019.

Table of Contents

Critical Accounting Policies

The preparation of our condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States (“GAAP”) and the requirements of the United States Securities and Exchange Commission requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2017.

We determine revenue recognition through the following steps:

	●	Identification of the contract, or contracts, with a customer

	●	Identification of the performance obligations in the contract

	●	Determination of the transaction price

	●	Allocation of the transaction price to the performance obligations in the contract

	●	Recognition of revenue when, or as, we satisfy a performance obligation

There have been no other material changes to our critical accounting policies during the six months ended June 30, 2018.

Table of Contents

Results of Operations

Net sales. Our net sales are derived primarily from the sale of our Argus II product. We began selling the Argus II in Europe at the end of 2011, Saudi Arabia in 2012, the United States and Canada in 2014, Turkey in 2015, Iran, Taiwan, South Korea and Russia in 2017, and Singapore in 2018. Our objective is to increase our product revenue over the next several years as we pursue commercialization of our product, as our product becomes more well-known and accepted in the market, and as insurance coverage becomes more widespread.

Cost of sales. Cost of sales includes the salaries, benefits, material, overhead, third party costs, warranty, charges for excess and obsolete inventory, and other costs required to make our Argus II system at our Los Angeles, California facility. Our product involves technologically complex materials and processes. While we are currently experiencing low yields on our manufacturing process, we expect that over the next few years we will be able to refine our processes and improve our manufacturing yields. We are also producing at less than our capacity which results in unabsorbed overhead costs. In future years, we expect to produce in greater quantities and improve our manufacturing yields and we expect that we will more consistently generate positive gross margins. We record cost of sales when products are implanted, which may differ from the period we are able to record revenue. Such timing differences may cause our reported results of operations to be difficult to compare from period to period.

Operating Expenses. We generally recognize our operating expenses as we incur them in four general operational categories: research and development, clinical and regulatory, sales and marketing, and general and administrative. Our operating expenses also include a non-cash component related to the amortization of stock-based compensation for research and development, clinical and regulatory, sales and marketing and general and administrative personnel. From time-to-time we have received grants from institutions or agencies, such as the National Institutes of Health, to help fund the some of the cost of our development efforts. We have recorded these grants as reductions to operating expenses.

●

Research and development expenses consist primarily of employee compensation and consulting costs related to the design, development, and enhancements of our current and potential future products, offset by grant revenue received in support of specific research projects. We expense our research and development costs as they are incurred. We expect research and development expenses to increase in the future as we pursue further enhancements of our existing product and develop technology for our potential future products, such as the Orion visual cortical prosthesis. We also expect to receive additional grants in the future that will be offset primarily against research and development costs.

●

Clinical and regulatory expenses consist primarily of salaries, travel and related expenses for personnel engaged in clinical and regulatory functions, as well as internal and external costs associated with conducting clinical trials and maintaining relationships with regulatory agencies. We expect clinical and regulatory expenses to increase as we assess the safety and efficacy of enhancements to our current Argus II, seek to expand the indications for the Argus II, and prepare to initiate clinical studies of potential future products such as the Orion visual cortical prosthesis.

●

Sales and marketing expenses consist primarily of salaries, commissions, travel and related expenses for personnel engaged in sales, marketing and business development functions, as well as costs associated with promotional and other marketing activities including the cost of units consumed as demos or samples. We expect sales and marketing expenses to increase as we hire additional sales personnel, initiate additional marketing programs, develop relationships with new distributors, and expand the number of doctors and medical centers that buy and implant our Argus II product and any future products.

●

General and administrative expenses consist primarily of salaries and related expenses for executive, legal, finance, human resources, information technology and administrative personnel, as well as recruiting and professional fees, patent filing and annuity costs, insurance costs and other general corporate expenses, including rent. We expect general and administrative expenses to increase as we add personnel and incur additional costs related to the growth of our business and operate as a public company.

Comparison of the Three Months Ended June 30, 2018 and 2017

We implanted a total of 17 Argus II products during the second quarter of 2018 and 19 in the second quarter of 2017. Of these, eight implants were in Europe, the Middle East and Asia (EMEA) in the second quarter of 2018 and ten implants were in EMEA in the second quarter of 2017.

In North America, there were nine implants in the second quarter of 2018 which equaled the nine implants in the second quarter of the prior year. Of these, there were seven implants in the U.S. and two implants in Canada in the second quarter of 2017 as compared to eight implants in the U.S. and one implant in Canada in the second quarter of 2018.

Table of Contents

Net Sales. Net sales were $1.9 million in the second quarter of 2018 as compared to $2.2 million in same period in 2017, a reduction of $0.3 million or 14%. Revenue was recognized for 17 units in the current period while revenue from 20 units was recognized in the prior year quarter. Revenue recognized per implant was approximately $112,000 in the second quarter of 2018 and 2017. We expect our average revenue recognized per implant unit sold for the remainder of 2018 to be in a range of $100,000 to $120,000, depending on the geographic mix of implants.

Cost of sales. Cost of sales decreased by approximately $0.3 million, or 27%, from $1.1 million in the second quarter 2017 to $0.8 million in the second quarter of 2018. Cost of sales in the second quarter of 2018 consists primarily of the cost of products implanted in the quarter of $0.6 million and an increase in the reserve for excess inventory of $0.2 million. In the second quarter of 2017, the cost of sales included approximately $1.8 million for the cost of products implanted less an adjustment of $0.7 million for a reduction in the reserve for excess inventory. We expect cost of goods on a per-unit basis to stabilize, particularly related to overhead absorption and excess inventory reserve, as we produce more units.

Research and development expense. Research and development expense, net of funding received from grants, increased by $0.5 million, or 26%, from $1.9 million in the second quarter of 2017 to $2.4 million in the second quarter of 2018. The increase from the prior year was primarily due to increased headcount, outside services, and costs for internally produced prototypes for next generation products. In the second quarter of 2018, we utilized $0.1 million of grant funds to offset costs compared to $24,000 in the same quarter of the prior year. Excluding the effect of grants, research and development expense increased by $0.6 million in the current year quarter, primarily due to an increase in expenditures related to next generation products.

Clinical and regulatory expense. Clinical and regulatory expense increased $0.4 million, or 57%, from $0.7 million in the second quarter of 2017 to $1.1 million in the second quarter of 2018. This increase is primarily attributable to increased costs associated with the Orion feasibility study. We expect clinical and regulatory costs to increase in the future as we (i) increase our implant run rate and enroll more patients in post market clinical studies for regulatory authorities, and (ii) conduct additional clinical trials to assess new products such as the Orion I, enhancements to our existing product and for better sighted patients.

Selling and marketing expense. Selling and marketing expense increased $0.5 million, or 21%, from $2.4 million in the second quarter of 2017 to $2.9 million in the second quarter of 2018. This increase in costs was primarily the result of a $0.2 million increase due to increased market development activities, $0.2 million increase in costs related to additional travel costs, and $0.1 million increase in headcount and related compensation expenses. While we expect these costs to increase in the future as we increase our selling and marketing resources to accelerate the commercialization of our product, we expect selling and marketing expense to decrease over time when expressed as a percentage of product revenue.

General and administrative expense. General and administrative expense decreased $0.3 million, or 10%, from $2.9 million in the second quarter of 2017 to $2.6 million in the same period of 2018. This decrease is primarily attributable to $0.1 million in lower compensation costs due to cancelled stock option grants. The remaining decrease relates to decreased outside service costs.

On April 25, 2018, we entered into a Confidential Separation Agreement and General Release (the “Separation Agreement”) with Dr. Robert J. Greenberg, a former executive and director of the Company. Pursuant to the terms of the Separation Agreement, the Company agreed to pay Dr. Greenberg, as severance, a gross amount of $0.4 million and to extend the exercise period of certain vested options until the earlier of (i) ten years from the applicable option grant date or (ii) October 3, 2019. This extension resulted in a charge of $0.1 million in the second quarter of 2018.

Table of Contents

Comparison of the Six Months Ended June 30, 2018 and 2017

We implanted a total of 33 Argus II products during the first six months of 2018 and 2017. Of these, 14 implants were in EMEA in the first six months of 2018 as compared 16 in the first six months of 2017.

In North America, there were 19 implants in the first six months of 2018 compared to 17 implants in the first six months of the prior year. Of these, there were 12 implants in the U.S. and five implants in Canada in the first six months of 2017 compared to 17 in the U.S. and two in Canada in the first six months of 2018.

Net Sales. Net sales were $2.9 million in the first six months of 2018 as compared to $3.2 million in 2017 a reduction of $0.3 million or 9%. Revenue was recognized for 26 units in the first six months of 2018 as compared to 29 units in the first six months of 2017. Revenue recognized per implant was approximately $111,000 in the first half of 2018 as compared to approximately $112,000 in the first half of 2017. We expect our average revenue recognized per implant unit sold for the remainder of 2018 to be in a range of $100,000 to $120,000, depending on the geographic mix of implants.

Cost of sales. Cost of sales decreased by approximately $0.8 million, or 35%, from $2.3 million in the first six months 2017 to $1.5 million in the first six months of 2018. Cost of sales in the first six months of 2018 consists primarily of the cost of products implanted in the period of $1.4 million and an increase in the reserve for excess inventory of $0.1 million. In the first six months of 2017, the cost of sales included approximately $3.7 million for the cost of products implanted less an adjustment of $1.4 million for a reduction in the reserve for excess inventory. We expect cost of goods on a per-unit basis to stabilize, particularly related to overhead absorption and excess inventory reserve, as we produce more units.

Research and development expense. Research and development expense, net of funding received from grants, increased by $1.1 million, or 29%, from $3.8 million in the first six months of 2017 to $4.9 million in the first six months of 2018. The increase from the prior year was primarily due to increased headcount, outside services, costs for internally produced prototypes for next generation products. In the first six months of 2018 and 2017, we utilized $0.1 million of grant funds to offset costs. Excluding the effect of grants, research and development expense increased by $1.2 million in the current year period, primarily due to an increase in expenditures related to next generation products.

Clinical and regulatory expense. Clinical and regulatory expense increased $1.2 million, or 92%, from $1.3 million in the first six months of 2017 to $2.5 million in the first six months of 2018. This increase is primarily attributable to increased costs associated with the Orion feasibility study. We expect clinical and regulatory costs to increase in the future as we (i) increase our implant run rate and enroll more patients in post market clinical studies for regulatory authorities, and (ii) conduct additional clinical trials to assess new products such as the Orion I, enhancements to our existing product and for better sighted patients.

Selling and marketing expense. Selling and marketing expense increased $1.2 million, or 26%, from $4.7 million in the first six months of 2017 to $5.9 million in the first six months of 2018. This increase in costs was primarily the result of a $0.5 million increase due to increased market development activities, increased headcount and related $0.4 million increase in compensation expense, and a $0.3 million increase in costs related to additional travel costs. While we expect these costs to increase in the future as we increase our selling and marketing resources to accelerate the commercialization of our product, we expect selling and marketing expense to decrease over time when expressed as a percentage of product revenue.

General and administrative expense. General and administrative expense increased $0.3 million, or 5%, from $5.6 million in the first six months of 2017 to $5.9 million in the same period of 2018. This increase is primarily attributable to $0.2 million in higher compensation costs. The remaining increase relates to increased travel costs.

Table of Contents

Liquidity and Capital Resources

Our consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring operating losses and negative operating cash flows since inception, and have financed our working capital requirements through the recurring sale of our equity securities in both public and private offerings. As a result, our independent registered public accounting firm, in its report on our 2017 consolidated financial statements, has raised substantial doubt about our ability to continue as a going concern (see “Going Concern” above).

In March 2017, we successfully completed a rights offering to existing shareholders, raising proceeds of approximately $19.7 million net of offering costs, through the sale of 13,652,341 units at $1.47 per unit. Each unit consisted of a share of common stock and a five-year warrant with an exercise price of $1.47.

During the first three months of 2018, we issued 2,224,000 shares of common stock for net proceeds of approximately $4.0 million as part of our At Market Issuance Sales Agreement (“Sales Agreement”) with two separate investment banks.

We entered into a stock purchase agreement on May 3, 2018 with entities beneficially owned by Gregg Williams for the purchase of 6,756,757 shares of common stock priced at $1.48 per share, the last reported sale price of the common stock on that date. Gregg Williams is Chairman of the Board of Directors of Second Sight. This placement of common stock provided net proceeds of approximately $10 million. No warrants or discounts were provided and no placement agent or investment banking fees were incurred in connection with this transaction. The shares issuable to the purchasers under the Securities Purchase Agreement were issued pursuant to an exemption from registration under Rule 506 of Regulation D, which is promulgated under the Securities Act of 1933. We relied on this exemption from registration based in part on representations made by the purchasers

We do not have sufficient funds to support our operations for the next 12 months from the date of issuance of these financial statements. In order to continue business operations past that point, we will need to raise additional debt and/or equity capital. However, there can be no assurances that we will be able to secure any such additional financing on acceptable terms and conditions, or at all. If cash resources become insufficient to satisfy our ongoing cash requirements, then we would be required to scale back or discontinue our technology and product development programs and/or clinical trials, or obtain funds, if available (although there can be no certainty), through strategic alliances that may require us to relinquish rights to our products, or to discontinue our operations entirely.

Cash and cash equivalents decreased by $0.3 million, or 4%, from $7.8 million as of December 31, 2017 to $7.5 million as of June 30, 2018. Working capital was $5.3 million as of June 30, 2018, as compared to $6.6 million as of December 31, 2017, a decrease of $1.3 million, or 20%. We use our cash, money market funds and working capital to fund our operating activities.

Cash Flows from Operating Activities

During the first six months of 2018, we used $14.6 million of cash in operating activities, consisting primarily of a net loss of $17.7 million, offset by non-cash charges of $2.3 million for depreciation and amortization of property and equipment, stock-based compensation, excess inventory reserve and common stock issuable and increased by a net change in operating assets and liabilities of $0.8 million. During the first six months of 2017, we used $12.6 million of cash in operating activities, consisting primarily of a net loss of $14.4 million, offset by non-cash charges of $0.8 million for depreciation and amortization of property and equipment, stock-based compensation, excess inventory reserve, bad debt expense and common stock issuable and cash increased by a net change in operating assets and liabilities of $1.0 million.

Table of Contents

Cash Flows from Investing Activities

Cash used for investing activities in the first six months of 2018 was $0.1 million and was $0.2 million in the first six months of 2017 primarily for the purchase of property and equipment.

Cash Flows from Financing Activities

Financing activities provided $14.4 million of cash in the first six months of 2018, $14.0 million from proceeds of common stock sold during the period and the remainder from the proceeds from exercise of warrants, options and employee stock plan purchases. Financing activities provided $19.9 million of cash in the first six months of 2017, $19.7 million from the rights offering with the remainder from employee stock plan purchases.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Interest Rate Sensitivity

The primary objective of our investment activities is to maintain the safety of principal and preserve liquidity without incurring significant risk. We invest cash in excess of our current needs in money market funds. As of June 30, 2018, our investments consisted solely of money market funds.

Exchange Rate Sensitivity

During the six months ended June 30, 2018, approximately 66% of our revenue was denominated in U.S. dollars, 34% in Euros and the majority of our operating expenses were denominated in U.S. dollars. We have not entered into foreign currency forward contracts to hedge our operating expense exposure to foreign currencies, but we may do so in the future.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, including our Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”), evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2018. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. As of June 30, 2018, based on the evaluation of these disclosure controls and procedures, our CEO and CFO have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

Table of Contents

Remediation Plan

We identified control deficiencies which constituted material weaknesses in our internal control over financial reporting as noted in our Annual Report on Form 10-K for the year ended December 31, 2017.

In response to the identified weaknesses in our internal control over financial reporting, we continue to remediate the deficiencies that were identified as well as enhance our internal control policies and procedures. We plan to evaluate and test our internal control policies and procedures through the use of internal and external resources, to support management conclusions regarding the effectiveness of our internal controls for the year ended December 31, 2018.

Our CEO and CFO, along with other key members of management, are and will be active participants in the remediation process plan. We believe the steps taken to date have improved the effectiveness of our internal control over financial reporting.

In addition, we have implemented new disclosure controls and procedures with key members of management for the three month period ended June 30, 2018.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting during the quarter ended June 30, 2018 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Our CFO is involved in the operation of key review controls over financial reporting.

Inherent Limitations on Effectiveness of Controls

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

PART II-OTHER INFORMATION

Item 1.

Legal Proceedings

Twenty-two oppositions have been filed by third parties in the European Patent Office each challenging the validity of a European patent owned or exclusively licensed by us. The outcome of the challenges is not certain. However, if successful, they may affect our ability to block competitors from utilizing some of its patented technology in Europe. We do not believe a successful challenge will have a material effect on our ability to manufacture and sell our products, or otherwise have a material effect on our operations.

We are party to litigation arising in the ordinary course of business. It is our opinion that the outcome of such matters will not have a material effect on our financial statements.

Item 1A.

Risk Factors

Entities controlled by Gregg Williams, our Chairman of the Board, have the ability to influence or control the outcome of matters submitted for stockholder approval and may have interests that differ from those of our other stockholders.

As of July 31, 2018 entities controlled and beneficially owned by Gregg Williams, our Chairman of the Board, own in the aggregate approximately 39.7% of the outstanding shares of our common stock (or 45.3% after giving effect to Mr. Williams’ right to acquire beneficial ownership of 6,802,721 shares of common stock upon exercise of options or warrants). As a result, Mr. Williams may be able to exercise substantial influence over all matters requiring stockholder approval, including the election of directors and the approval of significant corporate transactions. Mr. Williams may also have interests that differ from other stockholders and he may vote in a manner that is or could be deemed as adverse to interests of other stockholders. This concentration of voting power may have the effect of deterring, delaying or impeding actions that could be beneficial to other stockholders.

In addition, Mr. Williams may acquire additional shares of common stock through open market transactions or through future offerings of our common stock that may result in a greater than 50% beneficial ownership of our outstanding shares of common stock. Our equity compensation plans and certain of our executive compensation arrangements contain provisions that accelerate vesting of outstanding equity awards upon a change-in-control and some of our agreements may contain provisions related to change-in-control that may adversely affect our results of operations. Our equity awards are generally structured with four year vesting schedules as long-term incentive compensation. Should equity awards fully vest, our ability to retain key employees may be adversely affected.

We have obtained significant invested amounts from entities affiliated with Mr. Williams, our Chairman of the Board, and if as we seek additional funding to support our business Mr. Williams does not participate in our future offerings we may not be able to raise needed amounts and our operations may be adversely affected.

During 2016 and 2017 and the six months ended June 30, 2018, we funded our business primarily through the issuance and sale of our securities and we received $9,008,022 in 2016, $10,000,000 in 2017, and $10,000,000 in May 2018 of proceeds from the sale of our securities from entities affiliated with Mr. Williams, our Chairman of the Board, constituting 45.5%, 49.8% and 100%, respectively, of amounts receiving in the offering we then completed. We do not have sufficient funds to support our operations for the next 12 months from the date of issuance of these financial statements. We anticipate that we will seek to fund our operations through public or private equity or debt financings, grants, collaborations, strategic partnerships or other sources. No assurance can be given that Mr. Williams or entities affiliated with him will continue to participate in any offerings of our securities or that we will be able to obtain additional capital from him. If we are unable to obtain funding on a timely basis, our business and operations may be materially and adversely affected. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations -Going Concern” above.

Table of Contents

Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.

In order to obtain marketing approval for Orion we must demonstrate the safety and efficacy of Orion through clinical trials as well as additional supporting data. If Orion is associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may need to interrupt, delay or abandon Orion’s development, cause it to have reduced functionality, or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective.

We are conducting at UCLA and Baylor a six subject initial feasibility clinical study of Orion, but we cannot guarantee that any positive results in this limited trial will successfully translate to a pivotal clinical trial. It is not uncommon to observe results in human clinical trials that are unexpected based on limited trials testing, and many product candidates fail in large clinical trials despite promising limited clinical trial results. Moreover, clinical data is often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products. No assurance can be given that we will not encounter similar results in our Orion trials. Human subjects in our clinical trials may suffer significant adverse events, tolerability issues or other side effects, including, but not limited to, adverse events associated with the surgical implantation, chronic implantation, and chronic use of the Orion device (Events that are also anticipated during or following explantation of the Orion device are identified with an asterisk (*)): intracranial hemorrhage*; subcutaneous hematoma*; vascular injury causing stroke or hemorrhage (e.g. injury to the superior sagittal sinus or posterior cerebral artery perforators)*; hydrocephalus*; intracranial hypotension or cerebrospinal fluid (CSF) leak*; headache or pain in the head, including deep pain*; tingling at the implant site*; brain edema*; infection*; meningitis*; implant site pain, swelling, discharge or effusion*; suture-related complications or stitch abscess*; skin erosion on and/or around the implant site; adverse tissue reaction to the implant; tissue damage at the implant/explant site*; cranial defect/bone damage*; decline in residual vision*; dizziness/syncope*; foreign body sensation at the implant site*; activation of motor or sensory neurons (e.g., muscle twitch); clinically symptomatic seizure*; development of epilepsy; coma*; death*; psychiatric events, including but not limited to mood changes, depression, suicidality, and psychosis*; neurological deficit, including but not limited to language (dysphemia), dysesthesias, paresis, parathesias, visual field, motor deficit (including apraxia), and memory impairment*; drug hypersensitivity, adverse drug reaction, or therapeutic agent toxicity*; events related to any surgery and general anesthesia including cardiac risks, including stroke/transient ischemic attack, arrhythmia, cardiac arrest, and myocardial infarction*, venous thromboembolic (VTE) disease*; pneumonia*, urinary tract infection*, post-operative delirium*, post-operative constipation*, post-operative vomiting or nausea*, or post-operative fever*; injuries due to falls or bumps; skin irritation or burns; Orion system failure or malfunction; array migration; damage to the Orion electronics case; device interaction including the Orion device may interfere with the proper functioning of other electronic devices and emissions from other electronic equipment may interfere with the proper functioning of the Orion device; and (explant only) inability to remove all or part of the Orion device due to fibrosis or other reason. No assurance can be given that we will not encounter adverse events in our Orion trials. The observed efficacy and extent of light perception and vision restoration for subjects implanted with Orion in our feasibility study may not be observed in a larger pivotal clinical trial. If general clinical trials of Orion fail to demonstrate efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of Orion.

If significant adverse events or other side effects are observed in any of our future clinical trials, we may have difficulty recruiting subjects to the clinical trial, subjects may drop out of our trial, or we may be required to abandon the trial or our development efforts of that product candidate altogether. We, the FDA or other applicable regulatory authorities may suspend clinical trials of Orion at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential devices developed in the prosthesis industry that initially showed promise in early-stage studies have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude Orion from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its safety and tolerability profile. Any of these developments could materially harm our business, financial condition and prospects.

Further, if Orion obtains marketing approval, adverse effects associated with it may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional warnings being added to the labeling, significant restrictions on the use of Orion or the withdrawal from the market together with attendant costs of explants and exposure to litigation. We cannot predict whether Orion will cause adverse effects in humans that would preclude or lead to the revocation of regulatory approval. However, any such event, were it to occur, would cause substantial harm to our business and financial condition and would result in the diversion of our management’s attention.

Our revenue from sales of Orion will be dependent upon the pricing and reimbursement guidelines adopted in each country and if pricing and reimbursement levels are inadequate to achieve profitability our operations will suffer.

Our financial success is dependent on our ability to price our products in a manner acceptable to government and private payers while still maintaining our profit margins. Numerous factors that may be beyond our control may ultimately impact our pricing of Orion and determine whether we are able to obtain reimbursement or reimbursement at adequate levels from governmental programs and private insurance. If we are unable to obtain reimbursement or our product is not adequately reimbursed, we will experience reduced sales, our revenues likely will be adversely affected, and we may not become profitable.

Obtaining reimbursement approvals is time consuming, requires substantial management attention, and is expensive. Our business will be materially adversely affected if we do not receive approval for reimbursement of Orion under government programs and from private insurers on a timely or satisfactory basis. Limitations on coverage could also be imposed at the local Medicare Administrative Contractor level or by fiscal intermediaries in the US and by regional, or national funding agencies in Europe. Our business could be materially adversely affected if the Medicare program, local Medicare Administrative Contractors or fiscal intermediaries were to make such a determination and deny, restrict or limit the reimbursement of Orion. Similarly in Europe these governmental and other agencies could deny, restrict or limit the reimbursement of Orion at the hospital, regional or national level. Our business also could be adversely affected if surgeons and the facilities within which they operate are not adequately reimbursed by Medicare and other funding agencies for the cost of the procedure in which they implant the Orion on a basis satisfactory to the administering surgeons and their facilities. If the local contractors that administer the Medicare program and other funding agencies are slow to reimburse surgeons or provider facilities for the Argus II System, the surgeons and facilities may delay their payments to us, which would adversely affect our working capital requirements. Also if the funding agencies delay reimbursement payments to the hospitals, any increase to their working capital requirements could reduce their willingness to treat blind patients who wish to have our Orion devices implanted. If reimbursement for our products is unavailable, limited in scope or amount, or if pricing is set at unsatisfactory levels, our business will be materially harmed.

We further incorporate herein by reference the risk factors included in our Annual Report on Form 10-K, which we filed with the Securities and Exchange Commission on March 20, 2018.

Table of Contents

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

Item 3.

Defaults upon Senior Securities

Not applicable.

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

Not applicable.

Item 6.

Exhibits

Table of Contents

EXHIBIT INDEX

Exhibit No.		Exhibit Description
3.1		Restated Articles of Incorporation of the Registrant.(1)
3.2		Amended and Restated Bylaws of the Registrant, as currently in effect.(1)
31.1		Certification of Principal Executive Officer of Second Sight Medical Products, Inc. pursuant to Section 302 of Sarbanes-Oxley Act of 2002.*
31.2		Certification of Principal Financial and Accounting Officer of Second Sight Medical Products, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
32.1		Certifications of Principal Executive Officer and Principal Financial and Accounting Officer of Second Sight Medical Products, Inc. pursuant to Rule 13a-14(b) under the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
101.INS		XBRL Instant Document.*
101.SCH		XBRL Taxonomy Extension Schema Document.*
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.*
101.LAB		XBRL Taxonomy Extension Label Linkbase Document.*
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.*

*	Included herein.

(1) Incorporated by reference to the registrant’s registration statement on Form S-1, file no. 333-198073, originally filed with the Securities and Exchange Commission on August 12, 2014, as amended.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Name	Title	Date

/s/ Jonathan Will McGuire	Chief Executive Officer and Director	August 7, 2018
Jonathan Will McGuire	(Principal Executive Officer)

/s/ John T. Blake	Chief Financial Officer	August 7, 2018
John T. Blake	(Principal Financial and Accounting Officer)

EX-31.1 2 ex_120648.htm EXHIBIT 31.1 ex_120648.htm

Exhibit 31.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jonathan Will McGuire, hereby certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Second Sight Medical Products, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2018	/s/ Jonathan Will McGuire
	Jonathan Will McGuire
	Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 ex_120649.htm EXHIBIT 31.2 ex_120649.htm

Exhibit 31.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John T. Blake, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Second Sight Medical Products, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2018	/s/ John T. Blake
	John T. Blake
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-32.1 4 ex_120650.htm EXHIBIT 32.1 ex_120650.htm

Exhibit 32.1

Certifications of Principal Executive Officer and Principal Financial Officer

Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant To

Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), Jonathan Will McGuire, Chief Executive Officer (Principal Executive Officer) and John T. Blake, Chief Financial Officer (Principal Financial and Accounting Officer) of Second Sight Medical Products, Inc. (the “Company”), each hereby certifies that, to the best of his knowledge:

1.	The Quarterly Report of the Company on Form 10-Q (the “Report”) for the quarter ended June 30, 2018, to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for periods indicated.

Date: August 7, 2018	/s/ Jonathan Will McGuire
	Jonathan Will McGuire
	Chief Executive Officer
	(Principal Executive Officer)
	/s/ John T. Blake
	John T. Blake
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-101.INS 5 eyes-20180630.xml XBRL INSTANCE DOCUMENT false --12-31 Q2 2018 2018-06-30 10-Q 0001266806 67074542 Yes Smaller Reporting Company SECOND SIGHT MEDICAL PRODUCTS INC No No eyes 1074000 779000 676000 5 14449000 2.01 P3Y219D 5000 1.47 2600000 P3Y328D P3Y219D 1126000 684000 2475000 1298000 109000 130000 153000 233000 66000 33000 294000 3000 417000 189000 1000 1000 0.03 3100000 5000 7000 7000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.</div> Warrants</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">A summary of warrants activity for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>is presented below (in thousands, except per share and contractual life data).</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted Average</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;"> </div></div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Remaining</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise Price</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Life (in Years)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants outstanding as of December 31, 2017</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,130</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.15</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Issued</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.47</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited or expired</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(676</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style=""> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants outstanding as of June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,449</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.01</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.60</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants exercisable as of June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,449</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.01</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.60</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">The intrinsic value of warrants outstanding as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.6</div> million.</div></div>

1220000

752000

718000

1831000

2071000

2425000

3044000

2824000

-604000

-572000

42434000

40522000

20000

1916000

1912000

400000

63000

67000

127000

148000

107000

75000

211000

132000

11000

44000

103000

93000

92000

112000

215000

206000

354000

637000

1256000

1337000

627000

935000

1912000

1916000

802000

1038000

13647000

13652000

7072000

5536000

18000

59000

107000

234000

222000

21814000

21375000

2200000

2700000

13617000

14497000

12360000

13165000

7839000

10875000

7476000

18129000

7379000

7235000

-363000

7254000

2.15

2.01

15130000

14449000

200000000

67075000

57630000

67075000

57630000

42701000

77000

56794000

18000

57630000

82000

67075000

216805000

202156000

-8038000

-6751000

-17746000

-14269000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.</div> Concentration of Risk</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"><div style="display: inline; font-style: italic;">Credit Risk</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">Financial instruments that subject us to concentrations of credit risk consist primarily of cash, money market funds, and trade accounts receivable. We maintain cash and money market funds with financial institutions that management deems reputable. We extend differing levels of credit to our customers, and typically do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> require collateral.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"><div style="display: inline; font-style: italic;">Customer Concentration</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">The following tables provide information about disaggregated revenue by service type, customer and geographical market.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">The following table shows our revenues by customer type during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017:</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div> <table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Six Months Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Direct customers</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,798</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,695</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,456</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,704</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Distributors</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">109</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">541</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">427</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">541</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,907</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,236</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,883</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,245</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the following customers each comprises greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of our total revenues<div style="display: inline; font-weight: bold;">:</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div> <table style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Six Months Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 1</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 2</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 3</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 4</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 5</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 6</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 7</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>the following customers each comprises greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of our total accounts receivable:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div> <table style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30</div><div style="display: inline; font-weight: bold;">,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(unaudited)</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 1</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 2</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 3</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 4</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 5</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 6</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 7</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 8</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"><div style="display: inline; font-style: italic;">Geographic Concentration</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> regional revenue based on customer locations which each comprises greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of our total revenues, consist of the following<div style="display: inline; font-weight: bold;">:</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"> </div> <div> <table style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Six Months Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">United States</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">56</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">55</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">52</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">France</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Italy</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">Korea</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Taiwan</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"><div style="display: inline; font-style: italic;">Foreign Operations</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">The accompanying condensed consolidated financial statements as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>include assets amounting to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.2</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.7</div> million, respectively, relating to operations of our subsidiary based in Switzerland. It is possible that unanticipated events in foreign countries could disrupt our operations.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div></div>

0.15

0.11

0.15

0.11

0.12

0.08

0.07

0.1

0.06

0.1

0.08

0.07

0.14

0.03

0.09

0.13

0.02

0.09

0.12

0.07

0.12

0.2

0.17

0.2

0.08

0.19

0.16

0.12

0.16

0.11

0.56

0.5

0.55

0.52

0.19

0.11

0.13

0.1

0.15

0.11

0.15

0.11

0.06

0.1

0.08

0.07

0.14

0.03

0.09

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin: 0pt auto 0pt 54pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0pt" cellpadding="0pt" border="0px"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 84%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Beginning balance, December 31, 2017</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48</div></td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Consideration received in advance of revenue recognition</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">233</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">Revenue recognized</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(21</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 0%; padding: 0px 0px 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Ending Balance, June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">260</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"> </td> </tr> </table></div>

48000

260000

21000

836000

1127000

1504000

2254000

222000

229000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.</div> Stock-Based Compensation</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">A summary of stock option activity under our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011</div> Equity Incentive Plan (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">“2011</div> Plan”) for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>is presented below (in thousands, except per share and contractual life data).</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div> <table style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted Average</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;"> </div></div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Remaining</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise Price</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Life (in Years)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options outstanding as of December 31, 2017</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,675</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.87</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.40</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,465</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.00</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(76</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.95</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited or expired</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(992</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.98</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options outstanding as of June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,072</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.03</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.97</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options exercisable as of June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,766</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.17</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.40</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">The estimated aggregate intrinsic value of stock options exercisable as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8,000.</div> As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018, </div>there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.0</div> million of total unrecognized compensation cost related to outstanding stock options that will be recognized over a weighted average period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.9</div> years.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June, 2018, </div>we granted stock options to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,464,872</div> shares of common stock to certain employees and a contractor. The options are exercisable for a period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years from the date of grant at prices ranging from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.80</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.07</div> per share, which was the fair value of our common stock on the respective grant dates. The options generally vest over a period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div> years. The fair value of these options, calculated using the Black-Scholes option-pricing model, was determined to be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.1</div> million (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.09</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.30</div> per share) using the following assumptions: expected term of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.50</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.11</div> years, volatility of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">67.0%,</div> risk-free interest rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.32%</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.00%,</div> and expected dividend rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0%.</div> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018, </div>we recorded <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.4</div> million of stock-based compensation expense related to stock option modifications for executive transitions.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">The following table summarizes restricted stock unit (“RSU”) activity for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 (</div>in thousands, except per share data):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div> <table style="margin-right: 15%; margin-left: 36pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number<br /> of </div><div style="display: inline; font-weight: bold;">Shares</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted<br /> Average Grant<br /> Date Fair Value<br /> Per Share</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of December 31, 2017</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">83</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.43</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Awarded</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(24</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited/canceled</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.43</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018, </div>there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.7</div> million of total unrecognized compensation cost related to the outstanding RSUs that will be recognized over a weighted average period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.1</div> years.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">We adopted an employee stock purchase plan in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June, 2015 </div>for all eligible employees. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>the maximum number of shares that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be issued under the plan is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,550,000.</div> During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">225,887</div> shares were issued under the stock purchase plan.</div>   <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">Stock-based compensation expense recognized for stock-based awards in the condensed consolidated statements of operations for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> is as follows (in thousands):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div> <table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Six Months Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of sales</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">67</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">127</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">148</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">107</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">211</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">132</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Clinical and regulatory</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">103</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">93</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Selling and marketing</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">92</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">112</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">215</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">206</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">354</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">637</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,256</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,337</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">627</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">935</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,912</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,916</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div></div>

-0.12

-0.29

-0.28

-10000

82000

2448000

2611000

P2Y328D

P1Y36D

700000

5000000

2632000

2901000

5875000

5642000

1071000

1109000

1379000

991000

471000

-528000

-1100000

704000

-344000

206000

213000

56000

-104000

-162000

224000

947000

-1887000

-161000

-13000

27000

29000

43000

36000

2126000

2065000

2913000

1660000

5693000

4765000

61000

-1456000

3567000

2700000

643000

485000

2137000

2620000

13617000

14497000

7073000

6615000

0.005

0.995

14387000

19878000

-116000

-151000

-14624000

-12555000

-14391000

-17714000

-7961000

-6843000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"><div style="display: inline; font-style: italic;">Recent Accounting Pronouncements</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 18pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2014, </div>the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div>). </div>This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services.<div style="display: inline; font-style: italic;"> </div>We adopted this ASU on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018 </div>retrospectively, the cumulative effect of the initial application on our accumulated deficit on that date was immaterial.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 18pt;">We generate our revenue from the sale of our Argus II retinal prosthesis systems, which include the implant and external components. Our product sales generally consist of the implant and related surgical supplies and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>include performance obligations related to post-surgical support.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 18pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 18pt;">We sell our products through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> main sales channels: <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>) directly to customers who use our products (the “Direct Channel”) and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>) to distribution partners who resell our products (the “Indirect Channel”).</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 18pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 18pt;">Under the Direct Channel, we sell our systems to customers who use our products and we receive payment directly from customers who use our products. Under our Indirect Channel, we have entered into distribution agreements that allow the distributors to sell our systems and fulfill performance obligations for surgical support and post-surgical support.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 18pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 18pt;">We determine revenue recognition through the following steps:</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 18pt;"> </div> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">•</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Identification of the contract, or contracts, with a customer</div> </td> </tr> </table> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">•</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Identification of the performance obligations in the contract</div> </td> </tr> </table> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">•</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Determination of the transaction price</div> </td> </tr> </table> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">•</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Allocation of the transaction price to the performance obligations in the contract</div> </td> </tr> </table> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">•</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Recognition of revenue when, or as, we satisfy a performance obligation</div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 18pt;">Revenue is generally recognized upon surgical implant, unless we have significant post-surgical support performance obligations. We recognize revenue when a material reversal is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer probable. Conditions that preclude us from recognizing revenue generally involve new sites with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> reimbursement or reimbursement history, and depends on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party behavior beyond our control, uncertain payment cycles over an extended period of time, and our limited historical experience with these arrangements.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;">Management does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe that any other recently issued, but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> yet effective, accounting standards, if adopted, will have a material effect on the financial statements.</div></div></div></div>

9059000

7981000

19136000

15418000

-7988000

-6872000

-17757000

-14427000

122000

-32000

-77000

92000

116000

151000

10000000

599000

795000

1000

19688000

10000000

13970000

19500000

19700000

5100000

10000000

4000000

2468000

2450000

1423000

1329000

298000

46000

4235000

4123000

1191000

1299000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30</div><div style="display: inline; font-weight: bold;">,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(unaudited)</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Laboratory equipment</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,468</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,450</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Computer hardware and software</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,423</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,329</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">298</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">298</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Furniture, fixtures and equipment</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">46</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">46</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,235</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,123</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation and amortization</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,044</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,824</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,191</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,299</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

-36000

2422000

1949000

4895000

3796000

-252091000

-234377000

2900000

8000000

4000000

1907000

2236000

2883000

3245000

1798000

1695000

2456000

2704000

109000

541000

427000

541000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Six Months Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of sales</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">67</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">127</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">148</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">107</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">211</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">132</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Clinical and regulatory</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">103</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">93</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Selling and marketing</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">92</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">112</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">215</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">206</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">354</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">637</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,256</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,337</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">627</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">935</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,912</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,916</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; margin-left: 36pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number<br /> of </div><div style="display: inline; font-weight: bold;">Shares</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted<br /> Average Grant<br /> Date Fair Value<br /> Per Share</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of December 31, 2017</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">83</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.43</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Awarded</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(24</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited/canceled</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.43</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted Average</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;"> </div></div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Remaining</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise Price</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Life (in Years)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants outstanding as of December 31, 2017</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,130</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.15</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Issued</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.47</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited or expired</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(676</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style=""> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants outstanding as of June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,449</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.01</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.60</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants exercisable as of June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,449</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.01</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.60</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Six Months Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 1</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 2</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 3</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 4</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 5</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 6</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 7</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30</div><div style="display: inline; font-weight: bold;">,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(unaudited)</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 1</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 2</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 3</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 4</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 5</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 6</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 7</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer 8</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> </table></div>

2879000

2447000

5891000

4682000

1912000

1916000

P4Y

0.67

0.0232

0.03

24000

83000

59000

1550000

2766000

6.17

992000

3.98

2464872

2465000

1.09

1.30

5675000

7072000

4.87

4.03

225887

1.95

1.80

2.07

1.48

P10Y

P5Y182D

P6Y40D

8000

P4Y146D

12.43

P7Y146D

P6Y354D

20000

193000

226000

132996

223000

-59000

133000

-82000

6756757

2200000

13653000

8981000

24000

76000

189000

261000

262000

-132000

130000

262000

-153000

109000

13647000

6021000

19668000

13970000

149000

186769000

153000

30697000

-2000

-608000

-205861000

11148000

200867000

21000

38654000

-1000

-486000

-220252000

18803000

202156000

153000

40522000

-572000

-234377000

7882000

216805000

42434000

-604000

-252091000

6544000

64418000

56513000

61750000

51380000

xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0001266806 eyes:ArgusIIProductMember 2016-01-01 2016-12-31 0001266806 eyes:RightOfferingMember 2016-06-01 2016-06-30 0001266806 2017-01-01 2017-06-30 0001266806 eyes:CommonStockIssuableMember 2017-01-01 2017-06-30 0001266806 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0001266806 eyes:EmployeeStockPurchasePlanMember 2017-01-01 2017-06-30 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-06-30 0001266806 eyes:UnderwritersWithInitialPublicOfferingMember 2017-01-01 2017-06-30 0001266806 eyes:WarrantsIssuedInConnectionWithConvertibleDebtMember 2017-01-01 2017-06-30 0001266806 eyes:WarrantsIssuedInConnectionWithMarch2017RightsOfferingMember 2017-01-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer1Member 2017-01-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer2Member 2017-01-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer3Member 2017-01-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer4Member 2017-01-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer5Member 2017-01-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer6Member 2017-01-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer7Member 2017-01-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:FR 2017-01-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:IT 2017-01-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:KR 2017-01-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:TW 2017-01-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:US 2017-01-01 2017-06-30 0001266806 us-gaap:SalesChannelDirectlyToConsumerMember 2017-01-01 2017-06-30 0001266806 us-gaap:SalesChannelThroughIntermediaryMember 2017-01-01 2017-06-30 0001266806 eyes:ClinicalAndRegulatoryMember 2017-01-01 2017-06-30 0001266806 us-gaap:CostOfSalesMember 2017-01-01 2017-06-30 0001266806 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-06-30 0001266806 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-06-30 0001266806 us-gaap:SellingAndMarketingExpenseMember 2017-01-01 2017-06-30 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-06-30 0001266806 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-06-30 0001266806 eyes:CommonStockIssuableMember 2017-01-01 2017-06-30 0001266806 us-gaap:CommonStockMember 2017-01-01 2017-06-30 0001266806 eyes:NotesReceivableForStockOptionExercisesMember 2017-01-01 2017-06-30 0001266806 us-gaap:RetainedEarningsMember 2017-01-01 2017-06-30 0001266806 2017-01-01 2017-12-31 0001266806 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember eyes:Customer1Member 2017-01-01 2017-12-31 0001266806 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember eyes:Customer2Member 2017-01-01 2017-12-31 0001266806 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember eyes:Customer3Member 2017-01-01 2017-12-31 0001266806 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember eyes:Customer4Member 2017-01-01 2017-12-31 0001266806 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember eyes:Customer5Member 2017-01-01 2017-12-31 0001266806 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember eyes:Customer6Member 2017-01-01 2017-12-31 0001266806 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember eyes:Customer7Member 2017-01-01 2017-12-31 0001266806 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember eyes:Customer8Member 2017-01-01 2017-12-31 0001266806 eyes:The2011EquityIncentivePlanMember 2017-01-01 2017-12-31 0001266806 eyes:ArgusIIProductMember 2017-01-01 2017-12-31 0001266806 eyes:RightOfferingMember 2017-03-01 2017-03-31 0001266806 2017-04-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer1Member 2017-04-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer2Member 2017-04-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer3Member 2017-04-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer4Member 2017-04-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer5Member 2017-04-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer6Member 2017-04-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer7Member 2017-04-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:FR 2017-04-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:IT 2017-04-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:KR 2017-04-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:TW 2017-04-01 2017-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:US 2017-04-01 2017-06-30 0001266806 us-gaap:SalesChannelDirectlyToConsumerMember 2017-04-01 2017-06-30 0001266806 us-gaap:SalesChannelThroughIntermediaryMember 2017-04-01 2017-06-30 0001266806 eyes:ClinicalAndRegulatoryMember 2017-04-01 2017-06-30 0001266806 us-gaap:CostOfSalesMember 2017-04-01 2017-06-30 0001266806 us-gaap:GeneralAndAdministrativeExpenseMember 2017-04-01 2017-06-30 0001266806 us-gaap:ResearchAndDevelopmentExpenseMember 2017-04-01 2017-06-30 0001266806 us-gaap:SellingAndMarketingExpenseMember 2017-04-01 2017-06-30 0001266806 eyes:AtMarketIssuanceSalesAgreementMember 2017-10-01 2017-12-31 0001266806 eyes:AtMarketIssuanceSalesAgreementMember 2017-11-01 2017-11-30 0001266806 eyes:AtMarketIssuanceSalesAgreementMember 2018-01-01 2018-02-28 0001266806 2018-01-01 2018-06-30 0001266806 eyes:CommonStockIssuableMember 2018-01-01 2018-06-30 0001266806 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0001266806 eyes:EmployeeStockPurchasePlanMember 2018-01-01 2018-06-30 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0001266806 eyes:UnderwritersWithInitialPublicOfferingMember 2018-01-01 2018-06-30 0001266806 eyes:WarrantsIssuedInConnectionWithConvertibleDebtMember 2018-01-01 2018-06-30 0001266806 eyes:WarrantsIssuedInConnectionWithMarch2017RightsOfferingMember 2018-01-01 2018-06-30 0001266806 us-gaap:EmployeeStockOptionMember eyes:The2011EquityIncentivePlanMember 2018-01-01 2018-06-30 0001266806 us-gaap:EmployeeStockOptionMember eyes:The2011EquityIncentivePlanMember srt:MaximumMember eyes:CertainEmployeesAndAContractorMember 2018-01-01 2018-06-30 0001266806 us-gaap:EmployeeStockOptionMember eyes:The2011EquityIncentivePlanMember srt:MinimumMember eyes:CertainEmployeesAndAContractorMember 2018-01-01 2018-06-30 0001266806 us-gaap:EmployeeStockOptionMember eyes:The2011EquityIncentivePlanMember eyes:CertainEmployeesAndAContractorMember 2018-01-01 2018-06-30 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0001266806 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember eyes:Customer1Member 2018-01-01 2018-06-30 0001266806 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember eyes:Customer2Member 2018-01-01 2018-06-30 0001266806 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember eyes:Customer3Member 2018-01-01 2018-06-30 0001266806 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember eyes:Customer4Member 2018-01-01 2018-06-30 0001266806 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember eyes:Customer5Member 2018-01-01 2018-06-30 0001266806 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember eyes:Customer6Member 2018-01-01 2018-06-30 0001266806 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember eyes:Customer7Member 2018-01-01 2018-06-30 0001266806 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember eyes:Customer8Member 2018-01-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer1Member 2018-01-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer2Member 2018-01-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer3Member 2018-01-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer4Member 2018-01-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer5Member 2018-01-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer6Member 2018-01-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer7Member 2018-01-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:FR 2018-01-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:IT 2018-01-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:KR 2018-01-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:TW 2018-01-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:US 2018-01-01 2018-06-30 0001266806 us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-06-30 0001266806 us-gaap:SalesChannelThroughIntermediaryMember 2018-01-01 2018-06-30 0001266806 eyes:ClinicalAndRegulatoryMember 2018-01-01 2018-06-30 0001266806 us-gaap:CostOfSalesMember 2018-01-01 2018-06-30 0001266806 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-06-30 0001266806 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0001266806 us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-06-30 0001266806 eyes:The2011EquityIncentivePlanMember 2018-01-01 2018-06-30 0001266806 eyes:The2011EquityIncentivePlanMember srt:MaximumMember eyes:CertainEmployeesAndAContractorMember 2018-01-01 2018-06-30 0001266806 eyes:The2011EquityIncentivePlanMember srt:MinimumMember eyes:CertainEmployeesAndAContractorMember 2018-01-01 2018-06-30 0001266806 eyes:The2011EquityIncentivePlanMember eyes:CertainEmployeesAndAContractorMember 2018-01-01 2018-06-30 0001266806 eyes:The2011EquityIncentivePlanMember eyes:ConsultantMember 2018-01-01 2018-06-30 0001266806 eyes:The2015EmployeeStockPurchasePlanMember 2018-01-01 2018-06-30 0001266806 eyes:ArgusIIProductMember 2018-01-01 2018-06-30 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-06-30 0001266806 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0001266806 eyes:CommonStockIssuableMember 2018-01-01 2018-06-30 0001266806 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0001266806 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0001266806 eyes:AtMarketIssuanceSalesAgreementMember 2018-03-01 2018-06-30 0001266806 2018-04-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer1Member 2018-04-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer2Member 2018-04-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer3Member 2018-04-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer4Member 2018-04-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer5Member 2018-04-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer6Member 2018-04-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember eyes:Customer7Member 2018-04-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:FR 2018-04-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:IT 2018-04-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:KR 2018-04-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:TW 2018-04-01 2018-06-30 0001266806 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:US 2018-04-01 2018-06-30 0001266806 us-gaap:SalesChannelDirectlyToConsumerMember 2018-04-01 2018-06-30 0001266806 us-gaap:SalesChannelThroughIntermediaryMember 2018-04-01 2018-06-30 0001266806 eyes:ClinicalAndRegulatoryMember 2018-04-01 2018-06-30 0001266806 us-gaap:CostOfSalesMember 2018-04-01 2018-06-30 0001266806 us-gaap:GeneralAndAdministrativeExpenseMember 2018-04-01 2018-06-30 0001266806 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0001266806 us-gaap:SellingAndMarketingExpenseMember 2018-04-01 2018-06-30 0001266806 eyes:StockPurchaseAgreementMember 2018-05-01 2018-05-31 0001266806 eyes:EntitesBeneficiallyOwnedByMrGreggWilliamsMember eyes:StockPurchaseAgreementMember 2018-05-03 2018-05-03 0001266806 eyes:SecondSightSwitzerlandSarlMember 2007-12-31 0001266806 2016-12-31 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001266806 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001266806 eyes:CommonStockIssuableMember 2016-12-31 0001266806 us-gaap:CommonStockMember 2016-12-31 0001266806 eyes:NotesReceivableForStockOptionExercisesMember 2016-12-31 0001266806 us-gaap:RetainedEarningsMember 2016-12-31 0001266806 2017-06-30 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-06-30 0001266806 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0001266806 eyes:CommonStockIssuableMember 2017-06-30 0001266806 us-gaap:CommonStockMember 2017-06-30 0001266806 eyes:NotesReceivableForStockOptionExercisesMember 2017-06-30 0001266806 us-gaap:RetainedEarningsMember 2017-06-30 0001266806 2017-12-31 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001266806 eyes:SecondSightSwitzerlandSarlMember 2017-12-31 0001266806 eyes:The2011EquityIncentivePlanMember 2017-12-31 0001266806 eyes:ComputerHardwareAndSoftwareMember 2017-12-31 0001266806 eyes:FurnitureFixturesAndEquipmentMember 2017-12-31 0001266806 eyes:LaboratoryEquipmentMember 2017-12-31 0001266806 us-gaap:LeaseholdImprovementsMember 2017-12-31 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001266806 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001266806 eyes:CommonStockIssuableMember 2017-12-31 0001266806 us-gaap:CommonStockMember 2017-12-31 0001266806 us-gaap:RetainedEarningsMember 2017-12-31 0001266806 eyes:EntitesBeneficiallyOwnedByMrGreggWilliamsMember eyes:StockPurchaseAgreementMember 2018-05-03 0001266806 2018-06-30 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2018-06-30 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0001266806 eyes:SecondSightSwitzerlandSarlMember 2018-06-30 0001266806 eyes:SecondSightSwitzerlandSarlMember us-gaap:ExecutiveOfficerMember 2018-06-30 0001266806 eyes:The2011EquityIncentivePlanMember 2018-06-30 0001266806 eyes:The2015EmployeeStockPurchasePlanMember 2018-06-30 0001266806 eyes:ComputerHardwareAndSoftwareMember 2018-06-30 0001266806 eyes:FurnitureFixturesAndEquipmentMember 2018-06-30 0001266806 eyes:LaboratoryEquipmentMember 2018-06-30 0001266806 us-gaap:LeaseholdImprovementsMember 2018-06-30 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001266806 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001266806 eyes:CommonStockIssuableMember 2018-06-30 0001266806 us-gaap:CommonStockMember 2018-06-30 0001266806 us-gaap:RetainedEarningsMember 2018-06-30 0001266806 2018-08-03

EX-101.SCH 6 eyes-20180630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Organization and Business Operations link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Concentration of Risk link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Selected Balance Sheet Detail link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Equity Securities link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Warrants link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Stock-based Compensation link:calculationLink link:definitionLink link:presentationLink 015 - Document - Note 9 - Litigation, Claims and Assessments link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 3 - Concentration of Risk (Tables) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 4 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 5 - Selected Balance Sheet Detail (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 6 - Equity Securities (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 7 - Warrants (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 8 - Stock-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 1 - Organization and Business Operations (Details Textual) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 3 - Concentration of Risk (Details Textual) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 3 - Concentration of Risk - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 3 - Concentration of Risk - Concentration of Risk (Details) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 3 - Concentration of Risk - Revenue Based on Geographic Location (Details) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 4 - Fair Value Measurements - Fair Value on a Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 5 - Selected Balance Sheet Detail - Inventories, Net (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 5 - Selected Balance Sheet Detail - Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 5 - Selected Balance Sheet Detail - Contract Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 6 - Equity Securities (Details Textual) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 6 - Equities Securities - Anti-dilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 7 - Warrants (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 7 - Warrants - Summary of Warrants Activity (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 8 - Stock-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 8 - Stock-based Compensation - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 8 - Stock-based Compensation - Restricted Stock Unit (RSU) Activity (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 eyes-20180630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 eyes-20180630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 eyes-20180630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Customer 2 [Member] Represents the information pertaining to the second customer. Note To Financial Statement Details Textual Customer 1 [Member] Represents the information pertaining to the first customer. Significant Accounting Policies Note 3 - Concentration of Risk us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Note 4 - Fair Value Measurements Customer 6 [Member] Represents the information pertaining to the sixth customer. Note 5 - Selected Balance Sheet Detail Customer 5 [Member] Represents the information pertaining to the fifth customer. Note 6 - Equity Securities Customer 4 [Member] Represents the information pertaining to the fourth customer. Note 7 - Warrants Customer 3 [Member] Represents the information pertaining to the third customer. Note 8 - Stock-based Compensation Laboratory Equipment [Member] Represents the information pertaining to the laboratory equipment. Note 3 - Concentration of Risk - Disaggregation of Revenue (Details) Note 3 - Concentration of Risk - Concentration of Risk (Details) Customer 8 [Member] Represents the information pertaining to the eighth customer. Customer 7 [Member] Represents the information pertaining to the seventh customer. Note 3 - Concentration of Risk - Revenue Based on Geographic Location (Details) Note 4 - Fair Value Measurements - Fair Value on a Recurring Basis (Details) Note 5 - Selected Balance Sheet Detail - Inventories, Net (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Stock-based compensation Note 5 - Selected Balance Sheet Detail - Property and Equipment (Details) Furniture, Fixtures and Equipment [Member] Represents the information pertaining to the furniture, fixtures and equipment. Note 5 - Selected Balance Sheet Detail - Contract Liabilities (Details) Computer Hardware and Software [Member] Represents the information pertaining to computer hardware and software. us-gaap_LiabilitiesCurrent Total current liabilities Note 6 - Equities Securities - Anti-dilutive Securities (Details) Underwriter's With Initial Public Offering [Member] Represents the information pertaining to underwriter's with initial public offering. Title of Individual [Axis] Note 7 - Warrants - Summary of Warrants Activity (Details) Relationship to Entity [Domain] Note 8 - Stock-based Compensation - Stock Option Activity (Details) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Note 8 - Stock-based Compensation - Restricted Stock Unit (RSU) Activity (Details) Warrant Disclosure [Text Block] The entire disclosure for warrants. Proceeds from repayment of note receivable Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) The 2015 Employee Stock Purchase Plan [Member] Refers to information regarding the 2015 Employee Stock Purchase Plan. Employee Stock Purchase Plan [Member] Represents the information pertaining to the employee stock purchase plan. Notes To Financial Statements Warrants Issued in Connection With March 2017 Rights Offering [Member] Represents the information pertaining to the warrants issued in connection with the March 2017 rights offering. Notes To Financial Statements [Abstract] Warrants Issued in Connection With Convertible Debt [Member] Represents the information pertaining to warrants issued in connection with convertible debt. eyes_ClassOfWarrantOrRightCancelledDuringPeriod Forfeited or expired, number of shares (in shares) The number of warrants or rights cancelled during period. eyes_ClassOfWarrantOrRightExercisedDuringPeriod Exercised, number of shares (in shares) The number of warrants or rights exercised during period. Operating expenses: eyes_ClassOfWarrantOrRightIssuedDuringPeriod Issued, number of shares (in shares) The number of warrants or rights issued during period. eyes_ClassOfWarrantOrRightOutstandingIntrinsicValue Class of Warrant or Right, Outstanding, Intrinsic Value Amount by which the current fair value of the underlying stock exceeds the exercise price of warrants outstanding. eyes_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice Forfeited or expired, weighted average exercise price (in dollars per share) Exercise price per share of warrants or rights cancelled during period. Interest income eyes_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice Exercised, weighted average exercise price (in dollars per share) Exercise price per share of warrants or rights exercised during period. Share-based Compensation, Stock Options, Activity [Table Text Block] eyes_ClassOfWarrantOrRightExercisable Warrants exercisable, number of shares (in shares) The number of warrants shares into which fully or partially vested warrants outstanding as of the balance sheet date. 2011 Equity Incentive Plan [Member] Represents the information pertaining to the 2011 Equity Incentive Plan. Foreign currency translation adjustment Inventory reserve eyes_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualLife Warrants exercisable, weighted average remaining contractual life (Year) Weighted average remaining contractual term for warrants outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] eyes_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife Warrants outstanding, weighted average remaining contractual life (Year) Weighted average remaining contractual term for warrants outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. eyes_ClassOfWarrantOrRightExercisableExercisePrice Warrants exercisable, weighted average exercise price (in dollars per share) Exercise price per share of warrants or rights exercisable. Certain Employees and a Contractor [Member] Represents the information pertaining to certain employees and a contractor. Depreciation and amortization Consultant [Member] Represents the information pertaining to the consultant. us-gaap_AssetsCurrent Total current assets Options exercisable, weighted average exercise price (in dollars per share) Money market funds Options exercisable, weighted average remaining contractual life (Year) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Stockholders' Equity Note Disclosure [Text Block] Options exercisable, number of shares (in shares) Options outstanding, weighted average remaining contractual life (Year) Awarded, weighted average grant date fair value per share (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Clinical And Regulatory [Member] Represents the information pertaining to clinical and regulatory. Vested, weighted average grant date fair value per share (in dollars per share) Forfeited/canceled, weighted average grant date fair value per share (in dollars per share) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Outstanding, weighted average grant date fair value per share (in dollars per share) Outstanding, weighted average grant date fair value per share (in dollars per share) Stock Purchase Agreement [Member] Represents the information pertaining to the stock purchase agreement. Common stock, no par value; 200,000 shares authorized; shares issued and outstanding: 67,075 and 57,630 as of June 30, 2018 and December 31, 2017, respectively Entities Beneficially Owned by Mr. Gregg Williams [Member] Represents the information pertaining to the entities beneficially owned by Mr. Gregg Williams. Measurement Frequency [Axis] Adjustments to reconcile net loss to net cash used in operating activities: Fair Value, Measurement Frequency [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Options outstanding, weighted average exercise price (in dollars per share) Options outstanding, weighted average exercise price (in dollars per share) Fair Value, Measurements, Recurring [Member] Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Contract liabilities Beginning balance, December 31, 2017 Ending Balance, June 30, 2018 Forfeited or expired, weighted average exercise price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Outstanding, number of awards (in shares) Outstanding, number of awards (in shares) Common stock, no par value (in dollars per share) Granted, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised, weighted average exercise price (in dollars per share) Forfeited/canceled, number of awards (in shares) Accrued expenses Accrued compensation expense Range [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised Vested, number of awards (in shares) Maximum [Member] Minimum [Member] eyes_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value Fair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. Accounts payable Product and Service [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Options outstanding, number of shares (in shares) Options outstanding, number of shares (in shares) Product and Service [Domain] Range [Axis] Awarded, number of awards (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Forfeited or expired, number of shares (in shares) Preferred stock, no par value, 10,000 shares authorized; none outstanding us-gaap_PolicyTextBlockAbstract Accounting Policies Preferred stock, no par value (in dollars per share) Geographical [Axis] Property, Plant and Equipment [Table Text Block] Geographical [Domain] Preferred stock, shares authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Inventories, net Inventories, net us-gaap_StockIssued1 Fair value of stock options issued for services Work in process Net sales Revenue from Contract with Customer, Including Assessed Tax Raw materials Fair Value, Inputs, Level 3 [Member] us-gaap_InventoryAdjustments Allowance for excess and obsolete inventory us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment Finished goods Non-cash financing and investing activities: Fair Value Hierarchy and NAV [Domain] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Customer [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Customer [Domain] Fair Value, Inputs, Level 1 [Member] us-gaap_InventoryGross Inventories, gross Fair Value, Inputs, Level 2 [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Fair Value Hierarchy and NAV [Axis] Current liabilities: Supplemental Balance Sheet Disclosures [Text Block] us-gaap_Assets Assets, Total Total assets Plan Name [Axis] Deferred grant revenue Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Cash flows from operating activities: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Statement [Line Items] Legal Matters and Contingencies [Text Block] Accounts receivable, net Additional paid-in capital Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] AOCI Attributable to Parent [Member] Stockholders’ equity: Leasehold Improvements [Member] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Equity Award [Domain] Current assets: Fair Value Disclosures [Text Block] Basis of Presentation and Significant Accounting Policies [Text Block] Award Type [Axis] Net loss Net loss Restricted Stock Units (RSUs) [Member] us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities Commitments and contingencies Sale of Stock [Axis] Sale of Stock [Domain] us-gaap_OperatingIncomeLoss Loss from operations Employee Stock Option [Member] us-gaap_ContractWithCustomerLiabilityRevenueRecognized Revenue recognized us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Prepaid expenses and other current assets Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Effect of exchange rate changes on cash and cash equivalents us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Net increase (decrease) Antidilutive Securities [Axis] us-gaap_GrossProfit Gross profit Antidilutive Securities, Name [Domain] Cost of sales Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated depreciation and amortization Property and equipment, net Property and equipment, net Property and equipment, gross Consideration received in advance of revenue recognition The amount of consideration received in advance of revenue recognition associated with a contract with customer liability, EX-101.PRE 10 eyes-20180630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2018	Aug. 03, 2018
Document Information [Line Items]
Entity Registrant Name	SECOND SIGHT MEDICAL PRODUCTS INC
Entity Central Index Key	0001266806
Trading Symbol	eyes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		67,074,542
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Amendment Flag	false

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 7,476	$ 7,839
Accounts receivable, net	718	1,831
Inventories, net	3,567	2,700
Prepaid expenses and other current assets	599	795
Total current assets	12,360	13,165
Property and equipment, net	1,191	1,299
Deposits and other assets	66	33
Total assets	13,617	14,497
Current liabilities:
Accounts payable	1,220	752
Accrued expenses	2,071	2,425
Accrued compensation expense	2,448	2,611
Accrued clinical trial expenses	1,074	779
Contract liabilities	260	48
Total current liabilities	7,073	6,615
Commitments and contingencies
Stockholders’ equity:
Preferred stock, no par value, 10,000 shares authorized; none outstanding
Common stock, no par value; 200,000 shares authorized; shares issued and outstanding: 67,075 and 57,630 as of June 30, 2018 and December 31, 2017, respectively	216,805	202,156
Common stock issuable		153
Additional paid-in capital	42,434	40,522
Accumulated other comprehensive loss	(604)	(572)
Accumulated deficit	(252,091)	(234,377)
Total stockholders’ equity	6,544	7,882
Total liabilities and stockholders’ equity	$ 13,617	$ 14,497

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares shares in Thousands, $ / shares in Thousands	Jun. 30, 2018	Dec. 31, 2017
Preferred stock, no par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares authorized (in shares)	10,000	10,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, no par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized (in shares)	200,000	200,000
Common stock, shares issued (in shares)	67,075	57,630
Common stock, shares outstanding (in shares)	67,075	57,630

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net sales	$ 1,907	$ 2,236	$ 2,883	$ 3,245
Cost of sales	836	1,127	1,504	2,254
Gross profit	1,071	1,109	1,379	991
Operating expenses:
Research and development, net of grants	2,422	1,949	4,895	3,796
Clinical and regulatory	1,126	684	2,475	1,298
Selling and marketing	2,879	2,447	5,891	4,682
General and administrative	2,632	2,901	5,875	5,642
Total operating expenses	9,059	7,981	19,136	15,418
Loss from operations	(7,988)	(6,872)	(17,757)	(14,427)
Interest income	27	29	43	36
Net loss	$ (7,961)	$ (6,843)	$ (17,714)	$ (14,391)
Net loss per common share – basic and diluted (in dollars per share)	$ (0.12)	$ (0.12)	$ (0.29)	$ (0.28)
Weighted average common shares outstanding – basic and diluted (in shares)	64,418	56,513	61,750	51,380

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net loss	$ (7,961)	$ (6,843)	$ (17,714)	$ (14,391)
Other comprehensive income (loss):
Foreign currency translation adjustment	(77)	92	(32)	122
Comprehensive loss	$ (8,038)	$ (6,751)	$ (17,746)	$ (14,269)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Common Stock Issuable [Member]	Additional Paid-in Capital [Member]	Notes Receivable for Stock Option Exercises [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2016	42,701,000	77,000
Balance at Dec. 31, 2016	$ 186,769	$ 153	$ 30,697	$ (2)	$ (608)	$ (205,861)	$ 11,148
Issuance of shares of common stock and warrants, net of issuance costs (in shares)	13,653,000
Issuance of shares of common stock and warrants, net of issuance costs	$ 13,647		6,021				19,668
Issuance of shares of common stock in connection with employee stock purchase plan (in shares)	193,000
Issuance of shares of common stock in connection with employee stock purchase plan	$ 189						189
Fair value of stock options issued for services			20				20
Common stock issuance for services (in shares)	223,000	(59,000)
Common stock issuance for services	$ 262	$ (132)					130
Release of restricted stock units (in shares)	24,000
Stock-based compensation expense			1,916				1,916
Repayment of notes receivable for stock option exercises				1			1
Net loss						(14,391)	(14,391)
Foreign currency translation adjustment					122		122
Balance (in shares) at Jun. 30, 2017	56,794,000	18,000
Balance at Jun. 30, 2017	$ 200,867	$ 21	38,654	$ (1)	(486)	(220,252)	$ 18,803
Balance (in shares) at Dec. 31, 2017	57,630,000	82,000					57,630,000
Balance at Dec. 31, 2017	$ 202,156	$ 153	40,522		(572)	(234,377)	$ 7,882
Issuance of shares of common stock and warrants, net of issuance costs (in shares)	8,981,000
Issuance of shares of common stock and warrants, net of issuance costs	$ 13,970						13,970
Issuance of shares of common stock in connection with employee stock purchase plan (in shares)	226,000
Issuance of shares of common stock in connection with employee stock purchase plan	$ 261						$ 261
Common stock issuance for services (in shares)	133,000	(82,000)					132,996
Common stock issuance for services	$ 262	$ (153)					$ 109
Release of restricted stock units (in shares)	24,000
Stock-based compensation expense			1,912				1,912
Net loss						(17,714)	(17,714)
Foreign currency translation adjustment					(32)		$ (32)
Balance (in shares) at Jun. 30, 2018	67,075,000						67,075,000
Balance at Jun. 30, 2018	$ 216,805		$ 42,434		$ (604)	$ (252,091)	$ 6,544
Exercise of common stock warrants (in shares)	5,000
Exercise of common stock warrants	$ 7						7
Exercise of common stock options (in shares)	76,000
Exercise of common stock options	$ 149						$ 149

XML 17 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net loss	$ (17,714)	$ (14,391)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	222	229
Stock-based compensation	1,912	1,916
Bad debt recovery		(36)
Inventory reserve	61	(1,456)
Common stock issuance for services	109	130
Changes in operating assets and liabilities:
Accounts receivable	1,100	(704)
Inventories	(947)	1,887
Prepaid expenses and other assets	161	13
Accounts payable	471	(528)
Accrued expenses	(344)	206
Accrued compensation expenses	(162)	224
Accrued clinical trial expenses	294	3
Contract liabilities	213	56
Deferred grant revenue		(104)
Net cash used in operating activities	(14,624)	(12,555)
Cash flows from investing activities:
Purchases of property and equipment	(116)	(151)
Net cash used in investing activities	(116)	(151)
Cash flows from financing activities:
Net proceeds from rights offering		19,688
Net proceeds from sale of common stock	13,970
Proceeds from repayment of note receivable		1
Proceeds from exercise of options, warrants and employee stock purchase plan	417	189
Net cash provided by financing activities	14,387	19,878
Effect of exchange rate changes on cash and cash equivalents	(10)	82
Net increase (decrease)	(363)	7,254
Balance at beginning of period	7,839	10,875
Balance at end of period	7,476	18,129
Non-cash financing and investing activities:
Fair value of stock options issued for services		$ 20

XML 18 R8.htm IDEA: XBRL DOCUMENT

Note 1 - Organization and Business Operations

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Nature of Operations [Text Block]

Organization and Business Operations

Second Sight Medical Products, Inc. (“Second Sight,” “we,” “us,” or “the Company”) was incorporated in the State of California in

2003.

Second Sight develops, manufactures and markets implantable visual prosthetics to enable blind individuals to achieve greater independence.

2007,

Second Sight formed Second Sight Medical Products (Switzerland) Sàrl, initially to manage clinical trials for its products in Europe, and later to manage sales and marketing in Europe and the Middle East. As the laws of Switzerland require at least

two

corporate stockholders, Second Sight Medical Products (Switzerland) Sàrl is

99.5%

owned directly by us and

0.5%

owned by an executive of Second Sight as of

June 30, 2018.

Accordingly, Second Sight Medical Products (Switzerland) Sàrl is considered

100%

owned for financial statement purposes and is consolidated with Second Sight for all periods presented.

Our current product, the Argus II retinal prosthesis system (“Argus II”), entered clinical trials in

2006,

received CE Mark approval for marketing and sales in the European Union (“EU”) in

2011,

and approval by the United States Food and Drug Administration (“FDA”) for marketing and sales in the United States in

2013.

We began selling the Argus II in Europe at the end of

2011,

Saudi Arabia in

2012,

the United States and Canada in

2014,

Turkey in

2015,

Iran, Taiwan, South Korea and Russia in

2017,

and Singapore in

2018.

Going Concern

2016

and

2017

and the

six

months ended

June 30, 2018,

we funded our business primarily through:

	●	Issuance of common stock in our rights offering in June 2016, which provided net cash proceeds of $19.5 million.
	●	Issuance of common stock and warrants in our rights offering in March 2017, which provided net cash proceeds of $19.7 million.
	●	Issuance of common stock through our At Market Issuance Sales Agreement during the fourth quarter of 2017 and first quarter of 2018, which provided $5.1 million of net cash proceeds.

●

Issuance of common stock in a stock purchase agreement in

May 2018,

which provided net cash proceeds of

$10.0

million.

●

Revenue of

$2.9

million in the

first

six

months of

2018,

and

$8.0

million and

$4.0

million, for the year ended

December 31, 2017

and

2016,

respectively, generated by sales of our Argus II product.

We entered into a stock purchase agreement on

May 3, 2018

with entities beneficially owned by Gregg Williams for the purchase of

6,756,757

shares of common stock priced at

$1.48

per share, the last reported sale price of the common stock on that date. Gregg Williams is Chairman of the Board of Directors of Second Sight. This placement of common stock provided net proceeds of

$10

million.

warrants or discounts were provided and

placement agent or investment banking fees were incurred in connection with this transaction. The shares issuable to the purchasers under the Securities Purchase Agreement were issued pursuant to an exemption from registration under Rule

506

of Regulation D, which is promulgated under the Securities Act of

1933.

We relied on this exemption from registration based in part on representations made by the purchasers.

November 2017,

we entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley FBR Inc. and H.C. Wainwright & Co., LLC, as agents (“Agents”) pursuant to which we

may

offer and sell, from time to time through either of the Agents, shares of our common stock having an aggregate offering price as set forth in the Sales Agreement and a related prospectus supplement filed with the SEC. We agreed to pay the Agents a cash commission of

3.0%

of the aggregate gross proceeds from each sale of shares under the Sales Agreement. During

January

and

February 2018,

we sold

2.2

million shares of common stock which provided net proceeds of

$4.0

million under the Sales Agreement.

shares have been sold since

February 2018

under the Sales Agreement.

one

product line and limited commercial product revenues, including limitations on our operating capital resources and uncertain demand for our products. We have incurred recurring operating losses and negative operating cash flows since inception, and we expect to continue to incur operating losses and negative operating cash flows for the foreseeable future. Management has concluded that there is substantial doubt about our ability to continue as a going concern, and our independent registered public accounting firm, in its report on our

2017

consolidated financial statements, has raised substantial doubt about our ability to continue as a going concern.

We do

not

have sufficient funds to support our operations for the next

months from the date of issuance of these financial statements. We anticipate that we will seek to fund our operations through public or private equity or debt financings, grants, collaborations, strategic partnerships or other sources. However, we

may

be unable to raise additional capital or enter into such other arrangements when needed on favorable terms or at all. If we are unable to obtain funding on a timely basis, we

may

be required to significantly curtail, delay or discontinue

one

or more of our research or development programs or the commercialization of any product candidates, or we

may

be unable to expand our operations, maintain our current organization and employee base or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Note 2 - Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Basis of Presentation and Significant Accounting Policies [Text Block]

Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements

Basis of Presentation

not

include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended

December 31, 2017,

contained in our Annual Report on Form

-K filed with the SEC on

March 20, 2018.

The results of the interim periods are

not

necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.

Significant Accounting Policies

Our significant accounting policies are set forth in Note

of the financial statements in our Annual Report on Form

-K for the year ended

December 31, 2017.

Recent Accounting Pronouncements

May 2014,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

2014

09,

Revenue from Contracts with Customers (Topic

606

This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services.

We adopted this ASU on

January 1, 2018

retrospectively, the cumulative effect of the initial application on our accumulated deficit on that date was immaterial.

may

include a performance obligation related to post-surgical support.

We sell our products through

two

main sales channels:

) directly to customers who use our products (the “Direct Channel”) and

) to distribution partners who resell our products (the “Indirect Channel”).

We determine revenue recognition through the following steps:

•

Identification of the contract, or contracts, with a customer

•

Identification of the performance obligations in the contract

•

Determination of the transaction price

•

Allocation of the transaction price to the performance obligations in the contract

•

Recognition of revenue when, or as, we satisfy a performance obligation

Revenue is generally recognized upon surgical implant, unless we have a significant post-surgical support performance obligation. We recognize revenue when a material reversal is

longer probable. Conditions that preclude us from recognizing revenue generally involve new customers with

reimbursement or reimbursement history, and depends on

third

-party behavior beyond our control, uncertain payment cycles over an extended period of time, and our limited historical experience with these arrangements.

Management does

not

believe that any other recently issued, but

not

yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Note 3 - Concentration of Risk

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Concentration Risk Disclosure [Text Block]

Concentration of Risk

Credit Risk

not

require collateral.

Customer Concentration

The following tables provide information about disaggregated revenue by service type, customer and geographical market.

The following table shows our revenues by customer type during the

three

and

six

months ended

June 30, 2018

and

2017:

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017

Direct customers	$	1,798	$	1,695	$	2,456	$	2,704

Distributors		109		541		427		541

Total	$	1,907	$	2,236	$	2,883	$	3,245

During the

three

and

six

months ended

June 30, 2018

and

2017,

the following customers each comprises greater than

10%

of our total revenues

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017

Customer 1		15	%		11	%		15	%		11	%
Customer 2		12	%		—	%		8	%		—	%
Customer 3		7	%		—	%		10	%		—	%
Customer 4		6	%		10	%		8	%		7	%
Customer 5		—	%		14	%		3	%		9	%
Customer 6		—	%		13	%		2	%		9	%
Customer 7		—	%		12	%		7	%		12	%

As of

June 30, 2018

and

December 31, 2017,

the following customers each comprises greater than

10%

of our total accounts receivable:

	June 30 , 2018			December 31, 2017
	(unaudited)
Customer 1		20	%		17	%
Customer 2		20	%		8	%
Customer 3		19	%		—	%
Customer 4		16	%		—	%
Customer 5		12	%		—	%
Customer 6		12	%		—	%
Customer 7		—	%		16	%
Customer 8		—	%		11	%

Geographic Concentration

During the

three

and

six

months ended

June 30, 2018

and

2017,

regional revenue based on customer locations which each comprises greater than

10%

of our total revenues, consist of the following

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017

United States		56	%		50	%		55	%		52	%
France		19	%		11	%		13	%		10	%
Italy		15	%		11	%		15	%		11	%
Korea		6	%		10	%		8	%		7	%
Taiwan		—	%		14	%		3	%		9	%

Foreign Operations

The accompanying condensed consolidated financial statements as of

June 30, 2018

and

December 31, 2017

include assets amounting to

$2.2

million and

$2.7

million, respectively, relating to operations of our subsidiary based in Switzerland. It is possible that unanticipated events in foreign countries could disrupt our operations.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Note 4 - Fair Value Measurements

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Fair Value Disclosures [Text Block]

Fair Value Measurements

The authoritative guidance with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into

three

levels, and requires that assets and liabilities carried at fair value be classified and disclosed in

one

three

categories, as presented below. Disclosure as to transfers in and out of Levels

and

and activity in Level

fair value measurements, is also required.

Level

Observable inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the measurement date. Financial assets and liabilities utilizing Level

inputs include active-exchange traded securities and exchange-based derivatives.

Level

Inputs, other than quoted prices included within Level

which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level

inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.

Level

Unobservable inputs in which there is little or

market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level

inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.

Cash equivalents which includes money market funds are the only financial instrument measured and recorded at fair value on our consolidated balance sheet, and they are valued using Level

inputs.

Assets measured at fair value on a recurring basis are as follows (in thousands):

	Total		Level 1		Level 2		Level 3

June 30 , 2018 (unaudited):
Money market funds	$	7,379	$	7,379	$	—	$	—

December 31, 2017:
Money market funds	$	7,235	$	7,235	$	—	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 22 R12.htm IDEA: XBRL DOCUMENT

Note 5 - Selected Balance Sheet Detail

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Supplemental Balance Sheet Disclosures [Text Block]

Selected Balance Sheet Detail

Inventories, net

Inventories consist of the following (in thousands):

	June 30 ,			December 31,
	2018			2017
	(unaudited)
Raw materials	$	643		$	485
Work in process		2,137			2,620
Finished goods		2,913			1,660

		5,693			4,765

Allowance for excess and obsolete inventory		(2,126	)		(2,065	)
Inventories, net	$	3,567		$	2,700

Property and equipment

Property and equipment consist of the following (in thousands):

	June 30 ,			December 31,
	2018			2017
	(unaudited)
Laboratory equipment	$	2,468		$	2,450
Computer hardware and software		1,423			1,329
Leasehold improvements		298			298
Furniture, fixtures and equipment		46			46

		4,235			4,123

Accumulated depreciation and amortization		(3,044	)		(2,824	)

Property and equipment, net	$	1,191		$	1,299

Contract Liabilities

Contract liabilities consist of the following (in thousands):

Beginning balance, December 31, 2017	$	48
Consideration received in advance of revenue recognition		233
Revenue recognized		(21	)
Ending Balance, June 30, 2018	$	260

XML 23 R13.htm IDEA: XBRL DOCUMENT

Note 6 - Equity Securities

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

Equity Securities

Common Stock Issuable

Non-employee members of our Board of Directors have been paid for their services in common stock on

June 1

of each year based on the average closing prices for the immediately preceding

twenty

trading days. During the

six

months ended

June 30, 2018,

we issued a total of

132,996

shares of common stock for annual service through

May 31, 2018

to the board members. Our Director Compensation Policy was amended in

December 2017

and board members

may

elect to receive compensation in cash or stock options, effective with the annual period commencing

June 1, 2018.

Potentially Dilutive Common Stock Equivalents

As of

June 30, 2018

and

2017,

we excluded the potentially dilutive securities summarized below, which entitle the holders thereof to potentially acquire shares of common stock, from our calculations of net loss per share and weighted average common shares outstanding, as their effect would have been anti-dilutive (in thousands).

	June 30 ,
	2018		2017

Common stock warrants issued to underwriter of initial public offering		802		802
Common stock warrants issued in connection with convertible debt		—		1,038
Common stock warrants issued in connection with March 2017 rights offering		13,647		13,652
Common stock options		7,072		5,536
Common stock issuable		—		18
Restricted stock units		59		107
Employee stock purchase plan		234		222

Total		21,814		21,375

XML 24 R14.htm IDEA: XBRL DOCUMENT

Note 7 - Warrants

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Warrant Disclosure [Text Block]

Warrants

A summary of warrants activity for the

six

months ended

June 30, 2018

is presented below (in thousands, except per share and contractual life data).

						Weighted Average
				Weighted		Remaining
	Number of			Average		Contractual
	Shares			Exercise Price		Life (in Years)
Warrants outstanding as of December 31, 2017		15,130		$	2.15		3.90
Issued		—
Exercised		(5	)		1.47
Forfeited or expired		(676	)		5.00

Warrants outstanding as of June 30, 2018		14,449		$	2.01		3.60

Warrants exercisable as of June 30, 2018		14,449		$	2.01		3.60

The intrinsic value of warrants outstanding as of

June 30, 2018

was

$2.6

million.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Note 8 - Stock-based Compensation

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Stock-Based Compensation

A summary of stock option activity under our

2011

Equity Incentive Plan (

“2011

Plan”) for the

six

months ended

June 30, 2018

is presented below (in thousands, except per share and contractual life data).

						Weighted Average
				Weighted		Remaining
	Number of			Average		Contractual
	Shares			Exercise Price		Life (in Years)
Options outstanding as of December 31, 2017		5,675		$	4.87		7.40
Granted		2,465		$	2.00
Exercised		(76	)	$	1.95
Forfeited or expired		(992	)	$	3.98

Options outstanding as of June 30, 2018		7,072		$	4.03		6.97

Options exercisable as of June 30, 2018		2,766		$	6.17		4.40

The estimated aggregate intrinsic value of stock options exercisable as of

June 30, 2018

was

$8,000.

As of

June 30, 2018,

there was

$5.0

million of total unrecognized compensation cost related to outstanding stock options that will be recognized over a weighted average period of

2.9

years.

During the

six

months ended

June, 2018,

we granted stock options to purchase

2,464,872

shares of common stock to certain employees and a contractor. The options are exercisable for a period of

ten

years from the date of grant at prices ranging from

$1.80

$2.07

per share, which was the fair value of our common stock on the respective grant dates. The options generally vest over a period of

four

years. The fair value of these options, calculated using the Black-Scholes option-pricing model, was determined to be

$3.1

million (

$1.09

$1.30

per share) using the following assumptions: expected term of

5.50

6.11

years, volatility of

67.0%,

risk-free interest rate of

2.32%

3.00%,

and expected dividend rate of

0%.

During the

six

months ended

June 30, 2018,

we recorded

$0.4

million of stock-based compensation expense related to stock option modifications for executive transitions.

The following table summarizes restricted stock unit (“RSU”) activity for the

six

months ended

June 30, 2018 (

in thousands, except per share data):

	Number of Shares			Weighted Average Grant Date Fair Value Per Share

Outstanding as of December 31, 2017		83		$	12.43
Awarded		—			—
Vested		(24	)		—
Forfeited/canceled		—			—
Outstanding as of June 30, 2018		59		$	12.43

As of

June 30, 2018,

there was

$0.7

million of total unrecognized compensation cost related to the outstanding RSUs that will be recognized over a weighted average period of

1.1

years.

We adopted an employee stock purchase plan in

June, 2015

for all eligible employees. At

June 30, 2018

the maximum number of shares that

may

be issued under the plan is

1,550,000.

During the

six

months ended

June 30, 2018,

225,887

shares were issued under the stock purchase plan.

Stock-based compensation expense recognized for stock-based awards in the condensed consolidated statements of operations for the

three

and

six

months ended

June 30, 2018

and

2017

is as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017

Cost of sales	$	63	$	67	$	127	$	148
Research and development		107		75		211		132
Clinical and regulatory		11		44		103		93
Selling and marketing		92		112		215		206
General and administrative		354		637		1,256		1,337
Total	$	627	$	935	$	1,912	$	1,916

XML 26 R16.htm IDEA: XBRL DOCUMENT

Note 9 - Litigation, Claims and Assessments	6 Months Ended
Note 9 - Litigation, Claims and Assessments	Jun. 30, 2018
Notes to Financial Statements
Legal Matters and Contingencies [Text Block]	9. Litigation, Claims and Assessments Twenty- two oppositions have been filed by third -parties in the European Patent Office each challenging the validity of a European patent owned or exclusively licensed by us. The outcome of the challenges is not certain. However, if successful, they may affect our ability to block competitors from utilizing some of our patented technology in Europe. We do not believe a successful challenge will have a material effect on our ability to manufacture and sell our products, or otherwise have a material effect on our operations. We are party to litigation arising in the ordinary course of business. It is our opinion that the outcome of such matters will not have a material effect on our results of operations.

XML 27 R17.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

not

include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended

December 31, 2017,

contained in our Annual Report on Form

-K filed with the SEC on

March 20, 2018.

The results of the interim periods are

not

necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

May 2014,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

2014

09,

Revenue from Contracts with Customers (Topic

606

We adopted this ASU on

January 1, 2018

retrospectively, the cumulative effect of the initial application on our accumulated deficit on that date was immaterial.

may

include performance obligations related to post-surgical support.

We sell our products through

two

main sales channels:

) directly to customers who use our products (the “Direct Channel”) and

) to distribution partners who resell our products (the “Indirect Channel”).

We determine revenue recognition through the following steps:

•

Identification of the contract, or contracts, with a customer

•

Identification of the performance obligations in the contract

•

Determination of the transaction price

•

Allocation of the transaction price to the performance obligations in the contract

•

Recognition of revenue when, or as, we satisfy a performance obligation

Revenue is generally recognized upon surgical implant, unless we have significant post-surgical support performance obligations. We recognize revenue when a material reversal is

longer probable. Conditions that preclude us from recognizing revenue generally involve new sites with

reimbursement or reimbursement history, and depends on

third

-party behavior beyond our control, uncertain payment cycles over an extended period of time, and our limited historical experience with these arrangements.

Management does

not

believe that any other recently issued, but

not

yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

XML 28 R18.htm IDEA: XBRL DOCUMENT

Note 3 - Concentration of Risk (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017

Direct customers	$	1,798	$	1,695	$	2,456	$	2,704

Distributors		109		541		427		541

Total	$	1,907	$	2,236	$	2,883	$	3,245

Schedules of Concentration of Risk, by Risk Factor [Table Text Block]

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017

Customer 1		15	%		11	%		15	%		11	%
Customer 2		12	%		—	%		8	%		—	%
Customer 3		7	%		—	%		10	%		—	%
Customer 4		6	%		10	%		8	%		7	%
Customer 5		—	%		14	%		3	%		9	%
Customer 6		—	%		13	%		2	%		9	%
Customer 7		—	%		12	%		7	%		12	%

	June 30 , 2018			December 31, 2017
	(unaudited)
Customer 1		20	%		17	%
Customer 2		20	%		8	%
Customer 3		19	%		—	%
Customer 4		16	%		—	%
Customer 5		12	%		—	%
Customer 6		12	%		—	%
Customer 7		—	%		16	%
Customer 8		—	%		11	%

Revenue from External Customers by Geographic Areas [Table Text Block]

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017

United States		56	%		50	%		55	%		52	%
France		19	%		11	%		13	%		10	%
Italy		15	%		11	%		15	%		11	%
Korea		6	%		10	%		8	%		7	%
Taiwan		—	%		14	%		3	%		9	%

XML 29 R19.htm IDEA: XBRL DOCUMENT

Note 4 - Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Total		Level 1		Level 2		Level 3

June 30 , 2018 (unaudited):
Money market funds	$	7,379	$	7,379	$	—	$	—

December 31, 2017:
Money market funds	$	7,235	$	7,235	$	—	$	—

XML 30 R20.htm IDEA: XBRL DOCUMENT

Note 5 - Selected Balance Sheet Detail (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	June 30 ,			December 31,
	2018			2017
	(unaudited)
Raw materials	$	643		$	485
Work in process		2,137			2,620
Finished goods		2,913			1,660

		5,693			4,765

Allowance for excess and obsolete inventory		(2,126	)		(2,065	)
Inventories, net	$	3,567		$	2,700

Property, Plant and Equipment [Table Text Block]

	June 30 ,			December 31,
	2018			2017
	(unaudited)
Laboratory equipment	$	2,468		$	2,450
Computer hardware and software		1,423			1,329
Leasehold improvements		298			298
Furniture, fixtures and equipment		46			46

		4,235			4,123

Accumulated depreciation and amortization		(3,044	)		(2,824	)

Property and equipment, net	$	1,191		$	1,299

Contract with Customer, Asset and Liability [Table Text Block]

Beginning balance, December 31, 2017	$	48
Consideration received in advance of revenue recognition		233
Revenue recognized		(21	)
Ending Balance, June 30, 2018	$	260

XML 31 R21.htm IDEA: XBRL DOCUMENT

Note 6 - Equity Securities (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	June 30 ,
	2018		2017

Common stock warrants issued to underwriter of initial public offering		802		802
Common stock warrants issued in connection with convertible debt		—		1,038
Common stock warrants issued in connection with March 2017 rights offering		13,647		13,652
Common stock options		7,072		5,536
Common stock issuable		—		18
Restricted stock units		59		107
Employee stock purchase plan		234		222

Total		21,814		21,375

XML 32 R22.htm IDEA: XBRL DOCUMENT

Note 7 - Warrants (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

						Weighted Average
				Weighted		Remaining
	Number of			Average		Contractual
	Shares			Exercise Price		Life (in Years)
Warrants outstanding as of December 31, 2017		15,130		$	2.15		3.90
Issued		—
Exercised		(5	)		1.47
Forfeited or expired		(676	)		5.00

Warrants outstanding as of June 30, 2018		14,449		$	2.01		3.60

Warrants exercisable as of June 30, 2018		14,449		$	2.01		3.60

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 33 R23.htm IDEA: XBRL DOCUMENT

Note 8 - Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Share-based Compensation, Stock Options, Activity [Table Text Block]

						Weighted Average
				Weighted		Remaining
	Number of			Average		Contractual
	Shares			Exercise Price		Life (in Years)
Options outstanding as of December 31, 2017		5,675		$	4.87		7.40
Granted		2,465		$	2.00
Exercised		(76	)	$	1.95
Forfeited or expired		(992	)	$	3.98

Options outstanding as of June 30, 2018		7,072		$	4.03		6.97

Options exercisable as of June 30, 2018		2,766		$	6.17		4.40

Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]

	Number of Shares			Weighted Average Grant Date Fair Value Per Share

Outstanding as of December 31, 2017		83		$	12.43
Awarded		—			—
Vested		(24	)		—
Forfeited/canceled		—			—
Outstanding as of June 30, 2018		59		$	12.43

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017

Cost of sales	$	63	$	67	$	127	$	148
Research and development		107		75		211		132
Clinical and regulatory		11		44		103		93
Selling and marketing		92		112		215		206
General and administrative		354		637		1,256		1,337
Total	$	627	$	935	$	1,912	$	1,916

XML 34 R24.htm IDEA: XBRL DOCUMENT

Note 1 - Organization and Business Operations (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended				2 Months Ended	3 Months Ended			4 Months Ended	6 Months Ended		12 Months Ended
	May 03, 2018	May 31, 2018	Nov. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Feb. 28, 2018	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2007
Revenue from Contract with Customer, Including Assessed Tax							$ 1,907		$ 2,236		$ 2,883	$ 3,245
Proceeds from Issuance of Common Stock											13,970
Argus II Product [Member]
Revenue from Contract with Customer, Including Assessed Tax											$ 2,900		$ 8,000	$ 4,000
Right Offering [Member]
Proceeds from Issuance or Sale of Equity, Total				$ 19,700	$ 19,500
At Market Issuance Sales Agreement [Member]
Proceeds from Issuance or Sale of Equity, Total						$ 4,000		$ 5,100
Stock Issued During Period, Shares, New Issues						2,200,000				0
Sale of Stock, Commission Paid to Agents, Percentage of Gross Proceeds			3.00%
Stock Purchase Agreement [Member]
Proceeds from Issuance or Sale of Equity, Total		$ 10,000
Entities Beneficially Owned by Mr. Gregg Williams [Member] \| Stock Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues	6,756,757
Share Price	$ 1.48
Proceeds from Issuance of Common Stock	$ 10,000
Second Sight (Switzerland) Sarl [Member]
Noncontrolling Interest, Ownership Percentage by Parent							100.00%			100.00%	100.00%				99.50%
Second Sight (Switzerland) Sarl [Member] \| Executive Officer [Member]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners							0.50%			0.50%	0.50%

XML 35 R25.htm IDEA: XBRL DOCUMENT

Note 3 - Concentration of Risk (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Assets, Total	$ 13,617	$ 14,497
Second Sight (Switzerland) Sarl [Member]
Assets, Total	$ 2,200	$ 2,700

XML 36 R26.htm IDEA: XBRL DOCUMENT

Note 3 - Concentration of Risk - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue from Contract with Customer, Including Assessed Tax	$ 1,907	$ 2,236	$ 2,883	$ 3,245
Sales Channel, Directly to Consumer [Member]
Revenue from Contract with Customer, Including Assessed Tax	1,798	1,695	2,456	2,704
Sales Channel, Through Intermediary [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 109	$ 541	$ 427	$ 541

XML 37 R27.htm IDEA: XBRL DOCUMENT

Note 3 - Concentration of Risk - Concentration of Risk (Details) - Customer Concentration Risk [Member]	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Sales Revenue, Net [Member] \| Customer 1 [Member]
Concentration risk, percentage	15.00%	11.00%	15.00%	11.00%
Sales Revenue, Net [Member] \| Customer 2 [Member]
Concentration risk, percentage	12.00%		8.00%
Sales Revenue, Net [Member] \| Customer 3 [Member]
Concentration risk, percentage	7.00%		10.00%
Sales Revenue, Net [Member] \| Customer 4 [Member]
Concentration risk, percentage	6.00%	10.00%	8.00%	7.00%
Sales Revenue, Net [Member] \| Customer 5 [Member]
Concentration risk, percentage		14.00%	3.00%	9.00%
Sales Revenue, Net [Member] \| Customer 6 [Member]
Concentration risk, percentage		13.00%	2.00%	9.00%
Sales Revenue, Net [Member] \| Customer 7 [Member]
Concentration risk, percentage		12.00%	7.00%	12.00%
Accounts Receivable [Member] \| Customer 1 [Member]
Concentration risk, percentage			20.00%		17.00%
Accounts Receivable [Member] \| Customer 2 [Member]
Concentration risk, percentage			20.00%		8.00%
Accounts Receivable [Member] \| Customer 3 [Member]
Concentration risk, percentage			19.00%
Accounts Receivable [Member] \| Customer 4 [Member]
Concentration risk, percentage			16.00%
Accounts Receivable [Member] \| Customer 5 [Member]
Concentration risk, percentage			12.00%
Accounts Receivable [Member] \| Customer 6 [Member]
Concentration risk, percentage			12.00%
Accounts Receivable [Member] \| Customer 7 [Member]
Concentration risk, percentage					16.00%
Accounts Receivable [Member] \| Customer 8 [Member]
Concentration risk, percentage					11.00%

XML 38 R28.htm IDEA: XBRL DOCUMENT

Note 3 - Concentration of Risk - Revenue Based on Geographic Location (Details) - Sales Revenue, Net [Member] - Geographic Concentration Risk [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
UNITED STATES
Concentration risk, percentage	56.00%	50.00%	55.00%	52.00%
FRANCE
Concentration risk, percentage	19.00%	11.00%	13.00%	10.00%
ITALY
Concentration risk, percentage	15.00%	11.00%	15.00%	11.00%
KOREA, REPUBLIC OF
Concentration risk, percentage	6.00%	10.00%	8.00%	7.00%
TAIWAN, PROVINCE OF CHINA
Concentration risk, percentage		14.00%	3.00%	9.00%

XML 39 R29.htm IDEA: XBRL DOCUMENT

Note 4 - Fair Value Measurements - Fair Value on a Recurring Basis (Details) - Money Market Funds [Member] - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Money market funds	$ 7,379	$ 7,235
Fair Value, Inputs, Level 1 [Member]
Money market funds	7,379	7,235
Fair Value, Inputs, Level 2 [Member]
Money market funds
Fair Value, Inputs, Level 3 [Member]
Money market funds

XML 40 R30.htm IDEA: XBRL DOCUMENT

Note 5 - Selected Balance Sheet Detail - Inventories, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Raw materials	$ 643	$ 485
Work in process	2,137	2,620
Finished goods	2,913	1,660
Inventories, gross	5,693	4,765
Allowance for excess and obsolete inventory	(2,126)	(2,065)
Inventories, net	$ 3,567	$ 2,700

XML 41 R31.htm IDEA: XBRL DOCUMENT

Note 5 - Selected Balance Sheet Detail - Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Property and equipment, gross	$ 4,235	$ 4,123
Accumulated depreciation and amortization	(3,044)	(2,824)
Property and equipment, net	1,191	1,299
Laboratory Equipment [Member]
Property and equipment, gross	2,468	2,450
Computer Hardware and Software [Member]
Property and equipment, gross	1,423	1,329
Leasehold Improvements [Member]
Property and equipment, gross	298	298
Furniture, Fixtures and Equipment [Member]
Property and equipment, gross	$ 46	$ 46

XML 42 R32.htm IDEA: XBRL DOCUMENT

Note 5 - Selected Balance Sheet Detail - Contract Liabilities (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2018 USD ($)
Beginning balance, December 31, 2017	$ 48
Consideration received in advance of revenue recognition	233
Revenue recognized	(21)
Ending Balance, June 30, 2018	$ 260

XML 43 R33.htm IDEA: XBRL DOCUMENT

Note 6 - Equity Securities (Details Textual)	6 Months Ended
Note 6 - Equity Securities (Details Textual)	Jun. 30, 2018 shares
Stock Issued During Period, Shares, Issued for Services	132,996

XML 44 R34.htm IDEA: XBRL DOCUMENT

Note 6 - Equities Securities - Anti-dilutive Securities (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Anti-dilutive securities (in shares)	21,814	21,375
Underwriter's With Initial Public Offering [Member]
Anti-dilutive securities (in shares)	802	802
Warrants Issued in Connection With Convertible Debt [Member]
Anti-dilutive securities (in shares)		1,038
Warrants Issued in Connection With March 2017 Rights Offering [Member]
Anti-dilutive securities (in shares)	13,647	13,652
Employee Stock Option [Member]
Anti-dilutive securities (in shares)	7,072	5,536
Common Stock Issuable [Member]
Anti-dilutive securities (in shares)		18
Restricted Stock Units (RSUs) [Member]
Anti-dilutive securities (in shares)	59	107
Employee Stock Purchase Plan [Member]
Anti-dilutive securities (in shares)	234	222

XML 45 R35.htm IDEA: XBRL DOCUMENT

Note 7 - Warrants (Details Textual) $ in Millions	Jun. 30, 2018 USD ($)
Class of Warrant or Right, Outstanding, Intrinsic Value	$ 2.6

XML 46 R36.htm IDEA: XBRL DOCUMENT

Note 7 - Warrants - Summary of Warrants Activity (Details) - $ / shares shares in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Warrants outstanding, number of shares (in shares)	15,130
Warrants outstanding, weighted average exercise price (in dollars per share)	$ 2.15
Warrants outstanding, weighted average remaining contractual life (Year)	3 years 219 days	3 years 328 days
Issued, number of shares (in shares)
Exercised, number of shares (in shares)	(5)
Exercised, weighted average exercise price (in dollars per share)	$ 1.47
Forfeited or expired, number of shares (in shares)	(676)
Forfeited or expired, weighted average exercise price (in dollars per share)	$ 5
Warrants outstanding, number of shares (in shares)	14,449	15,130
Warrants outstanding, weighted average exercise price (in dollars per share)	$ 2.01	$ 2.15
Warrants exercisable, number of shares (in shares)	14,449
Warrants exercisable, weighted average exercise price (in dollars per share)	$ 2.01
Warrants exercisable, weighted average remaining contractual life (Year)	3 years 219 days

XML 47 R37.htm IDEA: XBRL DOCUMENT

Note 8 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Allocated Share-based Compensation Expense, Total	$ 627,000	$ 935,000	$ 1,912,000	$ 1,916,000
Restricted Stock Units (RSUs) [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			1 year 36 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	700,000		$ 700,000
2011 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	8,000		8,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 5,000,000		$ 5,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			2,465,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 2
2011 Equity Incentive Plan [Member] \| Certain Employees and a Contractor [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			2,464,872
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value			$ 3,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate			67.00%
2011 Equity Incentive Plan [Member] \| Certain Employees and a Contractor [Member] \| Minimum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 1.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 1.09
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term			5 years 182 days
2011 Equity Incentive Plan [Member] \| Certain Employees and a Contractor [Member] \| Maximum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 2.07
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 1.30
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term			6 years 40 days
2011 Equity Incentive Plan [Member] \| Consultant [Member]
Allocated Share-based Compensation Expense, Total			$ 400,000
2011 Equity Incentive Plan [Member] \| Employee Stock Option [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years 328 days
2011 Equity Incentive Plan [Member] \| Employee Stock Option [Member] \| Certain Employees and a Contractor [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			4 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate			0.00%
2011 Equity Incentive Plan [Member] \| Employee Stock Option [Member] \| Certain Employees and a Contractor [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			2.32%
2011 Equity Incentive Plan [Member] \| Employee Stock Option [Member] \| Certain Employees and a Contractor [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			3.00%
The 2015 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,550,000		1,550,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period			225,887

XML 48 R38.htm IDEA: XBRL DOCUMENT

Note 8 - Stock-based Compensation - Stock Option Activity (Details) - 2011 Equity Incentive Plan [Member] - $ / shares shares in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Options outstanding, number of shares (in shares)	5,675
Options outstanding, weighted average exercise price (in dollars per share)	$ 4.87
Options outstanding, weighted average remaining contractual life (Year)	6 years 354 days	7 years 146 days
Granted, number of shares (in shares)	2,465
Granted, weighted average exercise price (in dollars per share)	$ 2
Exercised, number of shares (in shares)	(76)
Exercised, weighted average exercise price (in dollars per share)	$ 1.95
Forfeited or expired, number of shares (in shares)	(992)
Forfeited or expired, weighted average exercise price (in dollars per share)	$ 3.98
Options outstanding, number of shares (in shares)	7,072	5,675
Options outstanding, weighted average exercise price (in dollars per share)	$ 4.03	$ 4.87
Options exercisable, number of shares (in shares)	2,766
Options exercisable, weighted average exercise price (in dollars per share)	$ 6.17
Options exercisable, weighted average remaining contractual life (Year)	4 years 146 days

XML 49 R39.htm IDEA: XBRL DOCUMENT

Note 8 - Stock-based Compensation - Restricted Stock Unit (RSU) Activity (Details) - Restricted Stock Units (RSUs) [Member] shares in Thousands	6 Months Ended
	Jun. 30, 2018 $ / shares shares
Outstanding, number of awards (in shares) \| shares	83
Outstanding, weighted average grant date fair value per share (in dollars per share) \| $ / shares	$ 12.43
Awarded, number of awards (in shares) \| shares
Awarded, weighted average grant date fair value per share (in dollars per share) \| $ / shares
Vested, number of awards (in shares) \| shares	(24)
Vested, weighted average grant date fair value per share (in dollars per share) \| $ / shares
Forfeited/canceled, number of awards (in shares) \| shares
Forfeited/canceled, weighted average grant date fair value per share (in dollars per share) \| $ / shares
Outstanding, number of awards (in shares) \| shares	59
Outstanding, weighted average grant date fair value per share (in dollars per share) \| $ / shares	$ 12.43

XML 50 R40.htm IDEA: XBRL DOCUMENT

Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Allocated share-based compensation expense	$ 627	$ 935	$ 1,912	$ 1,916
Cost of Sales [Member]
Allocated share-based compensation expense	63	67	127	148
Research and Development Expense [Member]
Allocated share-based compensation expense	107	75	211	132
Clinical And Regulatory [Member]
Allocated share-based compensation expense	11	44	103	93
Selling and Marketing Expense [Member]
Allocated share-based compensation expense	92	112	215	206
General and Administrative Expense [Member]
Allocated share-based compensation expense	$ 354	$ 637	$ 1,256	$ 1,337

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ⅅ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end XML 52 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 198 183 1 false 61 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.secondsight.com/20180630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.secondsight.com/20180630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.secondsight.com/20180630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.secondsight.com/20180630/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://www.secondsight.com/20180630/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.secondsight.com/20180630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.secondsight.com/20180630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - Note 1 - Organization and Business Operations Sheet http://www.secondsight.com/20180630/role/statement-note-1-organization-and-business-operations Note 1 - Organization and Business Operations Notes 8 false false R9.htm 008 - Disclosure - Note 2 - Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements Sheet http://www.secondsight.com/20180630/role/statement-note-2-basis-of-presentation-significant-accounting-policies-and-recent-accounting-pronouncements Note 2 - Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements Notes 9 false false R10.htm 009 - Disclosure - Note 3 - Concentration of Risk Sheet http://www.secondsight.com/20180630/role/statement-note-3-concentration-of-risk Note 3 - Concentration of Risk Notes 10 false false R11.htm 010 - Disclosure - Note 4 - Fair Value Measurements Sheet http://www.secondsight.com/20180630/role/statement-note-4-fair-value-measurements Note 4 - Fair Value Measurements Notes 11 false false R12.htm 011 - Disclosure - Note 5 - Selected Balance Sheet Detail Sheet http://www.secondsight.com/20180630/role/statement-note-5-selected-balance-sheet-detail Note 5 - Selected Balance Sheet Detail Notes 12 false false R13.htm 012 - Disclosure - Note 6 - Equity Securities Sheet http://www.secondsight.com/20180630/role/statement-note-6-equity-securities Note 6 - Equity Securities Notes 13 false false R14.htm 013 - Disclosure - Note 7 - Warrants Sheet http://www.secondsight.com/20180630/role/statement-note-7-warrants Note 7 - Warrants Notes 14 false false R15.htm 014 - Disclosure - Note 8 - Stock-based Compensation Sheet http://www.secondsight.com/20180630/role/statement-note-8-stockbased-compensation Note 8 - Stock-based Compensation Notes 15 false false R16.htm 015 - Document - Note 9 - Litigation, Claims and Assessments Sheet http://www.secondsight.com/20180630/role/statement-note-9-litigation-claims-and-assessments Note 9 - Litigation, Claims and Assessments Uncategorized 16 false false R17.htm 016 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.secondsight.com/20180630/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Uncategorized 17 false false R18.htm 017 - Disclosure - Note 3 - Concentration of Risk (Tables) Sheet http://www.secondsight.com/20180630/role/statement-note-3-concentration-of-risk-tables Note 3 - Concentration of Risk (Tables) Uncategorized 18 false false R19.htm 018 - Disclosure - Note 4 - Fair Value Measurements (Tables) Sheet http://www.secondsight.com/20180630/role/statement-note-4-fair-value-measurements-tables Note 4 - Fair Value Measurements (Tables) Uncategorized 19 false false R20.htm 019 - Disclosure - Note 5 - Selected Balance Sheet Detail (Tables) Sheet http://www.secondsight.com/20180630/role/statement-note-5-selected-balance-sheet-detail-tables Note 5 - Selected Balance Sheet Detail (Tables) Uncategorized 20 false false R21.htm 020 - Disclosure - Note 6 - Equity Securities (Tables) Sheet http://www.secondsight.com/20180630/role/statement-note-6-equity-securities-tables Note 6 - Equity Securities (Tables) Uncategorized 21 false false R22.htm 021 - Disclosure - Note 7 - Warrants (Tables) Sheet http://www.secondsight.com/20180630/role/statement-note-7-warrants-tables Note 7 - Warrants (Tables) Uncategorized 22 false false R23.htm 022 - Disclosure - Note 8 - Stock-based Compensation (Tables) Sheet http://www.secondsight.com/20180630/role/statement-note-8-stockbased-compensation-tables Note 8 - Stock-based Compensation (Tables) Uncategorized 23 false false R24.htm 023 - Disclosure - Note 1 - Organization and Business Operations (Details Textual) Sheet http://www.secondsight.com/20180630/role/statement-note-1-organization-and-business-operations-details-textual Note 1 - Organization and Business Operations (Details Textual) Uncategorized 24 false false R25.htm 024 - Disclosure - Note 3 - Concentration of Risk (Details Textual) Sheet http://www.secondsight.com/20180630/role/statement-note-3-concentration-of-risk-details-textual Note 3 - Concentration of Risk (Details Textual) Uncategorized 25 false false R26.htm 025 - Disclosure - Note 3 - Concentration of Risk - Disaggregation of Revenue (Details) Sheet http://www.secondsight.com/20180630/role/statement-note-3-concentration-of-risk-disaggregation-of-revenue-details Note 3 - Concentration of Risk - Disaggregation of Revenue (Details) Uncategorized 26 false false R27.htm 026 - Disclosure - Note 3 - Concentration of Risk - Concentration of Risk (Details) Sheet http://www.secondsight.com/20180630/role/statement-note-3-concentration-of-risk-concentration-of-risk-details Note 3 - Concentration of Risk - Concentration of Risk (Details) Uncategorized 27 false false R28.htm 027 - Disclosure - Note 3 - Concentration of Risk - Revenue Based on Geographic Location (Details) Sheet http://www.secondsight.com/20180630/role/statement-note-3-concentration-of-risk-revenue-based-on-geographic-location-details Note 3 - Concentration of Risk - Revenue Based on Geographic Location (Details) Uncategorized 28 false false R29.htm 028 - Disclosure - Note 4 - Fair Value Measurements - Fair Value on a Recurring Basis (Details) Sheet http://www.secondsight.com/20180630/role/statement-note-4-fair-value-measurements-fair-value-on-a-recurring-basis-details Note 4 - Fair Value Measurements - Fair Value on a Recurring Basis (Details) Uncategorized 29 false false R30.htm 029 - Disclosure - Note 5 - Selected Balance Sheet Detail - Inventories, Net (Details) Sheet http://www.secondsight.com/20180630/role/statement-note-5-selected-balance-sheet-detail-inventories-net-details Note 5 - Selected Balance Sheet Detail - Inventories, Net (Details) Uncategorized 30 false false R31.htm 030 - Disclosure - Note 5 - Selected Balance Sheet Detail - Property and Equipment (Details) Sheet http://www.secondsight.com/20180630/role/statement-note-5-selected-balance-sheet-detail-property-and-equipment-details Note 5 - Selected Balance Sheet Detail - Property and Equipment (Details) Uncategorized 31 false false R32.htm 031 - Disclosure - Note 5 - Selected Balance Sheet Detail - Contract Liabilities (Details) Sheet http://www.secondsight.com/20180630/role/statement-note-5-selected-balance-sheet-detail-contract-liabilities-details Note 5 - Selected Balance Sheet Detail - Contract Liabilities (Details) Uncategorized 32 false false R33.htm 032 - Disclosure - Note 6 - Equity Securities (Details Textual) Sheet http://www.secondsight.com/20180630/role/statement-note-6-equity-securities-details-textual Note 6 - Equity Securities (Details Textual) Uncategorized 33 false false R34.htm 033 - Disclosure - Note 6 - Equities Securities - Anti-dilutive Securities (Details) Sheet http://www.secondsight.com/20180630/role/statement-note-6-equities-securities-antidilutive-securities-details Note 6 - Equities Securities - Anti-dilutive Securities (Details) Uncategorized 34 false false R35.htm 034 - Disclosure - Note 7 - Warrants (Details Textual) Sheet http://www.secondsight.com/20180630/role/statement-note-7-warrants-details-textual Note 7 - Warrants (Details Textual) Uncategorized 35 false false R36.htm 035 - Disclosure - Note 7 - Warrants - Summary of Warrants Activity (Details) Sheet http://www.secondsight.com/20180630/role/statement-note-7-warrants-summary-of-warrants-activity-details Note 7 - Warrants - Summary of Warrants Activity (Details) Uncategorized 36 false false R37.htm 036 - Disclosure - Note 8 - Stock-based Compensation (Details Textual) Sheet http://www.secondsight.com/20180630/role/statement-note-8-stockbased-compensation-details-textual Note 8 - Stock-based Compensation (Details Textual) Uncategorized 37 false false R38.htm 037 - Disclosure - Note 8 - Stock-based Compensation - Stock Option Activity (Details) Sheet http://www.secondsight.com/20180630/role/statement-note-8-stockbased-compensation-stock-option-activity-details Note 8 - Stock-based Compensation - Stock Option Activity (Details) Uncategorized 38 false false R39.htm 038 - Disclosure - Note 8 - Stock-based Compensation - Restricted Stock Unit (RSU) Activity (Details) Sheet http://www.secondsight.com/20180630/role/statement-note-8-stockbased-compensation-restricted-stock-unit-rsu-activity-details Note 8 - Stock-based Compensation - Restricted Stock Unit (RSU) Activity (Details) Uncategorized 39 false false R40.htm 039 - Disclosure - Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) Sheet http://www.secondsight.com/20180630/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) Uncategorized 40 false false All Reports Book All Reports eyes-20180630.xml eyes-20180630.xsd eyes-20180630_cal.xml eyes-20180630_def.xml eyes-20180630_lab.xml eyes-20180630_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 57 0001437749-18-014778-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-18-014778-xbrl.zip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
OKA-Z";U51:^AT^XR MZ&UTJH]>VM\XB+_Q*_,8C[(X(L"[74[9,5B7DMD)-+DZF8LK5XZ+9 M+D'0F5I;D("454 ZS1+D,)* D("454#TFM$N@35+(D(B4EX1:9[M*D*[3@?Q M A^PP0$Y?/M+ ZU0/G+NKMAJ70 MQ#WV^_F$;6]^F%/9SN8!X/3)]:V_/O[/_Z%I?TM>]L7D'HQ-_& \><:QKCS[ ML^.&0=0BCL^@1 ]O+(7:<>M2:Z^%AO7.K&?)0;"-MS M%-WY*+HY1M$KYRA@ O0MYJ*_S2B,?H%SH>>?"Z.QU2AZNXYB,&!6<#OX\F*- M3&_([D"T;KUK4XS@"?SGR[]"Y\ET9:>H+2>FWDR/J--IKAX1#$!OP/^E1K % M48<3J2G([NGX( M=B6[JLG87/HZKD+?_>"?# A,.K*!X#F^_=7G\9_P/CV/\/PI/_(PG;"K%T?4 M9P1B<[?;";[F&\/>BW_^<$WONSF.;GL8,7B%CB@*IC<>5D-VGAC>$MV=9F>_ MT[[X^,/X9]/H?5YF7#&K?,G,&P[:0#&_Y[IC,?S]CC=G^Z[BO&ERXK1OS,1IDZZ< MRD5#OQT?4C6B&@[&:MJDTA M& P&+[AS&U&S3,X=[)\;I.E_9)KEPA/.0%[#6H>1=B)%O?BA+U_\F MYZ6 ,63J?Q346]BH+7W4M$ Z8:5%-LBQ%T!&Y@AS&LWCE'JMR<:_KO 3\; O MRZ3@RJEVBYI!/3L7MX\P@B?9USA6Q2+$TJM"P] N2"$H;(M%HF;)U2 ZKQSU M\S8]L&O0S).UDU#[:?#71/?%*O\9%@$3'D1U/[O@P^O@O;)!-,@N7DM!2,-> MXI?:5\>#=<=)WKVL6<, ?OHWGJ0NC'T9[L4L.2B]L%;:H'>MP)UJ_ES"462E%"Y+*OP"O%[Q#"S8?C@<@9/#N?_H M\\A$DY9@ZJY(*:#8FJ446V.=V Z<%VES6?Z8I82U!F_PYL*\)*TU;1P&(8QR M$'IV; _BBEB/#5]F#TFD2R32S>Q<_.[Y2VL?"&XD02CF#,T80&P UT$\CD^@ MYV<(3,G4.LF-"$XY(@Q^F?@<2XIHN#9'RVU<2!U(@P7WV<,WA>,HUE%*B6VN MDUC'&^" 873NM!ZOLFEA75Y:Y8A P,.- M_9'8S$5MCW\=^S;X&B3<&ZG";2B-I?;&(KC&$RF D1Z;)E"7,R$G 5'L>[ 2 M#6;(=#P1\%#.V&R*(A?#01JR'GB#!04$X$=1-=*=?UGX7V%M:? M8.2' I I?GY?IL&M9_D\GTBNIE$.U(>+QH5F,=>-TW]FOXN):26_Q\.)DX%X M)#?M-POI09*.Y;RB?1.5TD/5&C(I"3X99T)U&XVDP:F6[^1)86=*\B3O%?]A M:B)+,(&:0#U[+#+-EDMP$ZP)UI6']?*Y!H(UP;KRL%XN M?%P]6&]U!CWM"6P"+5U_S=TYJ-1?6T MPYM@'AIZ3WL;>F9H.P&SLZ&<$RF]$R_;.RX[*\-.:MK3JSVNQH=?ZXL<#=%. M\*WP:(AV@F^%1T.T$WPK/)KJT4YEW@[B_WQ;2JG(Z7&\^IHCS22X;W26KJU9K>_04LMU/HX11F2YNHR)"6 :AEH('$A<2%Q M(7$IG;C(H?S'B]'06YM,89(:DAJ2FM2ROW1B)=/^UU"EZ<5 MHGNGWD(R-C80JFI8C\2%Q(7$A<2%Q(7VCDAJ2&I(:DHC-;OWX%I;43];?/]7 MYC%NNE>>?66/'<\1 95*_O MJ+5(M:*A%E#=;^@%4KU-HR:]KVB@=?&QW>NVB^5U[GY,@ $EU9W6/@CAOA _ MN#]P@CTQW%-2J#>Z"VB8?W0+:K;"9D_96$G7&_T#4+,5YGJ&DIIF]Q#4;(,E MO:=L5=;OYYRH&\_BS!3L,XO^O?&N+,L/O4#\,*>R_-I^W=2:2A);"UC:2,G> MA&_5-ZVI;"%3;QN]XU!^QRSF/!V ZX9R&:K+9F3YJ)^3@?SOP=Y0&0:-SO @]IJ>EK*5:B]:7;V&M-G-F"<,_N./3$O MS*FDTG2K%@/M1;SW'/?#10#0N7BW-QW;<5.MZ?6-RF:!E$V4JWL_[JMQUFC\ MCK%A$&JJ#CF>[320VB4Q-LW)[L.Y\6 6 ]D^:-\56.F<]%O=#?2GJ-B+X.T8 MKK3ZZWJO=T"2?W V,1T[$9S8F0$G1[8FC,L>[RD,2J4/PK#)ZLQ#WW'&N-U\ M*=> ^L:%;9J#?U>BOF($:<3L7WW?WHU72E?>Z"^IG%4? MW8VP'/Q2&G!ZI[/H[&Y!F R:[,0II?O7[O05G)(?VXZ0')Q1^G&MK@I)ZPCY M[>;K[1W#/CT96>L82OVPM&+G(.8@]&\7L5!*1UUO+;EENP]A MD=*\D%0NMU+R/T),SWM!ZA>+]!N!P/'8AHSK9%FC4S79=X0W2J\]PDH ML&7CS(%FSI^<1$_ZSQZ,RN?8Z]4-A?/$W*D&)*/3+D<;BDL-&ZW[82"[3L8M M<).O($U%=++V_" S1Q;C@>EXE]I_^L_LB?&:Y@RP(3!JTD'HUJ)V:<>G2QN; MTTP2B2EM+=G1+=5"^#%6U^,)"QQ0_4(;@$I--2L4,6_QN6AJL)T\MI?W77\H M.V='4W>I_<$TNXA^\HLL?V2PL(,TF"D^SW&@/3NN&XF+"4R)+ *-Q=SP%AD" M*B,U$/[2"K*V2/[G%DQT00*1ZXZ['#F0C=0/;V5L!H=5Y8+@MMP:B;[Q:@J1S M#2.P4N %7_X5+F[=Y3.(]:XZHZ;9T;,6\:;O[TOM1BM9[ZHS;EJM_H&HO0XY MQ[5M!VZJ-Z>[C6Y315[\P>T)VLPP]=Y;IZ.WMR+HFP-" GQ+@J"WL/1S,7(F M/QC'OBOFD'V:?O<]I)+[+DCC,+I%R<@_I0Q\D9U[KUX<4;]G<*M]CW)Z_^P$ M_V;5^;W+WFRQZ\6>\;?8#=<\#-SV!C>A!WCY-TU?DN[Z\,"O$E+3(N.'1 M&]*LR@9),I[ARR-WG?H$5I>+CXW+1J,]9]/.;-B!FS":5?/>B.=]:_ZM&7U# M.?I^?]O11V0?;KP[XV7-> W%>/4#C/6[B7;)[>!VMAYLY6GW^KU>)3WMQ&XH MM[.M9Q?GF8VEW?*AZ3G_CDT9,"H_Q<:*-I_(T[G;6>:6TC*,Q%&3\JA]8S8> MK=9^S SR&\^ZU-[.#PM8F0=J\PMV' *)[WIFZFNAR%[#]O6IRVA-7H/79'K3 M]&T_:\^F[+'N\XG/9.CTK0ZLVL\Y'A9MS4 M'KB8\GRB8%!T&AN&,P::O*@O\9,C0N ].$,"1A4XED!+G7E1TV*@&0<,'W)L MN$U> ]=?>F=#SM#.QFQ@C =0Q(7BN%VMO40OFS M=B^Y:0XYN#B_<+<&-( !""YYXF3#&J=90+]\22"C]/@=&("8N=KSX$+4:=Z5 M )H_+TPW ]780XP>27K3:]\9S8Y!CZ$[WGGYX M6#@ )%8$\_5&8Q7S4;0'CF=Z%@8Z!"Z&N,N@@6T\\44LQ3&MV.13+ITPKM&2 M)M) B6A@-CF8.#&!M4J&)&DEV8*JVY!K5NSZQ[I6QJ6U*SX$*;VY 5T(RG2^ MS@N8&3$5,&=9,RNY/V,"U339*Q7F;U&_%V7O=+)K&9=G(H">ZR_:-U@H-'," MXWH"NA!.\Z5#AGOEDK*XF_&[#"-FAO[E]ZS=5]#8=#T[-J1Y-AS0<$@V4(O2 M(RU.H7WU?5O>]IF'0RU]J&YQ2%\_7V7'M($]V>\4Q8 %8_8/W 4#]TH&ZI.M MI1F.4]9 % $&P[,8Y;X\5??8RA)(,Q^+,_UU(TO#\K3AK%Z#.6471U,K2]-# M" B;%O;U=O;K-]ST0->:SC/^>^^'L.3\W0=?17+F+A2BP-GJ+@OW/6#:!*.0 M%49$3[G'4)X5[)01DMW"3[_ZJ)RN??!ZN7=Z!I>"GZMG^2MN0#O ITF4GI+= M1TTG/H3PJ TVB@.?<="S''$_'(ZDEHM6JGCCVO+'8UCMI%,EI>K9Y"#W&#L" M8_\9MWC->.<;GW6$",%2E2X"&)^RF!_&-VSV"(82FIPFMT;R13,39YB\#_U4 M9RQ5;&Q;P1/1D:VA/-N.5V:?0C(3*F>K5OS;_RR!Y4:6++UN+Y+M]&8O/QRH5D@RF)B6B U'RX:T>]QF1;Y>U3>!G^< M%UU)%_"<5>)9+. 9^)-9Q_9FGH;MQ67"K2XEM&X K5,- #R+MC4XQ!#ZQ4U" M9LF\R2P-J57%B9,V4/YQW1DP'HRFD'^Q M&+,+"G/]I/J2HCD M0I +,_YQ$H)E8@JFF3-]7I1)-%T5D2B)0=2X;.QN$)%>(;URSGHE M*0Q6C"P:E_U5HICL#9_"]CI9T/A$QEXQ-NY/O=5*MZC/MU9_OB:S$Q!J4V;R MXN+V2VU2LX%FQQ]L MEN/D>)CCK#;;_,+,MF:TEY0UW#"#CN&Y%CRD_0BX&#A6E(8[2XK\E;/A4/L# MQ[P3GR. B?W\G#GWR3 MRX2ESS*1%L]G+Z2MXB%X>!"&;<6 6V)6RFHOW&!?::X7\.GOV<3J6;P9P U? MBVHE:\\,CQLG_"E&=WM9PN;S9@[E[.$!B2<65373'DWO+PSB#1B+J74\F;@I MCY4 "#PFCRE&F;(! B&8'UZ,ZB/$,B1S&M#9 765%F] %.XU1S(/P IYI"M^ M).(_CRA&!,![,+4AY.C%!O*$A\RJ'LMTC2BS 7 ]SS&,7G\7ND58A>U&-H\! M<'['AJ$;D?*Y%D?(''G(8!RZ0[E,KN3 E144(R9ZO[FF#IXW#9&Q9.K*'N^'2IW3DNFVI?/]U%Y^E0'?[GY?6E]H?I>,]R@RYZ M)_Z_=NU?UK3??KN6"512=8F%U'#YM^R7TDHCDL/G(G3"4BD4N" D8N:*]_JTK^R1RV^O3!D3OEN([WEIK(P&*$SU%9'C@FU0 M1?Q@'9H*-T]CYLU36^5D"DR"+1Q8&5RIF52F9;JLEIQY"T]S;/C:Y&= MQ]"40QL>7<1,[J>#ZGOHQQ6I,84\L61E_0<\H(V'.? 5G %Q<:T!K*P6U5U/ M$FL%7!"#R#_ RVZJ>4&\%D706%E:*:[0),+'_\9"1;$KP1WQ5_2%T(O+G\GW MP:=]&/OL))\Y'X_\_?C(]CV6];;BA&Q\?R93&W46XW*B%I*V!1Y=MMP0]VFB MVV.C.EOA"R?&G""5&(N#"Q9;8(EFLS'^ >,KZ7IBDJL2$C/?CJ,3(A>T^=M= M7R3')#U<-N4)UM2W864?N/ZSB+5&*G]>YEN!'?DRB><,(>/@3@'\++^YRV>2 M,!'\"QAFTK4+8T4<#4D8H&!:)3$A;BD'XDP JGP\%BX;#() M9L^C'RZ5J)N1:ZX0 B04[Y]7%0ABYT@:S9/P$6"CF5%W).E*.WR,4RH/FD=A MFV0J3Y"FDCGNNDI9U"0'N>F@B[<_PTAMYXGMGJ2*H50!(L2:4HXT[V'ME04T MT.27*,V>@TD$T(-1%!&D6##[HIVOV3D6.ZYNDCXZ@P>'V4I41RL)H-1RL*9D MI!>>XU*-H$W^PG$C Q8'G?AEL5S[J$:=)WP%BTJ_87R//0;)5[TA0",YFF/Y MK@L"$[\+((,!%- 5E@R1V!V>&!^1S;'P'P"?LA7,SZ68X>9 M,%WW4KL9X'!QN9]_W'^4*QG.C%R=,&$%_64L\("6RPDY%%?OD(ZO "EW0(Y@ MVH$R6." :G#S;7"GI[,(<*PCBS="\% UGN>,PP>SXV02NK(8SS@^F _ C>8D MV4>(3)2T=>=-9P8+#->6*TE4HK0$6 63PUR282PT!! UX\SOI Z!OU@CB\4- MK61X,UMS-88\J/EDZ9X9EK[4E5B S6'1Z3Z;"<3%W%X.77M6;"WVX\A-UN,%LU12CHVZ7V^]U>\<#S4M+W6Q5;W46N@7FI^IPH]FN M&Z6RNFU=-]KM]J%&$_69^6VQL9""X#_O$X,UJNN+]?Y@,0EJ;\[0=U=K69P' MM(/G8^Q-NCT_?+!MI]%_=VA2$]'9;1H%%,^MPAL+MVFW]V/BC&BLIJS-4:%E M8:&RD,MIPZ^E*MJ:_U?H![\LT#>_L$#HXDRC,R=IU>0O*6JUA%PM3:]6=)Y$ M?#:EE=WZ1-_XZ\Q=2\TU+#">;7);Q%ETV5IG5_>?%@JX18E-*U_P^T3&M[() M#O<+%> *"1^WTD,OH 51HU];A\$M1#$ZG" #ADD_]G@?*&G)+K2W#_[$L8I( M-\VFB?V<+;XI,RIA?J-M-VR.P]F(>=B$*-*4\6 XL_RA%T4'QK[-W"B0&8>B MDFVY_(UD$);XM)C$[2-?05R=&E>2PB5"&#S6"1-)%\R"DH86 [3)H,%;QK+>T5[-HQLW M6A(S@C%_#!A7SQ#N\RT2/TX+FBJB?*G7V&R_Z_A 62Q%CD'Z&.BX2GC,%>^+ MV&;,+,OS^N&XK3TS$YY'OA8*EF754M)K=&0"CU0@]5E;K:!S6MG!X'J/6=O. M8RA7CV3748X'MX$69W]I2#>>K1X42>:1"/Y]E@27A93<[9S-6KRXY$!JG)"3 M6&(3U]>^XU"*B\&^+H)!DR6R"3.IX!GJS\VEQLADL8_YSM)&? MW(9GC7 O=7%\,HK'I 4:^@H!K&R MY$#\T'SD2Y.BY*&T_0\^9YG:"0W#V%0[H30TWR $9'Y(DD81.\TR*"&3)Y)? MT%>(4E<3?;QVD.G::VLKC1 8"8SKP*A:6.,4[02>!$8"XR%I_AQ;"QDLIDX4 M1R?8"'6$ND/2? 6&I[4>)822IG M?'640J5[+J-J#8N;>S+1WIPE&LN_; M[#YD=29D JDKY^:JM2!1MMGQ0APUHAYQ'(P3_%)*JF+(AWRYTGA.,\AT8D.30US1DD20"UZ*"7U+LI%9GLMT>V MW,IS8^FOYODYG3BX779@-K=PEES\!<3)$XKT[?Q9F UE*G"_T>YG,AZ7/KTU M95LE8S:4"<'=?D\_,&7;9-,:#67FJM[7FYW#,RUW%K714&:PZNV6WMN)M(-E M_#;41P5@2A7$J9)L#4B=N=7M[>QSV;0&]WIH$_I:Q M+7VXJERG$]ZB.[_Z8%D-O6MY6 ^TY-P_O_)L^5M48>W*QH44M>IW%MP.'LR7 M'V ZXX4@VE5$\_/!_V'*,W_[G\&XFF=>J4C?>"RCKYQAW5B 7Y'2W.O+55Y]E(F3M8KTVU0>0NUUBZ/;V=E/M>I8&H#^B^)=X\*\L M>98"''8P78/I#XS=PF=0 45E,O8\1JVTGA=/M^X,M=K86#C'!-5E-;!T+J+X_<=>I14<2+CVG*%13L M2F>WKAMU% @UG0KG^?!TWLO77(7!R.=RWV(7KJ9]Z2QU"(%&%@9K/[\?J3D8 MVRV0U-LPD('(N!+:UFSM*6G=0&3JPWM2F8.C_2-3N4G8T[2H#.RUAEZNS\T8 MD?[<3G8E?&YB.G8\*UDP\SHN2[0#6M3'V=O]_B*L-Q%P (HW(T=7 M1@B[_?:^%$?%?K]R?WSMNV[4K^!V\-T/F+B3&? RYV++L_B=MBIHLV'&=Z1F MNSHS:J-B@9FYJ%$/(2D ?Q,=3?PAB^+=)M7&MV;ICD*T,SW;,54=8N]W%J+8 MN6G:/)3;P;4L9RTUTDJ6MNN-9OK'N^@ W0_<[TW9QN+3-'U%>LQ?L#$/$Y]2 M;7ENL2O/I^DW+GO#)*UA(E?ZS_OP43BV8_(I5F.^'4BBY)OD3TG+CEF1YA5Q MD':FHH6N+E6U8@W>P)U#,'.+PE1*G:4W^]VB25\%Y32QJCV.K47KED=3'T5@ ME@GIX-1.6N,,- M5;DGI4?8*GRH>F,V5+F:KQGJ51#U!TE>+BNWY]<)ZJWIMGZ"H4=J59_]N';H M.ZI!]9YW3C5X^#&G%*%1-WK'FVY=&39H'6#HJ\,*O_+%?<^T:?VG\KE/TX?I MA,E1_Q85\O7Y='9U4]2_UU;CJM!",'I=Q5O<:KMH.;AJ+[F4Y9OK# 84.-R-[E1/G:H 2G0Q!G3T>5$3"AI.2:A^#'7_ MG>T2!.RO25;4^TMA(.6G]R$R!R_5:XFQ%*KCLU[STUE+ M![<6#W;%GX_RQ^L\2I5NOUEQE&7?LS&KSYVM.GV6XTC9HQ\$_GCEJ;+CG>_: M<#*M^ ];/LZE]^'"F$UD^HR1)4NE'/[T6'RJJ8['JZ*C3:L/XAW\/$,\H/SE M4Y/<_T>P7T[QV'^%'M.:C<5$_AW>5-OVD,"*DX_\S-R8>+Z-^+T\W7B5%4!AH(R6N0W%Z*ZE8/R0=9%]MM MN206N"Z6;2U,,E^T49SZ(DM7B3CYA5;%G6@X=Q6BUUI&L_HJI)S@*0,-YP_@ MIM&O/H KZAN6;0V^3[S?*H:]H@ MSJ2.VFU24#3#T"TVE2NA:K8:T-$U4JM3/H6T:J.9%ED2$!*00PK(D=W737![ MW=>K;$.1SJV0,BU*2]:,9KM\BI*,!@)P7@#KY["I0HLZ+>I5#XRD*IICERK. M+"?JAHC1$7.,17/_O;E_7#G5*/E_5?/_WC9KC5:K BN#.C__^+G<\W:)>?.W M22A)*/<02J/6,T@H#R.49#.2S5AUFS&ILI+=0:MI'J-MM)P:O0D:W?9#K *S MK-++G+F]U4".OS;I-;VOEV]I6ER(FK2I1N)2"G$Q^B5,!CV(N*SN89\>;(Z* M8HH6O'#_DR,T-96W: M>G.I3J"2B"RY=TPPDULC8.YG]L1<7[(W[MVP7ULNO:>NSME:Z&VXEHR]*-ZF M[Y7>6U/3N]4OB.)M2MSK/76ES-Y"7XZC\C@WBO6>LMAEL]OO[$YQMK%@*E[Z M639.V*E-2T?==]AH&XV%(HV;:=B?YLV-6CKJ9L38;W2A(=[V-#\Q+V11.Q(O MX*85_.$$H^M0P(K ^(UGN2&N$=CN!?YG/Y@ON=I&@L:R0RNXY?>,/SE65%7U MB@]#<7,37]M^MA'($/&;F9%9O=GP]*!/06R[67@P^=.1\Z MA^2#NJQN.?FPU>K:53ZJ9=EH+JX291C=5JMV5UE4U^CU MFB4#3\L27 B?NLIRWGIGR<8M Y]6V#>%\&E-[Y)V M&77FLE8IAD_JYB?=1JN$?#J$?GH8<3\Z MR MB= .5?HM1:5?T'B,:=_@XDAH7P#KMA8W;LA5DGY-.D(A9\8(Z@3UO(_=.R]G M"W0J4UW!,M4DF-%C>;LIE%P&"=.$Z:U;(1"F"=,5PC3I:<+TN6'Z'/3TSO9_ MN<^6T/737J]H@=BD>4BKA,U#?O>P29!V'Y@!HQJQN]'0./-2'NT25NPZ59.M M^1G0-R0M)"VKI*4RW4A(6LI/P]E+2V6*G)&TE)^&LY<6@Z1E6VFA@A"'J:[. M3<^B#EJDEU:>.2_A@?.RZZ5R(K4,-)R]M)2PF@E)"TE+2:6E,E6$25K*3\/9 M2PM%'T_C(5+?R1L [)34$JFE56J)PKRTB).TD(-(TD+20FL+24MI:3A[::&U MY4 .8KFV"O_N M6$$Y,5L&&LY=;O0J],\D:2%I*86T4%8?"0L)2TYAH>,5>^W9;&H5N$#*R]P;,<- ^>)W3,KA.EUF/CR@C6UF1W5W!Y/PL ,'-^['20M MM'XP?C\R^6Z%LHTF%X-%)[(-(<*T^3U1K= M,U HED*]8Y,J'+J+,'::ECS0'14L)Q^>)XQ5I@)5# M+SE^!UG^[I@(N&-A4]AH"0P])R#7C_3&2LNY,@?3JH:<,M!P[NC5&V<0L2>O M[R#+WI?QQ/6GC,6+WB3DUL@43 /,49T)0.Q6_:E;MNI/ M*Z9^7RQ1:26DR@IFWLI@)9=!PC1A>NNR7H1IPG2%,$UZFC!];I@^ M!SU-)1?I.FU7SR0HCLZVC3*6G!0!UI(4ILLHTWU=&NI/&XGIGWG.<*O5G" MHY14^> TNQ\ *F28=#DX&X:N&?A\2AX'*8X5BH-6/0)O5<';*N&140(O@3=G MK(=VG@F]545O_PS 2UL'6=T$OHK2IZ#9UVYPB]E45O@_KYT/Y&1,JOS&,\WMXP[;'C.2+@)A: M(J=CVV.'55 QY2I:VVR7,.A,99U)0,HB()UF"7,824!(0,HB('K-:)?0FB41 M(1$ICX@TSW85H5TG*D]?)FDN\7F]+UO?DW@V>034]IN%^=5[ MDV %,/9%&K5&H=*P&X,N%2\-NQ3%4?V\)KI3B$8G4!.H\S[V&Y;YT98/5A*L M"=:5A_6RMTJP)EA7'M;+Q]FJ!VLJ4$_7J4#]3()B'[G5*U^!^AU55=Q,;U$] M[? FF(>&WM/>AIX9VD[ [)_?ET#IG7C9WG'9R=*KCDVN6.UQ-3Y63+R8T1#M M!-\*CX9H)_A6>#1$.\&WPJ.I'NV4O'L0_^>;[[%I7"Q&&P!_J$M7SBA=<_*B MV7Z(^]B[I)+HC;+DDJP=2"X9WBN9I%MK=OL;M%0)DDF:E'A%XD+B0N)2 I21 MN.06%SF4_W@Q&GIKDRE,4D-20U+S6J3FR'MIY=Y(I.NGO4[!BU-NWGYF%AL_ M,JXU=;G[VJ4=5PJ:OHJ@*<&7X'L6,T'P)?@2[03?ZHZF>K17-/NT;$X+[;A2 M=._46TA&%J:DHW MWA/SL"'[-3P*/^U>*,EHE+]0TM*D[HL2JHITOB4)SK[6P $/\*HVCU_G1C+! MNPSP3J[+50/T[2N5% & M3R!CX=PUAE'3R]@#EM8^ G!> '>,I:V^Z@&XHAY@V1:]KX[GB!&SM:'O4_)] MS+WC-%$_G68I5\,\H];72^@]4G-)DI'2R(A>^__;^];>QG$E[>\+['\0LCM M#V"G+5N6[=Z9!G*=S3O3G2!.3^-\:B@2'7-;ECRDE,3GU[\D?;E')#*:K^Q!7[>LJNTU@=A6RISD9RG;-[$GH M3(#? !.N )=ZYBP!@V#>E4'=8G60GA)\C?+LQ%[!M'0.]\%T"S/T?QG-A- M 6)LGAV2@842F 1F/C1\:-;TIJG V! ?@IA]N)I(?B/>E31$#4@)I#R)E TE M'#852 F1"ZDX+O.SNY@_S4,!&,)DEN34\_K2F,2"S^NW:FU3PI@(2&\!=)&1 M+LU:IZ' YDZ.>2UV)Y^(2UG1'UH$75H4.5?^:(P\:@78]QX1#0BV ^3T W;S M-P\'].+-(LZ%'>!7'$Q.R&QARIW90N>I+=8TUC+'082J3\4.9+LH[S$S..IY MTFU?0YYJ@-_\3+2/0DC^0-NT]D<\6%@[NC5LJ'T0%1@'C#OUMN_B&^2L<>Z" MC3+6"]+^()87K%VYM@*D\41:FLBDM7;M 1%-\*QD-#OZO+?<^UY%7U=TWVUQ M"M60[Q3J?1C0P/(XP#6+\J%SJT 1K&X=U89VR0,INA &I YZCS^16G88Z\WS M,IRMAIV==$)2^,+5U+6%(0^&/*12GF08_ #'5<2QHK-"V8:^OQ$-8.0#BQ$3 MA66H8BCDB;:2$ZHRM*'L=($!%N:6VZD??#) /+?G1YL?>G!AL,TV@+HP(R-7 M +7%X\D3?^5(;TCV!1Q2B$,W[XC8F"+M@6!;-K\1N 1<4HA+?^$!TCY@3_L7 ML@C]M01D4O1(PSR/6[LI81ZW:.V:V5&ASHJ2X)'J($+9 MD6R<=R6LC@% !DN<#+^=%6N Y'9Z#G)?@R27- W+>*]64!#PY\.1D]N1@C6R1657SB8;>QYB 4Z=E MFEM5FM+2Q8:@?.CUF@H,=?$Q&N X@N,HC>/8.N]UY6-3RAF*P9L$;[)$L7;[ M0 #7B[P.\XN,@RLAA_3>*4=J.:2EF7,4G$.Z4VMT))QU0!IIF 6D 6_CO%'6 M+-*50;4,/0%7#"88*3CB^EE]<4J@VYU;'MNLV89SXQ)5WMI?WFDV')+_,ZA[[)Q MFM[\$[+[OOH!^FX1?CZ+WI-'KBAZ7)4E0_XJ2UNJ/14K4%))K1 MD-JF(DH^X*DUT $3@ EI,P%**@%U@;I*4A=**@$5@ KB-B77+8 (0(2TB0 E ME8"\4,*BW!R'DDK (> 0E%0"+@&79. 2E%22)">LS"65YK&=4%,ILS:4/2I; M;]?TEH1QV7"N $[-' CEYKE>JJRN)0#VS9L\)[;DB83 8F">"_E=-_@[4K*':4-#$@%#M*US$T ME2B("<6.)**D.ES+B41M*VO9@4^.JG"D=^2O<+2F);T[#B+4>RI>H.A1 M=IE<3(4RN60?B5)<;I6G(4%(^\(N#JEVP[#N+"9U6_9:O3PKLD"=^&_3S_I9 M9N(!0(O;^OB]M'"&')9'T$^EG&%E)N;F$J&B' 1, Z97,;U]G@@P#9A6&]-@ MIP'39<-T&>STT?Y_MOOL<%WMZXJFZIAGHS6Z\F6CO0HI^P(1;6TKK[I1$0>W MH5'R#3%UTG/^H@9@9&A#Z4$K86 "@!9 6Q)+FY?_,O-=5I6^/ K_"S@L0".E M;;\"-(+(]'1G64TP6F"THHQ64Q6C!0XK@%;AC.8 7X#O#+[;FX>28E8!/U%. M!,O0AK*S2,5!0 %"*;K5)>W$JP7F"\Q7A/E2)LLV.*Z 686'7( OP'>^UB7A M 5ME_40Y(2Q#&\I.(Q5' 04(!3M>Z4Z\##!?8+XBS)<*-1_ +3*@19B MH&"V!2RJCNE7@$;[:YHF4NB\3X'HB8=RJ@\JL+Y>(+3Q2X283I4[U =-_<50 M.46RRBFSZHD'4W_[2N:)H'3@=\6+3(&[4IP] M*L#0? @]*W1P@)Q?"T*WQ, H^L5YH%!6*2BZ5S@O9V8VH9Q9Z5;?S)*OOC65 M2>&0_2 ):]7 ECUKU>78\LF5+7#>(MV1'$KF@&V"D1Q&P9R7)F [S],68W@7;!+8) MQG08TX$WZ8SI.K#EE#$].J?:;Q]#6G^QK/&GOCU$3N@B>C^X\CU^@)]8 ?:] M^\$CIC\O)_S?6\L.?/+$&G+I^O;/S__Y'YKVV^(!R&6Z?KGPG"\6^8D"]OGF M?8P\BC2;=8K=](@&#!H_>%*B>L.H-_391[/>:IQI#K(QTS;]_:S>.M.P\_N9 MW6HU6X;>8W^&'I[>CJEO-/5./:3.V>=FM]-K-!HKG8AMP_%M[2S;VMG?5B.V MK8;1R;RM3)AZK&==6P^PVCVOKT"+HTJ+(N?)'_+J M^VDR-?5N7#OUGK[1SLCW']?&0V1IZKT=;313:N,%(9;W@D;,CEQ.EC]YL";\ MJXLWBSCBG[\1Y1IZ8,;/=_0DTO\A[GN:C-'%.Z;UF]'8]2<(]0-FD>['_-U? M1'ZH'P^NY7VU1M.?/0T1>X1^\T^(@\F=L&_X%?&?S'[]A ,7W0_N/&89L1-: MKKCMBLU_+.S-7T(9JBZ8>62VD5O"Z:VKPNUU]+//#\:_]HGP./&D)/A;"Y._ M+3=$%Y2&(R$RRBEB!\BYYKU'GO-H!8GLBX3:6 +?6%--M[&"^_=GXN+Z."3H M[/->P*X3+*)E5B\\9"Y=&I"07V5& Q$;LY\?H=A'UDB"NTWGLYE]&:]I:?$ M(GW;1,U9U&UES:*MWLH@WY2MU+8+-Y=ONZ>L?,7#[@?B*KT(@Z%/\+\W2(KW M^-+MM1'](23VD+UG.5*O"O7NZ^WZK,6,E:K>;C=2DFM,+U,2XOWYE)[[M8-$?.Q2LBU@N:C] /C+4H YFN0Y() MM1.]@%0?(U)?%[)YKJSM,!.G*/=8KN?.FRS+IS[!W 7I[$6,NZUXOR0)C MBAW/63$;GI MOC<2D_&S<=Y-H$+E/%]'N* V1<^H:P4DKA]M; MK@O'O-GNI@+LJ+X>*$::;-$'2;@.T(B)]HKTJWKM ^2=JE!25LA.ORIC;>0\ M/3)C0N4B%=P]9"Q.3\@EU6X>TZ)&8NTVSQN'F$O0[J&6-"86.4H5LN@AWFUJ MUQNM'X_(9=-+]E823)[8>RA#)7_GY63URC3@ATDJ0/02>6B ;6RY[N3^S4/. MY>0+^8.@EY?OV'6Q-:(S.O3#9XH=;)%)W^*\$,Z!>-*:FW#Q0I 0PUXJ= Y8 MT=;/C_W*)XW-;-_;Y06]LQOJFT>F49+DKZ/$) MD5&R>.OB!^A5F]UF0F__2^\VKU.0^UX!E4,1J8VEJXHPF2+,?QD-E?2PO8]\ MQ[J(/8IM\7H]\UDP,QNQQYFZV\LYF70R,V%N#*"/:,0@Q2;=N[X7C(I>V8XYF77,RG8:TCE,&FF$&6[Z MLLWDTPJ]>6YLKG/E(@1YA']B#.*6\ ]8DBF'\.,7-^,,4W// <*CEMM7)W,M M9G\[*=O?([HIH9S3'>?:P@5KM8TRR?GO(RQ)ZH-:XIV*W8,:?\UT<3R1S[-V M3#=NT_Z45QYT3K@3>SZ\N1%VO/+.V-9[:%3,E5O8I4HE7MM&)#2@^7MG3[]D$I8_(*[91 MHM[LFC/K\4$D>JO9ZYD)E;;5L'0[E:65:C5V'&5H'F"E));!)DSC91%/XOKF M6:,"99&I(>O&GEMDG) '#VF:K7A9Q =TUS?3PV0EBZ_H35R*EH'8$E)V=RC^ MT GS$ME_G83R7<@H-;FN8*M9;W9W=/XBF.8#$J!B,RM^G1XBA%V.0R/6(\Y# M"*U-@F4FA&8\$@KJ?J8S@_8N&VNV#["R$O5ZA^??CK6CQSN#B?F;\OC8CO<9 MN[VN7B1?L_#CV[&1PL>K;F/!1*RFQ!PPRM3U/2#_Q5'=D4\D\8IN'9NO(J5> M94GWN'+ $]D5N42Q0[GQ MGD41RDWML$_\/"P?U8JM@=A5M;S7E6,C/?1NHD6*W;W)22 [.MB-V>F6N8/9 M+B['IE9MFHD\3BD$LJ.#._:$\NU@X:NQ,3E0N" 2+3A%]T(: 21?BHV%?%UO MR2N)'3V*.Z;&Y_R)EGERZ%"V*\NQR;;EP78^R\JQV;SK>K+%GT(DL:-'O9BC MKPS;C>0C]@D=*FPE+Q;3>LOA ?-JWW3+-;4!>R7<&,)VNKUTD^%&7=Y5U=B*^'D'47 MI%CJB'+EKA>'-3?W[G8 :X>X73GHR?;#D>A"$>X#X:(\,L$#9%'\2NZ M\VQ_E !_L2:P;C8BANU<.O:(^&$WY-Q8A RA>GI="MKQ*]9U8UNQ,Y++AT[U,H:^@XKVVPTV^F/@WOGG88> M;V6[W4;Z'E0G;6?6:.TXQ]'4VUF@(R-GUFC%KKIGXQ9K85.S4V&NUF M%E#/R>4SXF=/]?9FSL+<.G:P,3)BI[AUODO0R<([V>/R&?&3N4XW*L[YQ :E MOB!BQN7YX6Z2V6VTB^]"?,R&&;OGMS]D(Y56'FEIS+@T=I))S\B2WO\E(]^]CE1W?%YR>] E-[VT)M&>.GMK8+>497,LRS>G:CQ\P+I MSTR >=5:-\_7RHK/4-1'=LANPXAN56)?+4">E_!XF7;OF8Z+:('X&WL.X_PG MO3L^1)_KBA'W34S"")M)(PK MU?R!YH=$N_0MXO _KC%!/',5U8;6*]*>$?*T,1LU6=N(QH8;3/C[IUOJF$=% M"150H0+V(7N.:?\O])"F:ZN"9.U&ECW4)L@BFLB/P-O"6JM9TS0(&C>9;$S1 MQD2T?-89#8]&R,%L4'(G[!*R$4_?D$,G@C>&C\D:%@)BB9<[UH2>:],M']'& M[%M#\?M:4YA&@R'5$$.QDYM&6XV:QH>KVIIFWYB.Q!Z89FF!SQ[/,9I]D_16 ML];KF6M2F0;D\O>O@9Y#R?*\D#5M1@RF->*'+\,\1/?%FF@M?2JY-<$%O@#/ ML^#UC.SGVM(.W3/2S[FNK28 5ESAQE=#&ST&@X8A(6%5:?D>N_U;2W(68N$;\I<)%XQFPN MR3\3Q 3+;-GJ8RV;X92@F(&NI@W8[$\XB[;EVGP!@MLW_C,/!9K+3W@Q@S:] M6^-B>YNEHEHZ8;/'S9Z_3)A5TRPZ\0W?$;!IMC\X9MS[HTINGCM M/Z$?_,]&%Y<7-OJJK;9?:XS?V5O9*]^P$PP_:9T&_^9,LY'KTK'%!Z??SQK3 MO\>6X\S_?O8)@Q3_*+HV[1N9=XSI/< ,+3/)L5\'@3^:<4[\U)G_]-3>;(HG M2AF!(\6+;9^+U/O]S#R;-V(%7AH_-X;(Z?K= LP:J,0W4^W5IVIA/QN_:Y1Y M?XY&7IX_,&O(__MU15V9\FK6[\Q7>%*[;39H; [I1SRI%N<6['07\L&S-J/[ M*DKV@?QC0)8M VN0S!HTP1JH; VXYU@R&@,M@!8IT*)3,EH6-BKU87J-XN(JDWS!74V^V?20^2-8&92^#P>>Y@O!6CC\-G% M-OMF@/@N1$)JSN2@_Y*^54X\3LG4AM8OLSGV#+EB>I_'B)739G>WT=PRX'DK M):+SK(UOQ!K_?C;]?R6A(T,; +X*P#>5,;/=%L-ECF.F4N.DB'+P/"3RS$[W M\&Q>LH3)F*_A.N@Y@!$23$R$B1%-_*]W-@4RMN&=I0=@"W:^V6J3Z 8:Z8_LB' M(T[HP= 'E@-62P'')<)Q1!B@#WZ&'"I2P,@=U*'-C MU&P9Q1NCJ),%,, "0^1@2%."789,&)+QU'4?WJI]'1RH5!RH)Y[I"CRE*+/9 M8F;3\4,>>5V2@6!WC[(?"?1:5Y?076J!NP0TD8HFK4Z[I#29#]NS/\0F[>*: M-#EJ5S_ORJ(UY5Y:KN79J#]$*%C>2(_+K]SM]3J07SFC M)?+UA(4+E&A]D9P1.=I,E9K0I7;-,XJ[<1@J'M$YM2#=K,MWWBM[D$\P;XJ' M@H+%JU(^PQ71<9M",0WXN7N>FV_@NZ[_QG. KB>W^R13^W=+=3D2[DYNMS6F MG3I(0B:[@EXL39*>TF??R3G7W([U!H WP#MU>"]2?[=TQ? )J0X5Y!/D=)LM M:B3,69@CW2!/(6#Z5$PG2C@H.:9A7%&0@P60ZT/H6:&# ^3\*J>#5.47YX%" M6:6@:"B S.D\'ZTW=HVA"%LNG"+898/_6^*-S9SV2DRC5?QN)>S? XY/Q+'1 ME6#77?*@Q*K$Q7WWR4^>8FQ,?!M1& +A*%)DJ$Y-;Y7@,)*4'L-G< MVNI3#\"*S@!E&_1NL8?I$#G:B^\[,.;!Z: \#%!/EV#V""?H@"/2\!C[1T#O?!= LS]'\9S830 %B;)X>L9G 0@E, C,?&CXT:WI3QG37 MT2&'40-&GJ<@DX:H 2F!E">1LB&EPZ8B*2%R(17'9=>AZ0H;PM.R?L@<'259 M^I)6K6U*$!,!27Z +BK0I5GK-"30[Z3: %"ZA9(W:+VV:R* MGYE,9$]3.Y!\Y&TY9WQ)."$%A@!#9&'(H4ECY(0X'/17D)*0;..DVY+FG2F( ML9"#!FA1$"T2I:Y1B!8PNBE(XP+X"6EL)'XQI+%1+G!/YC0V?UG,3;!XC%[T MHC3LAT,6D.T-.<,L05UM0#(@N6:T)=A:EOPT057BPJ[\T3AD#I4VM(CS9A$D MMAJI/PCX'S JPH&D"!.BUXPFG*@# "L,X%:SISZ %9T;RC8&_H4LBG@%-PV/ MQL1_%579(-$-F(Y(][D'TT" +\!7^7$/YGZW(?%P$!)4TP;XG7^@\9&ZU1T" MX;1DMMDM)#B^#(G>@"! $"6SO,5/7_?!K=K75?:AP.8J9$SSLI*U9DO&G O@ M- " $P)8+\.F"@SJ,*BKOC!R8=OA*'2M #F:@\8$V=@*L.^)U1%KY#-Q_EM\ M 0LD,/_+?&#XT*HU#$/"D4'%=%) 2B!E*J1LUKI-(*5$.=[ 9P2?L4"?,3I5 M"^3:@^1A!52&T7MZ\4,3Y-H#NJA!EV9/@F#0LN?:.^D\^WH'#TT>ER*,8_+U M;202.SUUWA7[GEAVH/V%K6?LX@ CJES?([4F:VL7$G>7$D^>:6_9U>(_9CF5X*NU=VM[M?(!"L9H5!K[XT#;&000(3D75$8D!Q\%F:D#^S2(YX/C] M;&F+4YKF9N/Z;(QZ$0LO:^-T^@R>B;EKR'=X_!*QKSUN IXMEU>"J6FK><"T MS1PJR29\N8OX&!)BW#.HM/ X\%X-:XK6P=9WVQIO^ M5KVWXF]1S WW5DES(;B5^0P9&N6\RI*;#&GBZ!7Y(6(7_9?/ Q[KOL,BPH[ M.7D==6E)$$ZC2N"LNG;O<=U$_!LY\9HNS!)DO;L;#)G=/&5[-_4&1EB6@]J< MPPYNPC7RK&8WC5\6YD',,,7_%BD-?P5G1WIG1S3EQN,:U"[GL\%9WG0Q$^P6 M[ZQ$KBO+Z<' !D=&CI I8[ZG:&"FO[VQ^OFWCR&MOUC6^%,_'(]=D>C!1+/_># M_M BZ#X,:& )@W!I46Q?>,XU=D,>1VHS@; '/J(!T_$/;AOJ#:/>T&O;9- R] MVV@TEGT[KH79]+*S[&5G?R^;L;ULFVV])6TOF0+UY+ILQ>M2[[0;TO:RL^QE M ET:\;K46]WT>LFLY,]/ ]\//#] ?[$_M'?Q%?&Y21L&P?C3QX]O;V_GO!'G M/GGYV&PT6A_YY8_\AV>SWP>3,?L]ZS#R'.2WC^C7QR(_+9^YXQYC]?N<;^ ^.>CZFOM%D&@RI$_."V2\^ M?>M?G_J&^IB-@SNDQ@PS=M#LN[4G,1 @D:5UB.^$=G!/^HB\8AM= MO&-:OR O(;V[FUW[(O8F-L3.QCT<3#;E@/D:'1Y@Q*87]I"-CFO\H<@^?_%? M/U[=_7GVF=%7;YIFMV'.F[^\>?.Q%+WP@793K YKQON8^3-XUD;-82Z$1['O M_7Y&2? IJG-GG]$$T4]179PV9.NI6XI9;\[\VS6)S!K.L(M]9ZL[@46":RM MGY,X%+ MQ(B>/P!.%&GG< 9V[+/@5]9$=$A%;#&XOP_67Z@(AP@"XGT0\0'&9WCGQ/P/V.TI#/@-1FVA1].!:@.,]9GB/X #* MN4/Y$=& 8#M CM#)-S8?I8_];P#DO09YI^0 R;DC^9OG(/+&OD"$?L?!\(Z' M#EGN0_C,%%".&6_V!OH (0+$$K'61\'*IP']G4(%"D12@$F0%ZF< M!C8_8OKSRL(#O_A+%3"78^?0=V5H^=3]^!G2JP\UL?V%D]=G[K SOCV"EJ.H@H_MDZ MFH#/U=#R/.0N&3K[XAH39 ?NY,EGMU*>+T;YQ=:] MA@UAY) -+20=K3D/CA MR_"./9J,D$A=4E6HQ8H"L!:)M3O/9L)=C M_^;88>J:;1"[VQ #A.8_HA=>P M]E4'UH[NSK=(XCL-$#H<0CX-[@>"H"4&SM)L;?06$',P8OY 'B*"?A?.B%&1 M"F?X%=V\CYE.%$](E A%B20 R#H868^((GX$D2?]9#,^UQ=5=:N#JP3]!U0= MC*H^%JO:1*U,9BP@JNK) ML:I-U,KDQP*BJIXBJ]I$K4R6+""JZHFRJDW4+A"UHD3M E%W$)670OUJC:;\ M>AHB=DF?[OS?";7AUQ*4F5WMY P=^[H*<(F&"_&=T [N21^15VQ/87-!7D)Z M=S>[IB94N"F)ZMP,+E%=!(B(YK26P5(M#I%^^$RQ.%[-CSO>#T2TV310BE=W M*T?%O-A.SO 2T=6BX-(Z/#:JE2%[X*@HH"B$1 %%I8Z' HI",!105.I(** HA$$!1:6.@0**0@ 44%3JZ">@ M*(0^ 46ECGL"BD+0$U!4ZHBGZE$42@.J0$^92C045QH0V'D(.Z$T8!7965QI M0&#G(>R$TH!59&=QI0&!G8>P$TH#5I&=Q94&!'8>PDXH#5A%=A97&E!^=@90 M&K 4I0'+AC0H#2AO:4#)L0:E 9<%;V0M#:@RA* T("#F(,1 :4"I2P,JC"PH M#2AM:4"%406E 24L#2@7GO3&1NJ%^'/U%\%4D*+4E&#XCTAQ9!EY/H!\S6;4I6ZC-#84E9*+3:\+T9C5U_ M@M!*>42 ;RQ\YR^)E1H@N%@$/X3$'EJT!.D;LS?#>P0'4,X=RH^(!@3; 7*$ M3KYY.*"/_6\ Y+T&>:?D ,FY(_F;YR#RQKY A/+0A#NF$&RY#^$S4T YLF%F M;Z /$") /'>(?[<(L;R \BD,E9\M2=[ MJ!\A3("\9)#_PK=,^0*LR -,PC3( :\)( M807CD'>K4H*@HI#^\6AY+].??K'>\2@L5\REB1Y/3_EL@# V>=I-I05%*39Q4A S7<#$L *K$(Q M5@%[8!7 *JRB *Q"1:T"L+\"[ =FYLC,) =YEQ.M3%$C M*"NR\>P)VJL#./V'LK" [_X2Q4PEV/GT'=E:/G4_?@9TJL/-;']A9 M/79^ZP,[X]@I\H2)I.ZS=30!GZNAY7G(73)T]L4U)L@.W,F3SVZE(?NY\HNM M>P6PP:P]D@"DI8.TIR'QPY?A'7LT&2%1VK*J4(L5!6 M$FN[BIY?N=@3 X3G M/**7T+4"7W5@[:QW/MTBB>\T0.AP"/DTN!\(@I88.$NSM=%;0,S!B/D#>8@( M^ETX(T9%*ISA5W3S/F8Z4;P^;2(4)9( (.M@9#TBBGA%&B;8:S;C<_TQ_TEU M<)6@_X"J@U'51R[S&%Z84*=5X]GGZD!J7^6K3,D]M]'0;H1$.'^$YH!_>DC\@KMJ<0NB O(;V[FUU3$S#<%XWJ MW PT45T$B$1"9+$4.1T.>.EZWV-_TGG"RG#$=VN1$5^P0FI40.M&=!OR(9["A H41U)SM01]+PI0+;D 9:P#J@!$G"Y20VJ12I9)"'+#5S*34,&Y MX8&BD!L>*"IU;GB@*.2&!XI*G1L>* JYX8&B4N>&!XI";GB@J-2YX8&BD!L> M*"IU;GB@*.2&!XI*G1N^>A2%W/ JT%.F''W%Y88'=D)N>&#G;G86EQL>V FY MX8&=N]E97&YX8"?DA@=V[F9G<;GA@9V0&Q[8N9N=Q>6&EY^=D!N^'+GARX8T MR TO;VYXR;$&N>'ESPVO,H0@-SP@YB#$0&YXJ7/#*XPLR TO;6YXA5$%N>$E MS TO&9[:2SRUZRU]Q\G[M8QR%3EQOZO/10&H?3B N&8S!%!K]>,C$MF_'EC# M)D_$\BB;*S.9T\O)ZA6!J!LN T0OF5,Q8 *T7'=R_^8AYW+RA?Q!T,O+=\PX M;(WH?#VX4MA,+L@96 \49YI+R8KRJ'4PCY:WI,4CS,C3Z-3U)K>^?Z$7RQ5Z MG,Q&/..B(VIZKL_26S! M(7*H)% @(VGN&4ESTG]'H020*R+IK*_Z9B$2F&@I/]&2 "4PT9)FHE4\&F"B M5?!$2RH(E%KU,DVTBMUK-RP^/B_3#\\('+R%P^'G.;:F5^[\\9A M0,4%??L17Y!%0R*LTBU!_X3(LR?K]Z_\@H]5(2',**D-OUB9+Z$8+?PT@V"2 MZ7'9HAT*S:A9<=B(:-,.D !O3^9M$WA;+MXF+'( O%6;MRW@;;EXF[#R ?!6 M+MX"Z20@':![![HADEN>2.Y<%/[ >OG5&DW7>)Z&B%W2I\N"=R)O#GY%_"=J M:GM.Z-5.SM2]KZME53?QV1."">]H<.$YO/_BT.IJ\G-_Q!P-1/[7(LZ;11#[ M6=\?!/RCXC#8W_GEYNAN$508'KI/UT!0,Q_O*/_)44%Q&BJ'Z-9.$H@ M1E.B&,VBT0 QFH7':$H$@5*K7JX8S:*U#J%WQ8;>9:=_2+T#J7>D3KVSPH.- M+#II\T#%LW[=#*-RYVD"(015EA#4/+0-(:BP.P\AJ,!;"$&M$&\A!+42O(40 MU)+Q%D)0E>0MD$X"T@&Z=Z ;0E E"D&54>$'+1B_,\[PR,[[P0#;JM8+S XR M62TOS^^)EG])@0RQU-+$4A>D[O;-:.SZ$X36MB]*K/1]'2ZKZB&,7M4P>EG@ M 6'TTH;1RP(1"*.7(HQ>&CA &+U$8?1YH +"Z%4/HY< )1!&+TT8??%H@##Z M@L/HI8) J54O4QA]\5J',/HBP^@SUC_[KZ5@^'#WM(CJ^3?\7_;G_P=02P,$ M% @ Y8L'31DI%-#\#@ OZ\ !$ !E>65S+3(P,3@P-C,P+GAS9.U= MZV_B.A;_OM+^#UZ^[%SIID [?4PUG15]S2*U4U3:G?OMRB0&K D)UT[:!#")$]P6"M)(D\8^/J^?3WR.@_/U/R\C%ST1QJGOG=6:>XT:(I[M.]0; MG-4>NU:K>]%NUQ /L.=@U_?(6O;UQ?NG')[2$88@00> M/X4;9[5A$(Q/Z_7GY^>]YX,]GPWJ^XU&L_['[4U7]JW%G6T_] (V20E>>LS= MX\3>&_A/];@12)O'5J-I'313LI QT&X97=RJ('0(5=- 0SU2+-N=O-A#=7_1 MHB*8$#ZC/?3W/8?3P3#8L_V1)&D<'302 NH]$1ZH>41M@N1@EHM+O5\S7"19 M;.6#NFCN84Z2[AZF-E>SD$V"0W.6@^=[7CA2\W "5@\F8U*'3A;T(HS:*5TQ MT2P!I[9:,FA0R,79U%9]S'MR;+BI< 4/QFS)T-"B&#ODU@#C\>+X<8."![0( MI;B21K8HB(0LSIS+8]\=UJ/&;%>:XVGJB?ELIYY^64!&//N:7[Y\J,B!?,=,@T!Y@-2/ #CP@?8YOH M 1XB#4(R7-#1V&4 M*55T:4T'T!8CS^E+9%@D$7]9"9TE;EG-_3)2Y,Z%/%,H">O$#7ARQYH.5 MM8H'J(XT&;+XVIH.46WBJI^9.O,W2_DC(A03^(N8P,VC,IH!I"$0# ^ MK!0S%I^%U8.&'*O*?"E8D)3S1G57+%VW:)DD(8K, 7^M'#GFE[Y:T2LA$A@()<6^FXB6T I%G-0[&=DFL]9NK8V.WK#I 8H>N],J:*N60?EFE M@(1Z=(UU&C-25B<@X9 .5/*4&. !.B#J0!\80V86EN/;H;S GF/!_S286&(N MLI'D4D."[O&^K95;1%+J#YZ*F @Y=5J42.DDU]\:C0:RT&7,*WO9\AQT)=FB M]I3MU_H#"0 MN.*^2QT9KGO8E?D('Q(2<"M:]@46@)GZCA5Z.'2H?!BL@H45>9N"2A/PT4V$ M@NN+1"QQE8J%SB.Q4%>*A3Y=1'*ACI0+/29R_;8#4S6'6F,L[@])0,$H_#VQ M-2^**:CM&X8:^M29$72'O7F'IQVXY?Q-H>ES%31=9"5#-R#9#E7:;N6! M;_\:^JY#&+?(7Z%8$;\EK/+YF\+5815<=3.B_1M=2=EVR-(/&)@/K;[K/[]Q MG%*Q-86CHTKQ"21"UT*B'7J$&ST_(%;3 @-CC_XM.M5+Q4">67D+U7DH_TSPC_9;C]D \D(2%HFDL M ,(H_V4 *-Q9#@DP=0WXO(B#*<\W ME9Z725',?[;HARXE_RWW_U&2CX)/0T;%/IH!GZM&->7G?:6?1=(29Z_=E.>6 M^_;8>L:,83.A.S.8*4\>*#TIDHN?,:LM=^!)5#D2]G)D;1+2< ,;Q 5CFW+O M9Z5[3V1U 3A;DK4L;":LM]S=7RP7I!I$BV#;Q704I568<\B@3:W!=+B8@L#A M["L"$@!B-7Z32O [NI BR RL-15A>Z%0E&@G%ZM!09N+*2@#HI3\4W*U M[57$)>FQ%>">:V2U5L# % +45<.E:3CZ]"#Y;[O[E^;,Y@!0R,(4!-1UNYSL M? <"K23:'!0T&9D"A+HT5YBT[V"Q-,\V!X6- O0I6A9P]!#)M>TP6I;1F<>-+B=30%$7%7.2R!TR]/Q%.1X, M&!E,;Y,GXD$^&'OR-;%2R-L4>@Y+HD?VSL@F&R+94F3M$*7V:FY<>$4TY?,U MA:2%-(>/DGQ-(49=ZDX1(X"2P8R% M6B"7E0BF@M.VPRBS>VD^EN0,;@H0ZI+V[![I+G(L\PH/1R/,)J)2D]Z#QR]] M$@\ .(F="=%VT4;?3 !XX!1.SK40U@W M!/DMQL.W158),4S!3%UB+H#9?2IGC+A'X(P^W7G)WHAH&_*.HE DUU98.0M]L=YCNA'=R248^P5$=U6Q7=H@_2G#K^"%-O M7K6L#DX8[0F74R*XQ>P7"=JP2WAHP(NGFE-+KNWY*7A &T]:[&HU= M?T) 9L]I);5:G\TJJ=GWW92<*N5BSN_Z<=)WQ^Y%B+X0?G%=XER&8B\V.M$T M5:T,1?5IR(<8PL\;ZG?U0IA-.>G 6H&45W:>O))KP:^@85>H_CJ:QU(*R7)5 MG.WWFE[,B9G:JNB[+H?H-1UF0LF?1-P@3NN),#P@]T3,?X!?$E8@_[ZA?6WU M]8>K[OT$IZ^*Y1)1:AG%>D8II;2EH;Z)44HL#4JX5=E]/7UZ%P;R"Y(@:1OF M&<0%:LO7GW(5S*-ZQ86N0WJEU[G:ZIL(9Y6&6XMP%B4ML"J\)P.1T_EL$B((BF"6EAK\UQ MV:(F&XGQ8^D2< MMM=RG@0L[OKQ^_;0X@^B&EU&5\/#O@NZJ_D_UK MDK'/:2#*WW?!D#!Q/%^0KIB7MJY93KO4$\G!A*# E?Q<83O[!<98R?P^*Y0I M1"%@8!Q=R9:%7!]W0F8/,2<=L-XLVHJ[K=_$D?8G_)QXI$]MBEUW=\ M M+#H!=)XY[.H0J1V:EZ']4.K>,OBP;^F'M@*/))^)RA^ M;^(A>")NW?7U9MH/DOJW(NWFE&6B39=^GPB@S88E==/[KQ+$VT4Q$$7=EW(. M%!U,G0>_-1!3KP.^$"^Y#: ;R,1Y N5$LY5&6&%_58QI/%AUY7N87>&L[C,- M_B8,D.)T,7-GW:G1;PU\*S9JY7N6V=:FJUGS)PX)'V7 MT:CM17O&XBB*F:W8UQM^[6;\U*3)GL[L?KK4D\?Q.WVQ(#542:)WWYI?(K!T M3TDEE]&LG8N7AX1L!K_DG>" LHB'U)>G.!IAKI M^B$W7X];#-,/)N6Q7#5S-9)7&V+]3)+YWJ"Z4UU#B(M:+M M=$;>?/N5.S"RHBE+,ME\JR9GT%>T5TJ^.98P<#ID@;%,QI&9\TQYF><=2DFV.!T@=\%9BE_'@;:2M-D*@H-D=?,T?K%)C($)./ M8-6"TZ\J&[)HW ]C.YUC=U:SHA:'CV!/S0"G,S272: M$+>'9(3AS_\#4$L#!!0 ( .6+!TW8]Q&UK0D !A] 5 97EE&UL[5WM;]LV$_\^X/D?/.^S8J=9UQV0^_W<]8 M:P%24<%/V\='W78+>"P2RF]/VY^OH]YU?S!HMY0F/"%,<#AM<]'^[=?__/#A MQRCZ'3A(HB%IC9>MFVG*$Y!G8@:M/S]>7;:B5O?M^^Z;T:?6YYM^ZU7W^&W4 MQ7]OHNC7#XSRK^_-CS%1T$(FN,H^GK:G6L_?=SIW=W=']V/)CH2\[;SJ=D\Z M&^KVFMQ\F^AM@UWBUYW5EUO2)UW?G62TQ^_>O>MDWVY)%5&(K'A1='W*GMX*6*B,S&60F@54IA/T88L,H^BXU?1R?'1O4K:*/56 M:R4Z*1A6DVS'$'61SE'E%)W-&;0[.P*("8M3E@G\$C^OR0W"9F2Q8A3N-6!'ZZ':\,I$ M7"(Q\^2OOIC-!+_6(OXZ4"HE8P870EZ#7- 8U.9%C(R!K?IP;+%BC1GU%'(M M1$_6!CR6@!IY!JO?O3B6*21];$EQ)&XD)>S\?FXDF,MHE?8'8'LD10R0J LI M9N?W(&.J8#C)Y#6<&]51/9Y$5(2'.$\OBMUX,/XKO&:$#7.+$&JHEM"YIFR M=H!IM7D2K8SH\=H@_+1^_%_R;@?D#V>[-A-3TG^QY 4"?IO4#.Y],(-;#R?E]/"7\%J[0[@QY M_J 4 *S21?U '^O2@*,M$*G1-;(T!JP G7.[D"!=00PH\BJHGC8-!)BQVY>4 MC"FCFCZQ]E6:A@"L+[B6)-9?J)[V4Z71B94;5I?.&)UZ"0'N&4Q 2DBN8 $\ M==?.@G8A0#I'%U$L ;UB9ERW*BI:WD4(0 <<98^O]T&6TR8$*",)L7&T<'0!/X 78C5HVW] MT/#EQKU 7WE!,?;YN/R,<=2 7U".(3+EM[U8TX5M)OIW$ Q(,S1*[P'2TD$P M((=SD^79 Z2E@T9 KB;-I5 6'$]IZF<57=LL^7 C>C$Z[Q)0L"A*O1PQ##C1 MM!F7?FY("G#X=] R)T8NR\80[.&H=AP\H?04.Y!>[9N%EZ6I.$Q+E8X!P@; MI6-&XR%:6ECU M0V3$$_[, N^INBH=#;+^HRHAMFF_0359:\E1_@A1FZ7/1BI%"V>^2,/EQ_ MSKOPP1GSR4L<Q;CO4"8OD**N"<\0YIZE[!62*7@F32C=;@S)&#R3#$HWS[_)X$/GL0@N\7,3Q>9B-7!(\&S%YK97 M!%5L7L[H?L7FZWP!JMX5W!IP0B[7T<.CW2%G^@8*GX5"(_B[$(E9^3?QW[5@ MR2,,[@WJ![$Z16,DVTMF*&6ES< O('\T/%LU $<*I= <36A154(.11,%61HD M.@RK'/%VR2A@N83Z>Q6+A=6MM I.B)32-,]WHX'#JX)*-KDS[)9T.E1V9X>K M;8WF<%+LZSNT^!ZJV^)>4S20(\0+(='P\'XJ)?!X>2,)5R1>5P]GG];&*OD? M>NA&K39B'YG*8OQ":TG'J38[4S=B1&3QF95&> @S2')1Y\-6/-:R]^6'JD%] MJ'D9XT)#]#I28/9TT4:/"3/[^Y&: N@H 4THB^BW I>(;Q\K]Q7L$&^I:_$Z M'*]UKEO;HP;?5*_X&',Q:8.'E"],?#2%),M)E+&>2]P@\UG44,;T Z(&F74X M]=WHX>XM%U?D[A-.2U->G&6ITOF2"RZ&!0Z:I7!>5-^K!%''H[ALYLI_/ MDLT?=&L4$)AB?]&E29@>BQ/GHMJ@!;4/[ OT>29E&,GY!\9717&6QM'1/"M\ M/6!FWO,]#:?E*W&[5R&H[U6^-5W=NW.6Y[^$I; YYI?'4AGM =C!*2<4UG2';J*O30 -T%+B\:>L!&AR8#WR9QJPHI@V:D;8-]V>6;C-BE[?\D, MR*,)Y6KUGNX3*9>4WV8+3M%NM$_;)@Y//%PVB_?4<\F:8-ARC8U=FWR:-G#[ M>^'E%794SNV^;W 4,KHC-),"-VH^%0QC0F7F;.'EWZ[-&@5DUYZ0U&4DUQ=8 ME)HC"V4C;)O;-W)OW; +WZ/E_T7VZ;E.D6A".23G1')<<-6#A,J$QH5'U-P; M-G!&Q-5&5;-*S>4!\[5?5(GM0MI!*H55P4\,:0NS%)^WK0OI;$$INF(W)J0J M]4<60U,P-E6?X%9+> M.0^;2Q8R)'/M!LP_'>"*L8Y[D>T8/7=I0C(F%H=5>$2 (5D2-TA.Z>.0[(<= MEL>N7$BVPVVL[/G0D.R$&Q[?4-<581T7I3O.KGWVG$*RC\Y)1^&T6 1G+*O@ M*TMR.%2[K+\P/\Q_NXU/_@502P,$% @ Y8L'33A1FQYB, .1D$ !4 M !E>65S+3(P,3@P-C,P7V1E9BYX;6SM76MSVS:7_KXS^Q^RV<]LZJ9ITL[; MW9%O6<\;6QY;:78_=6 2DOB&(E2 M*W^^@5(R98E7@YX 0YES'1260+ \X# MN>/@'__]N(C>W%,N0A;__O;HAQ_?OJ&QSX(PGOW^]NNM-[H]N;AX^T8D) Y( MQ&+Z^]N8O?WO__KW?_O'?WC>9QI33A(:O+E;O9G,TSB@_)0MZ)O_/;[Y\L9[ M\^.GWW[\>'WYYNODY,U//QY]\GZ4_WWTO/_Z1Q3&WW]3_]P10=]((F*1_?G[ MVWF2+'][]^[AX>&'QSL>_<#X[-U//_[X_MVF]=MU<_5KD#QUV&[\X5W^XU/3 MO:$?WF=MCW[]]==WV:]/3458U% .>O3N?R^_W/ISNB!>&*L9\14M(OQ-9%]^ M83Y)LFFLA?"FM(7ZR]LT\]17WM%/WONC'QY%\%;.^ILW^=01[G,6T1LZ?;/^ M^/7F8G\NPCAY%X2+=^LV[T@429*S$>:<3DM)W4R@HN"#>O9_;O5,5DNY#$2X M6$;T[;OV1 5L0<+86]#%'>4-R2L M4>_IB0TIKABIQSFF4Y)&2?M)?CE.*<$;:G=)5<\2U&=Q(,+9//G!9XMWBIG] M^,O[']]E-$M>D%#YN,2+64*]7^4&3L)9Q@P\/R+A0GB2?7I$""J$:B=>@J(K M*KS-D!GUS4G(8Q#-<(7^>>ZM2+?"-"<+/J84"DCUIQL0UG$_+UW+#9K M1!+TPXS=OPMHF!&C/GBY+#E:\\7_E%_]>18G8;(Z?;&A(G)'H]_?EOVJYLT52\2GND[0N=D2BG8/08B@+R2EKH4K8A;$K$7;9=4^'-"%GFU-$H M$9MO=LE26TKI.*)S!) 6GW-0[O=\ 7)6NB%_+B[GNH;6B1Z0NXB6D?PBT95 MQ#[SV1'WWS N5>+?WTJU.A=0OZEU28/?WR8\?1IN+?L::DI3SA:@&68--HA\ MLDE\)9I1#K&**;$Z-F\62(7"5/*Z7JXO!F#!0$1'G;^:EY*JT;LI%G=M$:V_ ME,Q1+NJS*)M7J0O1F?J@C7C+XFFRQ:HXA^%=5<\U(/R M1)'SY#_\:Y '^U# M#__@"1I1/Z&!=T.9E+_UB+)Z=Y.]WZUNK=3 M4'LG-ETN).$W>:^&O5Q)OS3 L*^<_> ME(3$W=X[3@FE7 @,4[]=NKWJU6_S^4.^4-M$ UM$-3'61+. MU>T4;*=@.P7;*=C]*-@:8LBL1ATP/\T^J(P+FBTX+XRGC"^R? RX2@T/E^ZBPE2$*;^@L5+ISG%R111$?JFIFB,8_6)3&">'Y M1)5OD9)VAJC\1J/HGS%[B&\I$2RFP840Z;,-LT=M3?O#<:)J4S;A1/'CV]7B MCD4%=!7^;LW-]6K<0"#=SCF#FKRIGIU!8"N"Z6CPAE]CN6-(%UZ]2 -"^PDI MM$K%'(CM/3IL%6P?B.EG=)A@/AX@O _HX-7JMT!DOR!%!C'*@! _(H58J50# ML7U"B@VD@@,Q_HH4(]SC 97G_4=ZFNHK^[XR*"9\2@K .0D%AT]- 7G@H?#P M:2K 8 @4(#ZUI2)V9C:&JEI)ZXX&ZI-@41B0O<,TPO-S,>TMLS?AI3%)@U"U M6Q+U_9PFH7Q/&DF,O3S64'RV1]I=BB0:__. 4B2W-)0K=DWR9(T=@D%MK9*> M*U>C-)DS'OXM]T M@+(>"&!D>C 8PLO6",@OCP3J=#$/Y%J.127?#6";H:ZY M;0# +0'KA -,_;]_QJ D(N+WAXH2#C><']>U;T(,&$)IH 4!MP MU:(431RH/<2V+LW^'2QZ& %6#IJ04&-DG:S._@-#+?$5V49H(D(ML0&VG;&3 MR4>>Q$[B\.^\EJ4Z>W"7"@E'"(\M58UC^;7N,66]04V>66Y"F?/.O2[OW/[R M5M_\.>*S5%Q<7',6I'YR^8(MK FH;=<%&P54'--8;F(_E/KT:OP0T^!X=I:V:44%5H<$V# M*&3+H+8#(KFM6''5)]9$G3U2/TW">RJ9E)Q>7K@[88W-$W]%$CF;X^EX3RW; M(;R\H7FB;VBDHL+2]BQ1H>H;#HIH^UMUFZ8))[&0.TZM@>/5]B\%/+[Y !;< M^5)9&T]SQP99R(];A%:^,7C'@P)E?UFZJ%'OQ*9W(@Q"PE=;ZZ%BG]>V=P5_ M7&"O!9!:FX%I:>J8H+40E0RN\F!$7,\T6'-A^VK#TF8RX0O9!FOD*7FUX?:. M$'6P]MJJZVB6)H =,CVK'-7J[$M6M%K&'>4;=+B,@=HHNE6K(>,8U$V.BK3I;%\RQD"+UDW='1"@\-O66G KY?9X\)+O'H5R*1-5L M]7V69G?!>4L6A>HZN"RYB%.?[OS,62P_^XWN?S!!BLET+'-X7!+7ZTKBZB;& M<*Q6YWAZO;4V1YG7:+,Z1T^K[WJ]-NMN=^AB2)<0X:)RN,]RN9#6,$):B((" MK\AY[JP)0]9$=\+6@MWQ7A4:43IN;@@I)9F'XHDNH,E0,XI);1]$BE/47Y>B MCCS[O:M*&UOK_D:N^0(^5J+8Z71U=H&S"YQ=X.R"@[(+7+*0LW>_2M5M]O)7BF7CZ*Z89"*$4S:,[5D.%OF==DR3J=V.K518N6+GK-( MRB1QEG&B*\F6X*:E=G]G-CBS82AF@U.OG7K=M7K=D&%:T+$_>@^$JSN:=%7K M_8XF->JRISM%^G4ITB5!@6_YXJC7<("MG6[O='OG+W>*KU-\G>+K%-\"Q5=+ MCEI0QE$LV\WUK:KVUXYA4@H'$.)W8Z<1R=YY0GDC,9W)E MLA6EZ@38Z(3%V59FQ17?M/MU02:+A7PEI*I$9%F;#AX_F5/YY5%NM%]D0;+P MGEY')"XG!]JG,_(^;%[&B\.E$"*A/AW M,Z3=D'A65HMT[S>#))7.5<&OR,BR7P9N]$!X,)&/K2A,5MC&IFMB/#W9TCK6 M1W-/F$A$5K_^6"DFUV25G;*KBS%U-*KSU#0M ;LM&,9+-?7556#KVIN'H,28 M*LM0L86*FM@CM+)X97&C01!KGYW>4+F?0C]9WV+S55I>XN;V:^6*!O6QX(U\ M8GK;;'&D3.U9?H#Y>+7'&#-1\2POX@#T%OM\E)LXS4?9WT3.>=\WL9,P406% M+N(@O ^#E$05HJNR+0+2OX7)/%/65"V.>;BE1K58XKKJ_)8%&-"NZS*1AM>%;5"L2:K)AT"=:O(WR.#\:")VQ MR,K<%71P36E+&L$7=',$,F[T,F^ &']&(Q-<4K(V(I>4;.@T7J>I)6:3E^OJ M6V\^;&BL3V/6'=%00G,SLEQJ\^M*;>XHUVZOEF=-PE9]!_,@UA5+=TA;Y?\" M:XL#.YL'=T4?MFA[4:U?!V;382PD6;TDI&8]UK1VF2+NF&>-N@=:09@"?0,* MPCMKREE30[*FZG@!TU>$T&$$$+Y?#5Y+/4+GE=*#W$Y5,FL45]6(]Q*UXW2+ MV< &,WFV5X]KX_1'1LZY MY(=G1^=H"D,U'8 M2U@ :Z4?H;,?ZU&VU@K,YG9V@KDS1=""R?RS-R4A]^Y)E%(Y#41%Q#,+OYG1 M#!W.I-FL1Y,SG)WAW-RL&D_/Y5K[0RVUD1 T4=G.7T)R%T;9#1^7^>H+QO&- MNO6#A_$L\RN"E.=>GN%,,6>*.5/,F6+.%'.FV*LQQ7J4I!94^ ^>H!%5:?+> M'8F(-+H\,:LR(6'43)'7&]2D.M^$,J?4.Z6^T<7+66Q;9&/09G]AB M$RN0LM5B) MYAYQ)@9^LU#D41: Z@;_,F'\-2GA'FP;:17PO26)\=2)9^D:D MP6TO6'=G5CFSRIE5SJQR9I4SJUZA6:4C) <8Y-)5= 88TVJML5HPA NNU&YF M_-8/9-+@A5+CC%QGY+8QC$:2FB",4E5F[?9IJ9T]^E$J5Y6*;JN#TFFRCN>? M$1Z'\4Q<4YX=E(:;4%T_R!E;SMARQI8SMIRQY8RM5VAL]2-.+>COSQ=X-U/; M2_N;U-9KB'!*NE/2VRCI6:6P.8LD/Q)Y:>0KN>K6MZR*,;]1J[3V8JW6XSF5 MVZG<3N5V*K=3N9W*_0I5[E92TX)F77HK>#-%&SJ<2;U;CR:GACLUO(T:_E2X ME_+[T*+P;QI(NSMD>8%1N)K>T_.L6C*%&(IJ/N>EH_TD MO(?FV_7T%'S3M761B.ATAN #.U/0F8+.%'2FH#,%G2GX&DW!3L3G )/@>M6Q M!I@Q9TA9M^ ]./+DI!%)7VY/DSCP[E(A=[L0GDJ$S*^Y69^_$IYB-REYXA9 MGT*[AYCT-'1!J?,_O"[_P_[RSZX!&O%9*BXNKCD+4G_G\JC=0$I8]VW:MIN'\+D;\HC MR9%O"8_*)QG:IPORMF_V FPI2/O6_@#!DRU?@/QKER^J"_C6S&;,UVI, 7.L M:V:44'5X?TV#*)0TH+8#(KFMI&SO)CI[I'Z6=B89EJ2+%RYK6&/SQ%^&,>/9 MU>()Y=)647* J\L:G[G6\>J*Q"Z0\X"T#J;"CC9*=&=W[\GE4F(K MU#<<%-'V&?@V31-.8D'\S'@]7FW_4B#YFP]@M?)[T:G&BU@E2DMNK(XWRO^" M"7DL1=MX) L!IV?M7%U$.YYNO9_*A0KO>%"@[._&S%%XS:5R5 9BKX$+OAY> M\#5;I$HVT^ T56Z W"FS!7#IG0B#D/#5UHZL$#"U[:W% MFP\E.%L-I-;$9UJ&-29H+708!M=%,2*NWU2LN3KP:E,+^H]/E[(-ULBQZ5(F MK*^]MG84FJ4)8(=,SQ>(:G7V)2M:+>..LA\Z7,9 ;0W=JM60<0P:J$.Y?CN6 M_!BX<#^O5S^TC2YEJ0%J>/01B/8]&A8%BU6BX4PPFXJ!\T-0<:/61N5 ^$ZU M,M0^(:7M:CVT#&&#$@4$J7%T%)\LZ0YO?0C>_[V1:$>FWH\ M%-];'B?0'-7D^8%&I+D# ^[ *)LYVZ"P?FE6SLT%__H$AUL)CJX0+H+1>Z_ M%Q>*;.^,[03O/5&-'V+19.XW4:K]/:#BD]-?_^G&VB M.HW25$L'<2KJX:BH3I5SJIP)SWP-,[&@\FW=$-!.TZL?R-+%!TZOK=7"U1QQ5FV%8]7STVNR4I]E15-7=>2 M_9P96!=Q;N&>DY"7JL<]/ZJ#R9C,J?SR*,^-O,A28L)[JBY5+W\WT#Z=D??A MJ9KK]MD(")'0GF9*CEV2QW"1+@J)+OW=$&E2DE625O2[&=)NU&8IJ7RW]YM! MDDKGJN!79&39K[.R+KU,@^+*S&>/ZF.9S:O7V0(XQ<(G\K$5134*VU@H'PBI MDWW%XGLJY'QG1(L)2TBT_;NJE7W%DO^CR6X5[7/&UU^I=D1 M\D[C9$[Y9$[BM1YA>MZA]!S2*]BZ;<#X=!<\V^+4/E-378RTKKV%DHY2,53G M="OX=E$3>X16UELK;C0(8NTK*$579]S%'N]:H=D_ M?TA03_'<,@G>QR,&-%%/EOE(B'21,V*EA:JEAP&-@QNIL'8]>[K//9 I M_8-%S,[$MGUI-4_:>C3]HVJT)*T%^XI)S.:_7@J=U*98]HR M%0.:[NWDM0W.KB>SZAD(ITI4ZG&9.RL.0/I^GX]R$Z?Y*/OF5G-4$'9T]DBY M'XKZPMYF*; TS4T"DE(!#O.S\O5\L,OQ!S1%57;#A/)%I>W6 M\SQ<3EA%FE3+45X)7!VUR&55MP92G-#!:I(J,"&H#N[O5O?JU?K!."W5+)1U MQ)8P(B^,&C)8J&YP!Q_J0Z5H2JC4S#]KE/&(ZEQ'LQ6(H;AOARNQ(MD*W5+L M531LW_\ 2[] N9BMR-<#NR<"8,^@VQM-]0+6^* #RN7?EQ[5:H7CNF:@)#$< MS8HN,VE8;;H]JA4)-=DPZ!,MWD;YN0PT$#ICD94'K]#!-:4M::3VH9LCD'&C M=U(*B+&CNOGN,+X[C'\XA_%-AZS,6BB=38^%TQ)F-5W\,P4X/F56$'2[]_K, M)P3."[H+5OK)WP#.!LH[6&RD! 'G"]LE+_V= @%."*[[8$P4?P!.S*]()@9% M\C%47S3H\^^7.6LFBD'G!Z5";?+$#W2BL*G6AD_Q0*<)FUYM^%@>=)JPZ=)- MJG% L6+3CY%43(!.W^ 4ZG9GWZ#3K=N[ M_??+>NVL5"A/ZAJY6T:*&AK>*S8Q"N[SVU?7MPAO.?=V:._S$>93R*N!I'S[ M"O"=O'&=KLB O7P#Y\%A?(@TL#-R_[C'0 M:&\;06W6&E2ME.M'5;*/!8O"0'F)O*<&0EV[GM6[G[-(SK787$^9QB0-PN29 M^GISL+MG&;('NR889A"6FA&+!8N?[O!27+*J-'M-XP[LFBMI+8M\3ZOQU=5A MSUD;F\"I**>Q2?\.R+ZAR]P[,Y["*+BBNR9'ZW&ZJ)!?=9G;^OZ0S:-W[8GF M _1'>.:+;T%W97\+Y:5]/UVDD>(7F9M8.0TYG2N=\)Y>Q)+K%._>QOTM0 R" MC-.2Z)J$4JB?D&68D*@:%J2/#2C_DE(Z8^D35D8CX=\G3/V[QP_:#H,3<'$H M^T:)."%EVSJ\DN^^+06NJIZ9JJGOK2+A:* M6F=*EUHM+)9+J[*Z1&7; 9)NORJ85&MR>?2EO#1D81OSI)9)4JFPT7 6YR:Y MOYI('4)(ZTW9F'&0_94?S7EF7Q+0>#HAC]>,9S\D"0_OTD1I?Q-V32KT8?LIT8@]SHC [=SMC++;*DL!MUJ,&3@MT\CE?DF MV@^$!G1F2I7R&CW;MGX<2Y#7X89]PN:A2G1GK^%OM5D$"MVA:C!@B!?*6A)91=W2;EBN2RW# M(5.@"4;00 PZL0)]9]7:*SI!H@%+TP>$3H2T@EIE.J*3'1V\5*C/%H@=W6G! M]FX?(')L!P+;)7L 06,IEM&%HQX(&5T9C.9>/JAR@:Z(10?.>RAV;)J5V10E MZ"QA4<\ZRGR%PL:FOE7DL4 A85/3+.:C0*<,B[[7-FT:BA>+CMVXI*]7P*3]\DTEBS]\2Q1Y_4E+R)EXJ*?&X2#W%P^[5 M&9UFU2RZ?*3)JA;=T^VJ6[RNZA8='3PHNA5F]Y1 ^4U 9E-8 >7D]S)9P27H M4=W<7%K3B:V+6VVNU9+PTLPXJDVI,/#(@YA(J6A/:9BD/+OJYKE&;VE*C@42 M#F*BLY*C)M?KS@,/8A*WXDQYO3=STUGZZ %-;+O2N%W-<1<%>E%-=XL+9'3G MM/6EKV[BP(^R?[BM;7WPIS*CZ[_7DI:VV_-6"1KP2[ ^Z0<\R7]8G6'-I[MS M>*XD'O*2>.X2>W?AM*'7.(@K% _UTFD\%[&["IK:^]RE.2,MNM_8BS34=&E+ M%LI0T[ -.7N'FKH]@)N_L"0%F8]W#353W(:)/]#<CI=4M/K2FJ"U]HN+P>CT:,#TBYBGU/)Q4YI M_O^1[TO.&YS(GJ%/H@D/Y9SDU_D5$MJD?P=D7W/F4QJ(<\G<-WK->+J=5BJE MTCJ?N)#N1@-8+:PK98IB.)G,FC!U#B3VPXB^.$,P82>RB<2F+IP,CE=?A;H> M8;S,;DR(9Z,\ S.4,OM.9#<*E*7,&7JLA2JUDE#Y9M7_E$YS3R(%] MDK16196T^F*!EAM-N]M4"V'U$.:!GM(EIWZ8Z63R39M5/M=D0!3,O[+\X65.L!*NF( 5GG/#A@C:!0,<$_IE').@_4- M0F" )?TP0-K4"+BA6:6A)DNT?@@,0"]B.??R\3K("OI@@/*D)ZZ/0]?HIOH# M8 !YS>F2A,%FZZQ-(BF3LP.S(R%HJ4AO-Y@-\/DR6WVY.!_?4"&-5KI62^+< M9MB_ JE17RN7$Q19.N=A3*15M&WIE.#3'P SR)J=VGP@-* O,C]NBS=;,0!F MD,W>+& @-* +O!-Z8"L&P RRV9M%Z>,G[+T+IFFT<:#5(ZFM@N6\V4E$*H;NR,9!WTUTE$IJ?M-W-D1 MEPSNDL%=,O@.I+:6#KI#/2T =5J3$%LRN]ED!G3+PAC\K2G7#[.C8R(VI@VB MTJ+;A#8F"FZ^H#M18F.Z&D15T!TU,3EOVBF8Z%893#(V#:6BDW$-@%1.0UW^ M#3IIU?4$E*8*H!,_72/7CZVCV_Q][8;"'#MT@J('])4I:^@.&'8] ="$*'0' M"9M-1,MC#>B."':]'#32&]&=_NMZ+BHS(8'HS5U0TPY]TS0(= *BE7L0G.*" M3D=N 6C;\FX8I$>G,7@2F M>CCU=+IZ.*X>C@JMKMVHDBO;)5II?4F)7I=$KO:<0ROWPU M*P3UL0$E"[#ESK3]^*.<[2A5-;A5?H;\+YB0QU* C4>R<.*%1E%N/5T2_IUN M[8H2=/4=W,&HPSL8M5-5-B]$/YYFJME6@7J8;M=N,'?8RAVVMW&&K'4BM MI2ZZ*"$,-]3D1Q?X@\$KM3[11>Y@>("V!SIW>SW=K)&*CX[;@(!J^@S1L1:M MMPG5^-%Q&"V46AXZ=,Q'"VJ-ZP9=$D S<"W/&)N+VVK! [DVT07IM2"V/Q]N M+MU;"YA63 ,(U5QNMQ;4+DQ\A*%X.<"2T[DR-N^I)R>\QRMJ (_"%)J'T^M" M]*\K1-]5+'QK?3T=*1]/R_WP@!XN$E@5DU+'40LF\9QQR=WCDY1S&ONK"2>Q M(/ZZ_D;V5Y1?9O9TGGXS[=>J-H?\(4EX>)'0_O(CPV(SPNR.&"'"[(\2J#'(=7.JT?T83/?=XU3, 4&M"1 MT&VC/N<9;$^8=5S$+*'>>V6:^S1.\O1X99#S4'R7PD^0V8Q+N?#T=1XGE?P_ M(6'TM"?KO1;=/,>0RZ)+8IV_PODKFO@K]I,0;DE$Q MA0D7- @)7X&1U?9U?A_G]T'N]ZD&TDC"LG;B:W!^K^9J"#JS6_-]L38<'Y4W MT,Q";^5$-.<4Z&85 *6C6?3.S>W-PU" MG=?M=7G=R@IYK/?\4:$56]6DPX?_5/_PGWI[^/OZA[_O[>$_US_\Y]X>_J'^ MX1]Z>_@O]0__I;>'?ZQ_^,?>'OZI_N&?.O8+"9YLN5?D7[ML2'[UYR7Y%^,; M"D0!)ZIN9(;(*[*@X^D+*@J9.JCM@$BV[]7>OU&ETO%9U]Q*[.%9.;J1BM$Q MC?WY@O#O=5$'4+># 61_J>U3N'JBL3JN!^J& M!$$J&'9;<' AC7E*LOR(R6 M7><+Z8( B)I;O4VSWV/@,!!L^[7$VR.R4M >UD*&ZY=+5&N6 M1[BT19>V>'AIB_!8$J+\Q,W1USNB"GS)'V:4S3A9SD/?RQS.^9KN,EVQR2,Q M9"\VIQN>S+B;FY?IX7RE"/ZX^4--^L>M ,/ZZS_/;S9/70<5]G]H&O5H0L[% MI(2?Y!Y/D?+TM(>?Y!TPYL!AI.LR\W.9Y9;>Y M8O'YB4F2XN/3H+8#(KGS1 48Z1L9MDU029)D;5L$J2(N^V&S-#E1BFA60W MW(8J'4P+R6ZD#E42F!:2W2"?2[]QZ3=ZB%WZ3:VNA"G]YF=O2D+NW9,HI1(K M$2E?WYVW];U9S+QIF.B70DQEZK0(&Y#A+JX M7/WO[*\TE(M.KUO'N(3,:J 8B(N\YT6C..; MS;92%[.*KS&[$Y1GYS\NXF6:W*C-[(=1F+'8XU76_20B0E3&M?I^G)O AH^S M'U5\0K9-7$7DO;:]50A/'_\GI%PJ&?/5%WI?>=6'7F>KX"Z?Y?$YIW^EZDXI M&+*ZGA9A9=M$9!-=7&%2HP<.&,6U*C5ZX(!17/52HX=%&$7K'<;?ZWL>&"Q$ M$FB+2+'/B[6!UH[Q"J B?;M/6A.,QP"ZF@=VR6*ZNB3\.TW.4VE@5T*I;NRR MEUSVTJ"SEQHJTZP3!HY\(DJLI"+LO5KGR*>IUD2I62R5VMI@\Z2 UC::N+RQ M)N#=.@#F5B= *Y5E['NB8XEP(-E:;?R6@UCK M]5I?T2S4.06Q+_8^U64,+-[68L!=8JQ7Z @JD;DT)Y?F=(!I3LWR"RSD/'WP M!(VHG]# NR,1B7WJB3FER3I;QPOC>]F6\9 *+W[Z6C?3J>533.8W=4*JRVIR M64WZWNN+]=):C8)_I2+)1'R)#[NJJ47"S^5NE+LE^,Q84$MZ86.+Q'_F3-02 M_:*116*O:%)'ZE83BX3>D(=+R6!Y2"(A1>)MNEQ&DG?6$5_3S2*@;XQ_OXBO M.?-I_7(I;.R">2Z8ASR8Y\PR9Y8=GEFF)UW0^8 T05;('K,^GNZA5:B.0&C] MGS=L"*U P01"ZK_F?$-(I38*$%C_A><; MO3L!$Z<):<25&>K#P2!Q[]*PV7 M6=]^_#BPAV%RY^A0[+PZK\NKL[\=\CL:V&*92N7A?P@/'@BG2H%@TT1]+,SP MU.O4 8'G*9>[*.7T/'Q4_U,JSMEF:9>3J-&M R*_D#O&5?<5@+3:QN:MTY'O MIXLTDLPF.*5+3OT\?49^CF@FO^)@M& \"?_.OK]>\YEKR8.2[8DML6N['M[\ M!'VA1- YBX*+A62R]WG$LC(%&M##/(S2F:VM0*O1$Q&L*B\HK!,B,.5>4D@7 M1$!JZ])J]#PP6/8/L#COJO.N=@BDB?Q@+3C!X#S+C04LNNQ&G7?%]'1A5-[U M_I?T0#(8F[QP3=,1G=M:$[.V-8#.F=WD)6L;WX,[?^'B@=KRQL4#^W7DZ]BS MZ-@J#&(_?B1T++?E^\80R/DE"S\D*J]4J$-9^4=):!B$49J$]W3[^V;QFU;/ M,!FVZ8!0%ZUQT9I<>UZP^#9A_O<+(5(ENRJC--6-.R#H3.X?MJ(T>\IUROVY MU',51RHG"]BE ^*^RAW#'^2VHEQ\"Y/YA=K7)+I.[Z+0'T^GM+0D2]/N'1#] MC7 N68-0KXP&%_$)BV/J*WZD:)!_W4NF'\IW>4KO*H),+8;I'<2E.MTE.WV\ M4?Q3U+^)#H:S$%/;XN^W3^S][-&/4LG(SZ7$SVWA3%493\^(M)GBF;BF_':N M#..%JMQ=%E#K/(0;*A(>JMRCC*BO4AB*F]NOE3! ?5R(RX6X#B+$94+&L*9L?+!Q M,6.2&UT\#?R"65N#!96S&NEV&DA,3GO1M#84T?F2.YX"#?,2G2=99RHT=4]T M1U.T7SO0/X;NP$J3EZJAB:,[QZ+]8K4\C"[T[$+/>HA=Z+EC';W('6DA9OG) M$XIAW$EF$7BR]5*NZXSBTN_IH_I,&\8O.WN>R5AFQT2[N*:+:RI53#;)+@". M@QLZ4QD>C*\J(IOUS2TXKZ/L:5+#RLQ/M1%.MO;!6;X-RES86IW-@SMA(AE/ M;TE$JT\]E;8S3_)G&E.>K9%1L%!'[+.+.N_I>BXK86CUM5&^1W)8^BR;U:.5 MAE >_P+T0 .C,M8#ZG, 4.S'K*3)2)7K0VZ"4U5?E67)99#=H]'30AR%1G+, MF:0MKZ$O/T,P0;NY:):+9AU$- LB,5@COCS84!18B*(+)<'>#@/K<:A<3'VL MV(%$>[3?J[9H1A?= 4/6LQ31A6ZT7ZV>AH(N?*.-MX&-YGS]SM>OA]CY^GS1D@9?&) U"V0[NQ._F.8:< M]UT2ZYSVSFDO=:N1[TM.%&Q4K(DJ0+O>_KN$@-MW>T8JOR)HG=M1&$BH:=L! M.:=TR428J"/PXV1.>7Z?81$QU2VM%(53<5EQ359J3DYRWE 6P*AL;(_X&^K3 M,+L>\HHF, A57:P 4;OF2TCNPBB+J]>BJ&YOM;I@MK"5OL#I7*F2]S37^[\P M(>1LCZ<3\E@.K,DH%N &02:V271-0I5.2)9A0J(R6-6M+9!?Q*"*?[1%7,T. M*&ICF=31G3)/?1#)NVTM1'L+;_P:)2>$\U48SS)9618!UNEK(Y"]6(1Y^6Y% MI303)4TT]LMO<0'TL -C6W&IH+VHF0V"XVQ19TGEJ4@DM^8;&;6JWL\Z7>T= M[;NAF6@"RVEP/QO![(' N09>"54US[77KE0X4=*\1#!;N7B 3&"+EA#4G2$1B3MO6 +M\( MOD1;@S)X-!S^_O2+QV(Y#EZ'$1Q,!4+[B =:51@&'8.$R7*H,PB=0 <07B#H MJN+CZ,2X-D1(Y!G=.M5#J>FW1R?B86@U$W;027>]=ZH?84(G^?4 =[1JS0E] MW?<)#-FBVYU0DQ[F.$,G,P&$OS0RJB,MZ 2F'K[JZ#PZ.0D#IY%7B7#WZ;P^ M4.86.LFHB;%-TATZ(:F'73<$ATYHZL&M"R6ALY;UX.DE?9@]L9)55OKH/:SK M4'HB72P(7WEL^OR=A!7>2SH;%IMJ.+K)TE*M2'1G4MR9E.R\+Q%B/%U7=!WS MK&;KB3KB%$62;:>JLU#O_@X2[NA^@*S?ECI M(1Q@'P/D-9OAN@$,$/Z-JB]H,+JGG,RD0%([7[[MC6QLEN=42L[B)\^+8C2:_O&M?Q([31"H7<2 ?V/7.:#ZTA:3[JJ64K9JG M'\7Z5W&T,Q.=C(4$^M:[TT%9T,TE7;HR7R[USZ7^N=0_PZ$//0:-T(?>&*2> MK$7H6Z]"WI^^A= !WVPBZK1HA-[V9D !MAI"5WN'6"OL.H1.^&; 5XU(-9/ MP\3:_B7_BAYXJ1,/JGR8S$QH#;']&SW"HFWUYQBT$%BKN;+$8]D=9VT#;"V? M@N@.%QBI+N#F FZ224SF5'YYE,?0+Z2LOBLN;CI0LG&6\]'CUW.2:K-17HP?"@_S*3+$E M**_2JHLE^GK.H*=L1[>H"II9>OKPIO><\2D-DY1G&5!GC\N09R.(B[@PH&?\ MN0]5?,ZO<%YC_,R9* V0]?>DX4W;EGNU5S%5^IQ!3YF%[:WY M=(33*V""F/;*1'LA8H"3_9*9V9AI?0HL3?-=_::]T]8MB[QF$\H796DX%BD9 MWK3KQ0X5V)]ZFO86E+A4HP.M[[8?T,V6D,A^W!%#I;99XX%)F+/7M0!IKJ:,4= M,K#D2#1&R,!R*8TY? >6>FG==3.P],VNC*V!)6]B\*4.+ ?44LAT8 FC"".= M0TM(-90],K2\5:NY(-#)0JF"VPPIU.<$K[]7_R@JY#?_#U!+ P04 " #E MBP=-]]^+1JU' #]#@0 %0 &5Y97,M,C Q.# V,S!?;&%B+GAM;.U]>W/C M-K+O_[?J?@><;-4FJ9(SXYDDDV0?I^17UC[H^G=Z>7E%Z HHSR),I3#OWR1HR_^^Z__^W_]^;^.CGZ& M.<11"1/PL 'WBW6>0'R&EA#\S\GM>W $7O_PT^OO;SZ C_>GX,WKXQ^.7I/_ MWAT=_?7/69K_]A/]WT-40$! Y 7[\R]?+,IR]=.K5T]/3]\\/^#L&X3GK]Z\ M?OWV5?WT%]7C]->D;%YH/_S=*_YC\^A!TT]OV;/'/_[XXROV:_-HD78]2!H] M?O4_'][?Q0NXC([2G'(DIEB*]*>"??D>Q5')V"CM A ^0?\ZJA\[HE\=';\Y M>GO\S7.1?$&X#@!G'489O(4S0/_]>'LII/GC*_K$JQS.Z3"]CQY@1C"S)A88 MSKK?RS#>>8WB^)'B./Z>XOA#5VOE9D5DHTB7JPQ^\6HPTAN(4Y2'2!?K#ABWCOT=EE-E%?MBD;$U %H> M@E1$E]&GWI-/U8.TP1ZERNA5*KS5,'PN(5F/*JW9M(WBG4[ #2R.Z-+T^ONW MKQE,^LT_SE"\7L*\G.9$691IN;G,9P@OF7ZOR3"8O 6EYSFLC*X2"%<=WNFR M9KM'69N;2DPZ9#^&!5KCF"^JA#1=]F%^]/'NB[_6M $A#CAUT"+_YU=;M(=] MF>*:SQ&.)=BJ)U[%B*RHJW*W7S.,ECI,1MJ6 ?6 MQ=$\BE:OJ B]@EE9U-\<<7OGN%J[_U!]_8^[183A"5G>WNEJBKDW?*ZGB[>.]$^\%\/=4K"\]K"803RBEG$"VOT K8[0G4C[N:HS M@/5F FA_ .L0:/5H NH^@;I30,YJRSK._TQ%P01$5><*EN?3=5&2;29^\P$N M'R#N6I$%CY@LPGM-N58D-3GP!GSF%/^OSI2W SFIEL\."Z8'^BU) $;Y");Q'%VD> MY7$:96135[)Y=@8)F[+BGIBOZRCKDFR]-TT$7HV"ZWE 48![!!H2S7E)F7D Q_Z7>DDN(*ROAVZ,9P7/T2 $=+6%4K#'[M3"Q$U0;LVHIR(AZL16^);9":ZI\ M:,$8D;6@/#Y2>T&/Z9;\#=_+_0W?V_,W?._9W_#]<'^#,60?OMGTN5R,P=^P M+R+[_H9.)KI2O]\=%3!C)QMD^LU:545JY'VHI"_ M(PKYK@(#3C@88N<0,)6G=T1J67/$I,K99!@LJ>COY"KZ.WLJ^CO/*OJ[X2K: M&+(7E_!L'"IZ7T3V570G$UVIZ.^/X+_6:;DADRI>X[2D#CP#M2QOQJHJ%I/S MHGZ_)^KWG $@6K@&,"*5JS :4C6KRF)+JO5;N6K]UIYJ_=:S:OUVN&HUANQ# MM9)6QJ%;]V5D7[=VD#%BP)]1Q3HIXKNB/2F MF.52=2GAHR4M^5:N)=_:TY)O/6O)M\.UI#%D#UJR7*1X%.%;^R*RKR0[F>A* M2?Y OD Q2]]*CN*6L]E$9ZHV9E6%RHAZT:@_4(\ A=%Q(#(B#:L\0%*%J\?U M@=+[/GI F,K*AIK]*XI"K(FE#YM(G[!1U]*U)0P:RN9ZVF(W/&CL;-MW6,,- MH+?E H7TV.L[*"=)BV@^QS3IKOX:/L)\#2N?G9UX'64J7D)YI&C"1OF0[\]V M$+(?.$+P515>^_6(5H[AHVX<)J0YE+YGEP"TQ9FE1,'+K.I%$GQ&=7__DF:3 MVD@;SR2-X;.T8_Y!OF/^P=Z.^0?/.^8?AN^8C2%[L+]@.E^,PZ^X+R/[6^9. M+EH2X7=R$7YG3X3?>1;A=\-%V!BREZ0]8BF,0X;WA61?ACO9Z-N8J2TKOJ\G M/\PAFN-HM4CCHZPJ&&35MC$AZ,74T0$6W/*I=PXL'A20GWYNP(*ZSM.+,H2, MQ,+8+C(?:_^1LZWO":B(8(_7&--4(((^+8PFIS5JGF)O%5&%#L[=_87,P(A, MU HIG:II,M& M^"*S\KJ[$CPOSQ:'QY69U]2=VG;K=Y*:)YFSKFM/]8G)&'2PEMITHNFUK0_0:%:VTPHD>+\%^2+7-:7A'[RJJ8_IT)-U8JBNR;[V M;V1/1/9%D$SO.S0KZ<>>LW;5EXQ.WV6-.S^/KP" &@%3W#6& 6?T]COF>"&+ M:TXLVIPH*M ASN^5!0^9,=WO]KZE"T_7&),1$6SMQ0\:;NL/&_3E;SRD;.(> MM(&_%%PLT],)=A<-B#E%T-+-01P3/5*!U%GE.)V>+ERMO.DH+],DS=9E^@C; MWYM8:H,HN$C"UT/B-S^?VEO;#'WR[92@.ZKAM7\:HU4V;*A5,_R'C-_ :?21 MWG_W1 A 7'Q*R\4EV76E47:S?LC2^'HV@_2\76R1&;QN,@$TR+B6[A:4+PM MP8 *#>!P0(W'W&)SVEW'MMMZAS]/E#]IQ9\5YP^J.A# CC,15S1T4/S:=O=I MF<'KV66>T)M,UE$V?4[WES>E9PTMO,XV74]*1I3&0F[)@L^4L&3N.3*0^OF* MM)CEH3)&L5XN([RAH9#-=U%,5A]:>\;$0#)LVU55#14,WFMN4-\5QT7EMOEV M6N$:I35D.JXZI3OT!RNP?J5KP2W,V%I8+-+5/3IGE_>=H259%54UKUHKMG1R M/S77FXGX7Z82+M2O+1)^@)S-%'=@8;);;!FUEOGPD:,%7MW^ 4 MK?P-9VD19XAFW-%K/$_(R[]US2_YTR:30]RJ:\FN*(,M:?"9$@>,NKZ_WF9/ MS-SS][14!]ES,G_6J/ET\H!T M!WG@?"3+*_GRN_/E*D,;"-G@W9#17Q 8-V3LQ0$2>F^:S!,U"LY/8(D!0F& M&D>U'ZB1 K%/"+"52=-@R%F$!?TZ*(=!T&K4^*$A4&H,". 0:8IC&@ \P=. M.(.9YG"*!9Y;;J;4:.:23C7"FA-L$0"KFA.K,/-)=R+YG$',/+U'%VD>Y7$: M97?U^MII LJ?-IDWXE9]F& %N$>@H0VVQ/T+B@)[D2;/[#B BLNB6,/D,C]% M>>G=+RW\6\CA0"\T-<"&9D/7D8RH QT84&]BBXW&C#!\U M%-X!CM!"Z*A7CGC0^+7["J0-&^,M&UEX*7VLQ4K,61DPRM3&9$"VQ]/96E;CWH,@,^US#\AC3IJ4IIUG&4S.UG2QNB%+%DJZIK;^VT9YW\I47$]D33CZ MB> N>OHC[VE.KV9AP22Z\4$7",]@2B,($ ;P>95BF$Q OJ;"2(^/"AK14H"O MR"SE'R4><<]#;'Y>N^UBHY (!RKS-:[1@83!HRJ,X N1^ZX_"]% OKO0.N?/ M$,=I8:AU>M^VIG4ZJ833.IUP[$R^H3T=K'4: #Y4C:5Q=:1J8(UNG*JF?^KU MJAH%OOL-*+DFK"6CE\^K4U[1YEGY><.@$6&[KI5-0QA4Q[7%3T'B0>2,1=K< MMU69113F,3+O.24"[2F*4#*"L3:0O6=(J04CC5(H1D9P): M[+&!HF&06BGH=/HQ6!/0 C8!#30PSJZ;J:#I$JUY^M'3(HWY65)=9HM>/P,> M^;T],_8+JVV2;:@RX@$(\)D'O;+8A,K8!"N"\ MN0]K2_^&\GZ8+[&S*;>.Q1V2(_,R[F!SZ'D;R ,#S=?M>'QB-YZ2+Z-'8O7/ M#^8UM;\2E&41+JA%PFTQER[)@8PQTXOGNYUN.OH[\E9VSW-]UV7/^/AU+A!% M#&DZV64>HR5L-JT"UX+D:4/'@J!5USJM)@M21C>(2T'&4*3))6].<+.U4[TI MM^[QD:R=(HZF?V>YOJ)DJ7M-VQ:@F4P .V")W ^;0>.C(>-9ZQ[8YX".[60F$U27-K%<&*WD3/0BWA#V>B9OU MT^IY0]7#-*>A@2R"M6)J+)T6T]MY\F$QZPV_(9L@&C5BD>E)%KY.^;IL^*V7:L62IQ7 MRM^ AKR5;%F;??*0Z2%F1+!,606)0T8L]QQU0MB+J36!X8(8% 07=SQ<($SV M;CF_G2/>W)/97T0L.GB:)^PO7KMTFOQS791T^*]@>3V[CYYO$&8_E"5.']8E M,T303=1SDTP0#*;1,3ZQ.K\CD8.N3K7B#2BW0$'4( T3A1-$*- H1MJW;_B1 M($!X\_[RXOJ6Z&3\",]G,QB7USGO,NF T%.L\:ZQWUB!AGLO<@4"8(X@D!]9 MA]UH$ \=;Q,_5:[!*?<,WL(E7_+K2QG74?8^G1GM)C6;=K'I5(0PBKVI(E;K M6SMG/+*VTSUP7^,:(XBW($%&4(*O_@XC;'__ZXQ)9E;[)S6.D!%8[E08W-T3 MYTD=2$-VSRV.TVUU*[MN0K/OOKS)_YY_R,_N\[^1?^Z^!'R?,&'-P^=HN:(/ M?GES_/?O/AR_/?N2UI=K;RS(GV39)8AG]*97LA='.00;,E;T$F2RB5@2V(MB MPD"5BY0\"G.R.]^$*(IH6[&I;N*-A&Q<_OAML5GF#J6E9@M6WMBJ<]Z0BB-/ MO28:YV[["BZ=9&(7?F=5X()7\WYQ#GU3>=#P[@\:9,RENG/W'?5E@A\]H+PIW+&I-.E-5]Y46HKE$*HH?$=9%,XMI MGDQKE8BP^+18YSTCA:30OFL]5&%H"@P7; &-P!:'^>FQF_XY/D&.*X; /8;$ M#? 0,T]'$I$Q^_UZ:<[HD,0I&P3R.8/5L=AT28^^_KTSOGO.#IU7#?TI*B1< M3\XV!BZ&+>)!?!Q:C$=#N#E4YZ.\6&?$+NZI^"=ZQDB7[[7E7&\W] ;HY\&8 M/43SQ W($'I7)"%(B85^]>FT*&!9\% #T1%\YS.&&G*G+5\W:NX0-;D$KC65CV;W'U+0%^%<%I5"R(F4C_H1&QCU%& MS8;F%MKM-7^"J:S]ON%D5*;C>CI]0#G<@&6$?X,EF*WS),Q2H\]W-)B9 98H MDRN4I9.ORVWOY/[VX4B&+%U^$8]C&1MXG.AR"0LD0#8N);Q63O*@ M)P0$PZN#/6"^=J7N>F"RQ1T3/PU."47A8*#5 UIHK?U&3;9)GV?M]6Q M5N6Y\>M:T21THU)[)<&SYJ2Q;0N4)42V>)XDV5CO-@RQ:0 M+^O42':YL-'%]:ZFAO:PH,&\?K%NK:MUQZF&125L7)V.UG=#%(%6?TVTKI4&@]99KW#.RI[38CWM MDM_;F,[A@:POAJ6!M_V\?S3M@/=P IH\AJJ3_!% NPEH/T.[! +,9HM&WB!Y M&IR 0%:).,JF>7(+Y^N,*J=-3]"7_'&SY )AL\Y#P2K2@- &6^(#XL)L]L5U MN&[=>1H>B1NT0:+CY8*%=#G\LK9'O[+:=H.L&G_4 VV#%%&Z5AHWW?GEU: MHV;N>9Z,G;5C7Q;#+H-^_5(L(N&&B,:"X)K.,618Q8XIE>=-/%-][7H)/ $U M<=!0-_=-V>V-A_Q%?K_GJF9!5$,.X*%2DC"DS6C/&2%HN:RN,>DSXD2/F>9W M[#7G/KV7TN/",P$YHA=(\!7B3X"T.7G]^G4=A1*MRP7"Z;]A\J?F!@I^W35U MB;:.MG\"W[^;O'[W'?O^NW<3HJVJ&R?^SSJ'X.WK"2V=_P/[^0S&;*3!VV/V M[;L)+66\@K2,',PV87)*1$.*5,=IH$8_STNR>RI.8 YG:DPL<0Z7$<#6.FYPD-S2P3=U,11L;@L MX;*X1[>0\B3-:&%^7J'_/2K(]S2%\@:CQS2AL^HCV1]=YLTML55-6*)DI@\% MB[ 2B+ OLJ9U*!S#S+BGL5A_GZ*,BB23U0G*LB2J]G,>Z[$R+\U1FGS4]AE#(1K!?& M?2$,U3]Y\<7.D88$ZRH\BZ' 1J(0WL JB.&XQO1N^4[GG&GWGLM^SW^./@H"-X MYJT*T[M/)?HY&5C8+MFYD:J@[3YM2\AXJT$$K#HV&YUP[3&Z3["ZN.=;J'BV MYJ>T7)RN"8.7$+]/HX-Q4U.PD/I9H8!9!7A%$J*]/GLB_$6 MY@3.TYP=83U$&8T&GAR>(H^MF]H;BW-^*>5)W<.=D_- VD)CTJ A;'U9'JB=ZY0SOO.RT]=YD6)691(VR7BIFR3 6G?6D0#XN@=W!I]\>J,=$> MF&V;X>*;QV25];.[VP\CXN'(K)AB2$47*WLE^PA5@R)JZW/"^2> MHS)4A<4Z5,T-L K1$*%6=@=356>!=R5!+TPEUST)JI6-0(12S%I@G2? 5,1^ M9XXI-P)C4ST,D(*1:0C]G8[0#>?/!26%,!Y7E!!JB#HZ_PD. +ELN'4$* ZX MYRR?.,9KF+S?G@Y+[G25/6^:5R-JUWE"#"=,#W+(*,L.QUUEM4BYBK19Y5>. MZHO?;V$6E1KRI/R>H5Q)V_U<)6Q!94^F/G**=Y_WAW_6XRWNUVG(\W)Q9PO#NY MAJ2L&%J7;V YP=W3!E$Q61^DC*H!NH'D6EA=8M>O03@6'H[NEAW5FW3&S%2S MXEX7VQ*NQ,9#5?[QG)_'?P/.G^-LG< "0'[Y:KJU8@ J%\0R+!=17K\W 3,6 MQQR1+3Z<@(=U"7)$\T66+,:Y1%7*$ECG*4W*Y#4FH]4*PSCEPXGI$4?!JO:5 M.(WI:^RI$&4G'6M!Y%."O+N"T9J (FCI!9I2/W#/P^9.X(Y&/7CH&%6PXF1# M>8#[^(GTF.3>2KW!*%G'Y36^@_@QC6%'43K98P8V:U=SKL6CHLDJE59D0Q2; MDW(3J;+HA3CN#DL\.+V&>C3)"R(\H_?+B8 'KA'C/P>AJQZ,^7W>(V>0G7(Y MO[OKSMUF&Z@-HCRE9-V),3.Q29WAP1;=)-%1-'2VZW^I4)+L2J"?@6'@_5(YRV-[E M!Q'_OB% &GSU+&(H2^/-/7PN3PB!WR179DB>-A6U[E9]K5T"\B8KCK6>&!R! M5ZE'[8^?(9KC:+5(XR@3N*:DSQJXJH1M.B_?T*(7RH,E9RC2XI)O MK43O12HW-X2O);53R1Y_14$VNE.HGU1?--94,@(>'.0,P00P#,Q1WJ G^]I MZ *@: "#$Z:PN\8X('/F>M!A<+X_-X3',-)G3728J$V_.BS4^8N1^T)KJY^E+\0)S3O!:]"[5K(63:.%:!!F@W5D-]>')]_4&3_5'4(T?Z>H MXKG"+ Y=,H%4F!9(-7]"^#>R5F!$.":J3M;_\%!UO=.H:^&GQ*C]L.+DPJK M;G9V*<,>'OF5FUM($*WA!>E0UTTVESG-MZ-7>Q<%00J3^^A9(%0#6C*4. .* MKL61+'*@B#*SBZB\],= 3U>X )5ZT-RZ]42@@1K;!#3H0 T/$'Q!YN,02406 MAR/0"G ;/7V(R#"G4<;"H=>K549,1-E:('EMZ*H@:-Y]%/,36-9TPZX.,@9W MK1-*7 MTZ^]EOEJ7Q7LR2[*W:I?]BM\8>L?O8 T0=O1W*E;P^W MNV[RE;$PD#:;)O\D"I?%%C0[56JTE?V[@NVH/<$69]&!(_.LTR]$0+ M\%;U%ZB1RXY)T4-!&BTAL=@K<&%5 M%OD5FRO2O:A84& %C:HEXDRPD664?+XLX;*0Q$IKOV\H7,ITG#M;4'Y$D8!9 M39XIN+0&!@B&])&5:6/#['9OM# M8G-LX/ :EV,#L'%,3AANA8G'V>(.'HEC=;+L1^'8'U,?5;+_B7!]ZE (\C?$ M#QG5R]YOS/6LKXF%RM;H81]2X\D+"2WEQ92N9XK!T,[H>*\W(L S^C!3$7"_ M]T!8XUZ8Y>VJ*5U0!9ZJ\G%L(:?2:66ELHO2:+M?^*ZB);R>[2A>8>Z/]%F# M95#8IK_5,%3>CYR=2(M'X8^HC[6/J(^='5$?ASZB/A[?$?4^MR5'U)TL#.3F M_QDC>:CESD-#W?JL,>\'THSJH*-H0]Q#8^/GQY2K? LS :5_0,J[,%=L+;GCHU-J71P RV6)YO#8RVF:SLXF$/>/T[^PU'(*N=56#KWYE\_ *:TGDB/P%0QD4-^S>A<+(@6R+($P,B )O MD3[#/-ML-.V :>0=4F&(;\=WC"'9GYU!_N]E?E:5X*I29H6^<,7WC-WCDO9= M2U%-CM]7"S"G&LCQK,IK9,S ,,JG-Y:X^Z&!"LC3O5M;%10R]%? P0XU%/Z< M]WRYRM &PNK&KV[?TA5B$?20>Y *ML"W?S]%17F%RK_#\A;&:)[32 =6U:6Z ML$$@:5YI&PJP%XR^3%TOG3&Q3D?*90-#O>Y)<^^?R+,] 4U_N.N:6/<[GF_2 M%; AF]QM9R: =0T6EL M">Z7K\4E'1R79K<^&N/3]JW&^$N ]1*4I)N_TU5 53=X61FT1,QSIC,L3Z-B M<8/18YK Y&3SL: %;J]7D.;9Y/-ID[U"#AO:KTZKAG6-EK5K=^WV9,?VSW(?MHB!"OHN'5W=TO4]SR(IOB,( M54(Q/&>1:O)&'+=93=1"G9 MIYU&JY2L^"+)ZG_:5*BZ6W4N3PU9L")TC](?1* X\62MC9#U4(V;ZHF'0ELHQ@ MS;8UN,C1B'G>LL0+F*PS EQIFT9+-L?LT_5L?R/&NBD-\'9-SW0#Y0J7\WU8 M!9Q.1@W/QK8#],5M%VK7!>O$6&XI=B\TR+LD>#?GU\LUTT;LA(?V ,,%Z43Z M""_S&"UA;PJW]OOFAKX:'>=6VO7I)9B6)4X?UB6;!"4BBQA+%@J:WJT_$F@P M>P-DPZF^:!JG+*3B/7*\@3 #P?RY#8P)H#""IM5H MC $:P-B1R"0%UY\CH?ZF;9G<4AB%3 ;-L] 8!16I%+%V9-5]BM[Z'FQBY8E2 MJH]+4JZJ_1A Q#2CSQGBG#O??OQ26F.Y\QSV_9MN7\_CY8@LRPI/1 H :5@=30NLNEZ1AC MI,0/OQ)["XEYF\9EE9O\,4_+XO;N8Z\[7ND=0XGN;=NUA&^)5]GOC#SXB@ H MO@[KF5?C.3)BY"BR"9O+,K<98F(%JMF W>S!#D*^\I34$1DJ:6?]-=3@[+[8 M506(%F5NW1VKV%>_Z9)]4BA/DY2RVN]4/47+95HR']M^<+Q@;BJ\83@9>UIV M[KS:DF9[L[A-/(CPJ; 9&?#.=YW:AR)-T@AO[B(:Y\46JIYME/1YXPJT@G:= M1Y=$/%Z0&QL!=UARSB)M=GF6I2T4?L?5/8[R@JX1*.\_EU)^T52ZI 0\BUG0 M0R-U;B-S%OH5O::V@73KW_.DH7!UM.C+%NT@;6)T6NF!@75)">V4X A5WZ9/ M*) &GP)5SMA6-.OU&4B?'UJ/8K]=YP?Q38Q_JTY>6!^!G,==U0#Z&>=[PY&S MP]9/:;FH[Z>L[UC85$5MM\']PCV(22/&VQ(=8KYTLQXJ$[7MK-\_\G[G<$ZC MX_5T>D679@@K=1V(+'KSK/1W MB#=O39/@TKRS\MF8/'E]$FA4\&R$T_22%?L9,$U[&K [33L(!9ZF'8@L3E,K M_;4Q3=,:R$BG:9\$RJ>IE,V^LP0@K45Q_DSC7&G8*LL.W(E'%,Q/C3>-LP2D M%-QG"3 ( '(,W!N/6)G:>"? -%"*@/H0H %\#5688)J7:9)F:S)1X!TD#&?3 MY?PYSM9D1ET07M [759)6&?1S@G$ZNX@9B%9ZM7)+!-:' I EN ?-8@:&,& M6]"@1LU]7RWL"Z='36'' SY)Y]=+,9C$L"[CE>T&2) M6[*COL[I,DA/ PT)G!*S0 &+-0\ _ M%P#EW$ABI\'T ]QB"^/Z,QDG9(/YGAV$G8AXE8_]Z[!$[D&#)DR=@QJDO+D& M-3 9.0:=]MEP1Y-6A,%7247ZZS">01/90S:8ZSDH?MCJ>;+I;J OQ-X]1=. M?7?(G(?_"VS(D+D 'L89!1@\O_/S9XR*X@:C62KR)W0\82C_K99\K7$MDB9+ MV"#$!BL4HT>C7*5X'4VJKL%&"OP8PZ(B+3R@^II5]>ZO((! 1T]&<#>I,N>E M"G<$$AI&6U4C+.Y0)HY$D+U@''4@:MA]+'3!]L4%,3U#Q3Y+ MF8KT.17*J7I8HNT*E?!31,M;E,4UODWG"YUJKH;M#7:1:M+UZ0EM0_L25 54 M*+H)J/$!>D$,0S@^?Z?IB':Z-0<-4[!2J6=PA6&<,B.;?,Y@E1T^72)*AY,\>ARE(H,EM%UCHXJ"IM< ,+)D.O MOW_[FDD0_:8_YIG\6*1)E:?#+U&BX5O3Y#$BO:85_]LQT?2A/7ES24)3.EU M<;_M;R&J;N#B\8$1!T4W6G@W_%YNVHR1+PDBMDM=@4J9/_<+2$VZ=E!T M611KAA'S=%:^_18OBXHOFB^-$@*^=I1R)(96IO7^&=QQ7,/@T78U$.INJI.R M.9@)8#?MAK(*5&4-F3-XK/D.D@J\Y@TYSW_P5KN7!KC-,O1427%71D"8BKX# M!LZC5$.7(^ME[-(CUWA MK9)+:BQ%VX? M!LGRK<#;\(+*;O9V^W[%\BB,B=C!@(4%(4UNWE8URR: MS>R>6]J_.WG_?%K+G;(E,Y;%7/5\T-I]G73_/90J[Y@>B?:U[3R<:GLK^$UU M*WA%/_!UDTH,EU\2'M[Z:$E]KX@)GQM00'*G/1]E(VM5%59XQ*Q$ROSQ*R3[ MR0R7>5VOJ+K+NW8(BBL6F#1A*%HZI'RYU70PF1@*;OML8#-,XQBO(:W.NKTE MJLD4#S+MC"00V6!QZ,E:C87))!6_:FUR'I((-RD/L=B9C#;Z.& 2CFS>]0A5 M[WR3<=%SU'!))CT]F^3^=9IYA')6U+FG9K+*.Z;1OWUM.T_1YG&\6Z)!ZR M51D:58+&^3/$<5K &YQ2/^)^^L:QR*,RI"U3KXL)36^U,$S &17%\,.%%2L$ M06P+7.I-WFT>U+HLRBA/TGP^ 4^0 B'6?/0(<32'Q*KGB,&*0@9?I3E(4)9% MF,QZB$%!4]XEA35&P)_S7#.1PQ]W7/G_!DU\9'6<1J ^K[?#J*,I.UZSJ11; MS0?5?RT7=]*J.NN273 M.T(>![K^I:K@*;W\9?^YH5>_U.UYO_CE7,G)YPR]0>H7"[)M51X/ZJ84"T37 MM2_=?/)<-@CF!$U&TS>399JG-!J2%NJHL D$7_$MT_)"_:V[GA05>9[3NP,@ M3"4?15XC0P:.H=KCM#PEZ\"&S(E?HVRM5^91\*[5^HY[-+R$9^L7(O7:(V,3 M[B3*6.175(('.$]S&D%+;1G>X.AZJ&VSM?H':2USM9YYK4XIFC+2LI2]/#51 M) 6,OYFCQU?,.8K'ZO7("B1IO6NX&BC1<"TSNR"H M0JDOQ1I)82.]D4"#V.LYCC9C(@,37OHS*F!RVHI%ZC>2]5XVC:Q5(N(\Q+9& MP=T01P\41V?8EE&1($=]-#D2:SIZU^IH&PVHX(1,_]24/#2,U3I3LMA?^!.8 M\NE(/NS/0O+5/Z9+8D31J(J++-IW[0I_UYQ+!^TXGRXU,4"I>141,<^0E!&C M\DST!IIKO>O&2^$G(+WMJ]B%4>NAL&'J>@.A[L(('\Y>!120K= -RM)8GG8N M?\&\WJ"@8>=ZK*$,:M+@TVE6&"Z(G!.!YW>#7\'R>G8? M/8L\8_(WS%-L1"U[.](40S"[YMABCPP.+';H@RQ4X3 5D4$&7/,[58B%FA;7 ML[UYO.'_EWD0]%XVG$!J1%S/)8:"W2'7X)APG;T!GZM_0[L1-(<##>.Q[^(U M3RUT&.7D8\RBQ0L=B35MQKAPC1XY]SGR3Z!M<^P@&IT\&P\6LC4"OLT6 BTO MJSIN:?';65K$9'U;RR\*U7G5V)"1D_!0CVC8$\V]/\7Q.9'6/52!H.6!E['H$'1UT4,!2_>T19I>C9! $W MPX:+-X"\9AX%G^89;3F69Y\B/!OL!5YU.M#4WW-5+ ES3N7 M8DZ?>6'9RSRSWW.#8 MK4;0%$F6)M5[RT93$\+>W#0-_@:KZ\/. PN%- N%5X97^SEHVE/A'U:#;5*' MW;>"\@=G'%CMV^#8O!'VQC@.+WARA,J,Z"[:)&&>[\J-< 8QAHF6/E!\R[AJ M8V_K[J\#J3]__/4C0 M9XLY2-QCIQ$\IVLB2GEYD19QE/T=1IAH\K.HW(^:4WG4(*Y'U*1S@X'3!9PP MH)0!(0TH;>\!/U*^(AUF^;9!Z6VO]!*"_KKHPN>,K0T1AT'N>I#WVYI30DM=>WX0^\WW?G5&0=2JF MN4IG\!%FB%UEI^+?UGC3^%8-*07W5VQP"$Q06R#&X>C6&0(T@*].[=NSZG8Y M;C7=,&?%!?EN?W51>M; PA6VZ3POJ2)_P MB_/R#K]X)D1Z3I?WS $N% M-N/-0*'$@EDE.PQ#,BYX&>++?(;PDNF-]VD.+XDJZ=O*]#T^0 2ZFO4F$BWB MX#,E#QA]OXN ,I.1+N=\B]%]1V%YE4?MB,^]C_+QW:+#2(]":N[W2ZNK,\NO M6?HAS1%.R\UE7D+"[_+Z*8>X6*0KLC6CH=G1')YLKDC_:9 =8D&R_!&!R3JX M/4-SUIBNKR,@8X FIT >N6$0CKI+&-0@)Z"!";8X:2[$W@LJ?'&T0Q@NWLCZ M*#E=7L[SDB"\2#.(3\DN9X[P?H"YY"F#1:6C->?WW3"2@-$$-5'O"TD?&Y$B M;SQ(0Q7G<@M7"--,";K_[72_JSQN+!_=S7H2E#H^J:$../E (B-A,=+EFP 9*7ABI7,:'D1,1,I,PA#Y+Q"6;9+SEZRN]@ M5* <)O1^\(,X!.7GC25%T*XGB:'4CWZCY$%-'W @61'QF:DS3N_.YU/U>TT M4WXYS16[!>)ZQN*S6^'9M!A&3$,CTFQ-GA9LO>4C391@_!:[ O9N2 EI7B=.'XXSDS/!<-Y L+TQII(_P#L9KS))9 MSY_C;)W Y(+TAY;:6I=518'S"-,"^07943/\TR4]S1'(N=6V3:L1VL#@O' A M 7E4HP1% S.X&K<[@LCIL'B>-\D_UT7)*A_=HVF2I!1HE-U$:7*9GT:KM(PR M!O5AOVCQ+;U HTA+TF_\2&8_C]FYA3&:YZR5OCM'?)$UG6V.X?E:YESWPZCL M^.AX:[(DTQ1.XWKLKK2(E8'+'&X/NX2W="N\8JNL8:MI MO^4,,2O\MFK(CZ.$81>G^TH7"MDW/FN7%OJZ1[SZ>K,+LNEIA! *PJJ "GUYR9@AC#9_[%U/?'C7GI0N;J'-6@+-=3KZ*2P]\"8/IZ"!++/.-6Q088, M]Q'BPJR:[#)/X/,O4!SR)'C./*AEMSU?T2R<*F!D :$;*HQ%P$VDS"(/HG$+ MY^PZI;R\BI9=8=9]CQD+QFYSGN1B2Q10JH&D0L!)I,H>#S+1F<4G^ME8!OSD MYE5C'R013\@R)..#TT%^#^=1QFEW9 3W/&$PU'LMN1YM1@[48^X_R;>/>4B! M(YZ=5U5YX0._1W]M-;6W3%U8_:V[K]3'R>]=9<"N+PA;A4V1Z\B0E7XEC_IB MV$')R895C3K-HJ+H*4\@?=Y0VH3M.H\YH-0 (Q>R&(&M-,_2\X#)?K4MZ8I?':9:R6='N46\- ]?DALJQ M95A>IT'(6@G.Q[5K'CD=K$".W*YLW?Z'AKIAO63H;KVL(=)R)0SL\I2^C%3< MFX@F[PC$Q: %E^FVG-*H$FPY)&W*IFR?;Q?I &OV. M@(IPBGK,\]YGA^KW=IO.U7Q%*Z1-WL_,+ETOYE"PT]R+-(^(K1)E-ZA@!]#J M1[C25X>?VPI)>#VL;5" &L:(CFKEH]!]/JO(6L^"64V0CWFQ@G$Z2V'2N\N3 M/F\J@J)V?>FU"6B1#KOCDO,8:3/.KU3]#-$<1ZM%&NLY4)7?,Y0R:?NNI6T+ M8'1N5'7>(V.&>H] /;@OD'D&IGG2W!O(=H,*]VZ;MF0>KZI+T4,8*[]<\HE@ M C6H">">*AJBT@ ;RT7&0\8-61R,P)'7)QM:\K!GEZ+PAJVXZVW+?L.NF8*E MI$-N8%3XW!=U+6)>8/FBH'JM1H4W;,G7MN5@\A72=E3A=)^$B=@7;+M\&A6+ MBPP]%>K;9.$KP[?'!TW[C6$FU $C/Z+ML)C;W=M@"0M]Q'RJ7]>L]Y)Y-&C M*YOKT% >?7S'+VCE*,#U""YHU1P"9,;78/J-@5N@+(&X./_7FL8^*2LZ^;O# M-9Z8AE?5UX;Q)>! 1J0$%4:B6QNJLM=[HG3[N@.)1$J>-D^'[FK5^XT5@85, MQESQ)15C$*1;^ CS-:1U4\Z?2XCS**LWT,7)9NL]FM(49B57C(46#05R &77 M0EM! U1T0 VN<=$4]%2XY7ED ,?BHK$QGLC!('DV".CUP!7V*UCV.LE[GS5= M\+O:=+[ LQN<*ZH30)/A@GK ^QF+M+CE.0W^H/)#KP3)'C=-:QQI5A\' MR5%'/W-#EW"ZS(D>)@*40O5[ZCO>L5:TJ=5VN&I-+1!VRC29]6I(?2;E+GBK MR]0E-;T%F81,&YJ!CW=T1D-#L7O/M;W'$77#WFV6 M#RC;$S[A[P8>]IUV7(M010QP:M[]Y-T\0U)&!-CLUF*78AB7V>8>$0$MUD0H MY7M?Q5>';(4E)/SLC"L0$U## "4"-9 1;)55QV%_YZS%W'"B>;_ :#U?L&2$ M)4S2"&^495/ZK@7A%-+P+)T5#M &,A[IE(^$0#P5V1L\M.L$YO%B&>'?].*[ M.E^S%^2UTWR 2)R&_LC"O;K9WA_SU'U['H%.3Z1OA,_:"ACAPTZ+PW(*-+0ARU-\#GT:5T/ M8Y$ZMWP'VQ!VL6O)DK,UK2' "]/S@*#SY2I#&PC90S=D+!91 6_(2(@3.@>U M9AR08T35>; $0101H6%E@ZMKP&9-(4M61SC-R=_$GHJ9=F2>%5CAK9Y858C! MBK0=_&:9H>.++ _:B.8*^_&:UX4^?X8X3@MAV5;SAES,D$Z"S@,K*T('4Z(N MK:TLZ@%Z/,1SW]";@)S=BM=2#Z.>WOURJ3JS%5CO=U(KQ559#97R&_W43=5D M2@W%;53>HR33@A$.<\XECZD:49A4][QC):.$"ZK>"J76EMU%JI_FRS/BQJ39 M%<=3KMQU!FD4LX*O1K>P*'$:DT6ELP V&2M[7>5J.W)J1#Y:J1:,X J.0>C9-+>Q4Y.TX6 -&N4\9DV0KC(JB M)A^=E4Y Q.S:V>O9+(TEY^#]#QM*9G>C'L2/4P45V;!GAQ+.(CUV^AN M_2;"Y>8>1WD1,8.M.-FT?^DY)]1OP#B71I60AT6>T@.,8,C#0@/>H^$,5150 MN($%$[O7W[]]S82.?L,.S*LD1IIKFQ8%(4KO4[M'TSG,RV);N?%ZQDR&&XQB M")-]";34FJ8X#J3J6C8'PM/Q@'CGA,D=S01>DPL\ 5N(@&*DP5$'@>8$E>:JH6,@-/,(Q^F7$ M>@$BTK&BI-&+9%=#OT>S&:16$ZOM5+_)6J%O?^-52]K2#\CRH(9;X'M#+L0/ M6EBP_815["W,(>,H>K@I6(+#QTH0<7U,J5!?('R&U@_E;)W5N68"H5%YQ5!\ M^IIV+4@G40(2^%#2B[[1(\1^+[W38BXRX9AGMTMU:R-DUXQ"8FBR4K:8V)QS M5G;@9+-]Y";:L$H$U&%4[;5_IG>W%9B+=43)UW=A'Y+S@*"4Y["1V MQ+PP,2(IJ*,'B@JTD8,6=%HOH?U!^HN<1[,>&F9AB'F(0EC2>F1,V28P.=E\)+ O\ZI4=SZ?DEWT8UJF4%9^SKPATXA$;8+. MXV!I=;H9JT[']ANS&@J(&BP_A8E:-!\<9(_CO@N[+V"RIIN(Q7W1>0Z6W75 X *&MRJE7.S44B:800T:T/CR&C9@N,=2 MQL>-*" OX^MY8D)VD0^!_2'"OT'J<#E_IBNI\&XPZ0NF4T;8L'/YYY29H"]K MVF'D5LY% 29M/YM;.F&Q:#HN-"Z:OZFN&$U;6O*^$(1D. MD\EIOV\E*J-,;SK>TU= UG(AL1".%I@__N&'-\?O_@2@0D<=S4-E(4.FW!W% MPLDL-\-=>/>[#LSW%[8''].Z(1@C19/>XD;4Q)0G0])MB6]_,#3E/]ZY%J6/ M5Y?WYV?@[GYZ?WX7Q'QO,0F)>^X[1*R A-:"J,9J5WC /' M>MIV'T/&B3.=DFS)-VIESK1,H* R%:8C(T[Z%KDR2G.8G$KEF MP7!G<);&J>C07/U%8^&3$?!0F[ZF2 20D0PD;PO)[=1\\"(31LQ?R.!!UJ/L4343S4%-L" EFH<";3 M44&66.U7DC^@'&[XD>+%.D^*WMR__H<-Y;*[4=?BQZ@"3A8PNF&3_R2L17K\ M\BM#?3)^ F<(0R+D-PBS>+VRQ.G#NF1!$>B&;,.DE[S9;MY03FW!<"W9UQW* M-.57RWU%E>K782+AK(\B=- MD@S[VO6PR%/:(*Z(@Y)2![ BKYT09[OQ0(A#U=SQ !IN2>"%M/@^<)&=PA8J4A=*Q2.\,#$K6->Z:H\=Z#+//<<#&D"*QKSW#CN>:_37G'$) M[W*I75:'K$)5+P+,0".Y18/'9N!L;=WFSHZ11-=OSUZR XO)^NJL^>ST^C55I&F?R>=\T&##?Y MZH20OG]"@(X4UW*(3R\T9F8T^[SE>PVO=%ERO<4-:""(:S'^_F\6SM(@S1&M --4> M)&X-A3<,MX\]+?O:1_9 ,-G-6.V1\6TY9,VJJNX0@XYLYTI6>2I,H)J*]" # M!KI9M'B*VH!5J[\!B\M6-Z'@ZY9I[J:/KIHM8E>[A0'KGH*OZ($5^X;==?)U MLX@E(.$)GLPWO\8T=@=P%\5X%C6)G$I6-941&3A!B67.J^-=S]0.U*[@_@(V MN!V3Z6I"SWV:1X6)2K'&R:OV!/;3>0]':KB/8P5CV;[=NG,G3(")/DC0D;4! M#%7%[S)_)+ 1WIQRC:M9H$_M]<&U]_K)^"RKUR"9@ K+^$KE*0Y*9Q4\'4[[ M/JZK#/+3+"J*JLA^SZ4STN>-#^\$[;IWN1-ZS445(>^4D;,6:?-KH-U37Z-P M08#66K:B594(GN9)97EUAJ :-6!BZ6@1;379517HVZV*/0TWXT1 W;&CE&#RC13;\P>=]D;NO0\7++DPX@[?GKMK<&;CS;&2EN M.VBNG](*%_@JJ9!]W7:><*=)?=U23";DAO[4G,=)\E?H+@[ADA\YM(O]E(NH M!-1SDZSI,3EX()_28H6H[X:>0! %20/:<@@V,,+,T\-CELF&,6L%NL6;.(,3 MD,Y AO(YQ%\'T(1&&@$-E@O[HEN%5<6(LNT3VJ0,C.'RGC)ZR/4)=_HE8O%=(XAT9S0*%]YW.B MK*M>- 7Q& S0X!@P2YSTS\.AA)PI(>:2CC0BXR$8>IJ8SA?E=75?JWAJ]3QF M=!9XV)SSHSY*$M0TS2>)%>@^#NHHSJ*YBC?$N5N/S"!5;@Z-9H$$97)'J=R1 MW>N_(28<3>XBG(EE7?4=HY@52=ON[\^A] $# +YJ0?@:4!#FT\)^QSS,$0DW M0@2EJ,H>,N+[_FQJ=_ ]^42^K+\B_Z-W6))O_A]02P,$% @ Y8L'35;" M;A9O,P 8'\$ !4 !E>65S+3(P,3@P-C,P7W!R92YX;6SM?5MSV[B6[ONI M.O\A)_/,3B?IW';MGBG;L3.N'4L/0$JV+!'$ M F\@851UI64)(-;ZN "L&Q;^^5_WR_C%+6:7 MWZ^#H^N3\_.7+WB*D@C%-,&_OTSHR__ZS__[?_[Y_X+@"TXP0RF.7MRL7TP7 M61)A]IDN\8O_.;[Z^B)X\>O'?_SZ_O+BQ??IR8LWO[[^&/PJ_OL0!/_YSY@D M/_\A_[E!'+\01"0\__/WEXLT7?WCU:N[N[M?[F]8_ ME\U=O?OWU[:MMZY>; MYO+7*'WHL-OXW:OBQX>F!X^^>YNW??WITZ=7^:\/33DI:R@>^OK5_UQ\O0X7 M>(D"DDA$0DD+)__@^9=?:8C2'$8M"R^4+>1?P;99(+\*7K\)WK[^Y9Y'+P7J M+UX4T#$:XRL\>R'___WJ_,F8'( MXB0-$IKBX),8+27SG/(@C!%9\D"\ZP!QCCF7[;A@,A]SP?#L]Y=XC7FP?:0D MZS_J/S%=KX1 <;)8W_(;[Z\S1)2;H6!A3GC$\%7)T+ ;YJ6#%H,?(V0C>V&,DE]T+E*9BLSM*HA,JQ#B9 MB\V."!':$JI@R:AO_ZP]B+U8*O&Y^+@_=_4-+1(]13.G! Q8*Y'_$,*-(Y^?YFR[($*Q,*# M_>CI@S8M7JT0DYM0N"!QM.T]8W1IOHI1BX(Y@D3, ?^T%&X#0TEJK3G?H M]",T53LQU>D/8V=>(_X4H*B (7@]5@B@Z[TKP@#1G&BC[?P1J7^^*K50NK#- MW@4'AN&(>,(&S;M M,6^T=$YLMA)KN"0$QX:TS;YUYZ\Q;9]XZ\]99'>NL M_IYCQ4C[+9@APH);%&@RV,;[MK(B&F;Y!YFKAW,! M#D@RHVR9CP@WLX /ZLW.,J*G0T/K2! 124+.8C0O,6E*?^_6AS&S27J?.0IKW16DBA>H)5MNN-RJD8J(*XW9\[IZE0I$[$L S% MYV)AOO\77BN]5(IV?5%)ETN:7*=B)[]>",6!3[(T/]!!DK+E'MZI+_J+Y?T* MKRB3B3I2A2M=KB#->Z)Y6&[+8M S$F-V(F;NG#*UK):VZHG"*SPG4D=-TF]H M63;7JYKU1.,?-,Z$$L@*H-1BJ&C7$Y4_4/C$KI*?W?''?>L/2L@)>TY^%=,@(!KX8Z*1ZE3%K9[ M.2HG&D0JU6,P)&_<@*1B/P%#\=8-*&!^'3 JO[F!BE9-!P/RSB5 (&8?&)GW M+B%3:8F (?G@$B0@7H($[?L#X?'(#'[6C$:ZV.:+) AS"<$PT*3!8X)>(%&V0]=S)L;\'[#JGW.=7=N'Z;)VCNZ$;?Z"4J,F;V" :U MM4IZH=8=9>F",O(WCO0,J'H,@(U<<0>S\+3U ,A7AV)-NO3/R.5V"X9-!EUS MVPP IP2LTS"8T4L6L)=/WCC)[2%N_I)SD^FOU<1"3KOY4PC 2C"&OROK1 M!!\B[E\PGE]PV"??USN? U.*G),. TRJ-:RQ1X:;(]/<-3]0;YH9- !3>^Q! MXMJ M#2%!AHJ;@A+F3M@[#'BAI EI0>BVN\#@3G*"%_%T7;Y4&IFXP+AC@/ MZ$K>/2"^-JVT8?;0?LMNU*'-^XO;]QXO)8MF_0=8B+T(!6TR*SP;:"D^[A!:^:;@'7UXS\7*SS>< M1 2Q]8X<5$P%;7MW GF^O)@O+^8CG";,:XT,:J3:CQV.!NH#A6M2KJ"DWUEH M?:7%&9">;^Z 9F6MX2T:.R+P;(JZ!HPK"#5;@2&> ^Y,S("AL0\BN1,.@H8(W@8P1ELE&L,+$HQ]J4%8B8!8\.N+"GU-NCF<5_G MDKV>?4*M835K77#%2B[3F^ &<<(#.@MVAPM$]X0((4>R$G08TBR_C398T9C( M"VGS'""&0[SW,Z.)^!S6NFNH#U+ZS9OJCR.?;;5'EK_Q"!Z8.99".IE=[B[" MN6MC*Z1'#T)XN1%1W04\;3QRY-D*CK#A;^,=1DQV7"J2#VCZ@*8/:/JPB[
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end